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ABSTRACT 
	  
Epilepsy is a chronic disorder affecting about 65 million people worldwide and temporal 
lobe epilepsy (TLE) is among the most frequent types of intractable epilepsy. In most 
cases the causes of TLE are unknown but it is believed that it may take place after an 
initial precipitating injury (IPI) such as brain tumor, ictus, head trauma, meningitis, 
encephalitis, and febrile seizures during childhood. Despite the development of new 
antiepileptic drugs (AEDs), about 35% of epileptic patients still suffer from 
pharmacoresistant seizures, with surgical resection of the epileptic locus as possible last 
option. In addition, AEDs don’t prevent the progression of the disease but they are 
designed only for treatment of patients with an already established syndrome. Hence, 
there is an unmet medical need for the prevention of seizures for the patients at high-risk 
of developing epilepsy. This clarify how urgent is the need to find novel therapeutic 
concepts to fill this gap.  
Epilepsy could develop when the intracerebral balance between excitation and inhibitory 
neurotransmission is impaired. Experimental findings show that after an epileptogenic 
insult the brain react to the injury with an enhanced hippocampal neurogenesis as a 
homotypic response to the neuronal loss in an attempt to restore the pre-existing cellular 
network. However, this plastic remodeling that the brain goes through is usually aberrant, 
since the cells that undergo the replacement of degenerating neurons upon severe brain 
injury are mostly high proliferating reactive astrocytes. This leads to important alterations 
of brain signals and, consequently, high risk of seizure development. 
Starting from this concept, we hypothesize that controlling the neural stem cells fate after 
an initial precipitating injury could prevent epileptogenesis or at least improve the clinical 
picture of the patient. 
Based on the recent literature, we decided to test the effects of Lhx2 protein 
overexpression on cells of central nervous system. Lhx2 is a transcription factor that 
plays a crucial role since early stages in telencephalic patterning but its function is not 
limited to the early embryonic neuroepithelium: recent evidences have shown a unique 
role for this protein in the phase of active neurogenesis, when its overexpression may 
enhances and prolongs the neurogenesis to generate neurons from progenitors that 
would otherwise give rise to astrocytes.  
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The recent advances of gene therapy promise innovative and revolutionary new 
treatments for neurological disorders. Various methods have been developed for gene 
delivery to target cells. However, gene transfer by viral vectors is thus far the widest used 
approach. In particular, up today the most efficient systems to achieve a long term 
transgene expression is based upon retroviral and lentiviral vectors. Unfortunately both 
these viruses cannot be designed for clinical applications since their infections result in 
insertion of viral DNA into the host chromosomes at an unpredictable position, a 
dangerous event which can seriously disturbs cellular genes functions potentially leading 
to cancer transformation of infected cells. It is then important to set up novel tools to 
safely deliver genes. Herpes simplex virus-1 (HSV-1) offers unique features that support 
its development as a great candidate viral vector especially for targeting the nervous 
system: it is a highly infectious, naturally neurotropic virus able to establish life-long 
latency in neurons, along with the largest capacity for exogenous DNA cloning. 
Moreover, it doesn’t integrate into the host genome, avoiding any possibility of insertional 
activation or inactivation of cellular genes. However, some technical problems still need 
to be overcome, such as the efficient delivery of the vector to target cells, the 
maintenance and control of foreign gene expression, and the control of unwanted host 
immune responses.  
This thesis describes the development of a highly efficient method for in vitro and in vivo 
targeting of the Lhx2 gene using novel replication-defective herpes simplex viral vectors, 
named JΔβββ4 and JΔΝΙ, opportunely engineered to reduce the innate toxicity of the 
virus and to allow a good expression of the transgene. HSV-mediated delivery of Lhx2 
resulted in highly effective gene overexpression in several cell types in vitro, including 
mouse neuronal and non-neuronal cells, along with reduced or null toxicity and a 
differential transgene expression, depending on the viral backbones. These vectors have 
been additionally tested in vivo by injection into the hippocampus of naïve rats and of rat 
models of epilepsy. Ex vivo analyses of injected brains showed good infection pattern 
from both viruses along with no evident toxicity. Moreover, the hippocampal delivery of 
Lhx2 by JΔβββ4-based vector was associated with reductions of both astrocyte density 
and recurring seizures, giving rise to more favorable pathologic features and improved 
outcomes. Put together, we can finally assess that both the JΔβββ4 and JΔΝΙ-based 
vectors could represent useful tools for differential purposes: while for in vitro applications 
the JΔΝΙ vector is the best compromise between transgene expression and low toxicity 
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effects, for in vivo gene transfer it result almost ineffective. On the other hand, the 
JΔβββ4 vector displayed an opposite behavior, too toxic for in vitro approaches but much 
more effective for gene delivery in vivo. 
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1. INTRODUCTION 
 
 
1.1 EPILEPSY 
 
1.1.1 Historical overview 
Epilepsy is a medical disorder old as human existence; few diseases have generated 
same interests and controversies as epilepsy. 
The term epilepsy derives from the Greek verb epilambanem, meaning "to take hold on 
or to seize upon." The astonishing manifestation of the epileptic seizures inspired in 
people of prehistoric civilizations the belief of a supernatural punishing event. 
Hippocrates, the Father of Medicine, made the first historical records of epilepsy in the 
fifth century BC referring to epilepsy as the “Sacred Disease”, an attack from demons. 
Later in the fifteenth century AD, it was believed to be a sign of witchcraft. It wasn't until 
the late nineteenth century when pioneering studies on human brain showed the true 
nature of epilepsy as a disease of the central nervous system, which could be identified 
by electroencephalography (Hughlings-Jackson, 1888; Berger, 1929). 
 
1.1.2 Epidemiology 
Epilepsy is the commonest neurological condition that affects people of all ages, race 
and social class. It is estimated that about 1% of the world’s population is affected by 
epilepsy and up to 5% may experience just a single unprovoked seizure (Adelöw et al., 
2009). Across all ages worldwide, the incidence is approximately 50-100000/year in 
developed countries and 100-200000/year in developing countries (Theodore et al., 
2006; Ngugi et al., 2010) 
Incidence and prevalence studies are critical to provide measures of frequency and 
therefore the burden of disease, and allow for proper planning of services. 
The epidemiology of epilepsy is subjected to several factors that vary worldwide as age, 
sex, comorbidities, overall health, etc.  The age distribution of the incidence of epileptic 
seizures follows a bimodal trend, showing two peaks of frequency in childhood and 
seniority.  
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1.1.3 Etiology 
It is a common misconception that epilepsy is a single homogeneous disease. In reality, 
epilepsies are highly heterogeneous disorders that can be categorized on the basis of 
several differentiating factors. Not even the origin of the disease is unique, since it may 
be acquired or inherent, pediatric or adult onset. There are many possible causes of 
epilepsy. The etiology of this syndrome is complex, arising from the contribution of 
multiple genetic and non-genetic factors. It is commonly accepted that epilepsy results 
from an abnormality in brain wiring and neurotransmitter imbalance. This atypical wiring 
can result from known brain pathology, traumatic brain injury, brain infections, prolonged 
febrile seizures, brain tumors, genetic propensity, neural developmental disorders or 
recreational drugs.  
The International League Against Epilepsy (ILAE) has also classified epilepsies by 
etiology in: 
-Familial epilepsies: inherited, these are identified in large families with an epileptic trait 
segregating in the absence of environmental factors. 
-Idiopathic: usually age-dependent, these have a genetic or presumed genetic origin and 
do not involve underlying structural brain lesions or other signs of neurologic dysfunction. 
About 500 genes have been estimated to play a role in disease development, either by 
directly altering protein production or by increasing one’s resistance to pharmacological 
treatments.  
-Symptomatic: caused by a specific systemic or environmental factor, without particular 
neuroanatomic abnormalities. 
Additionally, we can include the “Cryptogenic” epilepsies, or rather those without any well 
identified origin. Even if the number of such cases is diminishing, this category still counts 
about 40% of adult-onset cases of epilepsy. 
 
1.1.4 Definition 
The wide heterogeneity of clinical features regarding epileptic syndromes makes 
particularly complex to draw up any classification. 
Today is well known that epilepsy is not one condition, but a diverse family of disorders 
occurring when the electrical signals in the brain are disrupted, leading to changes in 
neuronal activity that give rise to seizures. This medical condition has always been 
controversial, even regarding its definition.  
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Several classifications have been proposed since 1970 but any attempts to get a 
consensus failed until 1997, when the ILAE and the International Bureau for Epilepsy 
(IBE) defined epilepsy as “a disorder of the brain characterized by an enduring 
predisposition to generate epileptic seizures and by neurobiological, cognitive, 
psychological and social consequences. The definition of epilepsy requires also the 
occurrence of at least one epileptic seizure” defined as “a transient occurrence of signs 
and symptoms due to abnormal, excessive or synchronous neuronal activity in brain” 
(Fisher et al., 2005). 
Epilepsy occurs when electrical signals in the brain are disrupted, leading to changes in 
neuronal activity (neurons may fire up to 6 times as fast as the normal rate of about 80 
times a second) that give rise to seizures. A seizure is a synchronized paroxymal event 
caused by an excessive electrical discharge of central nervous system neurons 
(Lowenstein et al. 2004), which can cause brief changes in sensations, emotions and 
behavior and, in worst cases, convulsions, muscle spams and loss of consciousness. 
Seizures can also be classified grounding on the evoked physical manifestations, which 
can range from wild swinging movements of arms and legs (tonic-clonic seizures) to brief 
losses of awareness appearing as staring spells (absence seizure) and from to the 
spatial extent of the brain involved at clinical onset: when localized within the brain at the 
onset of the seizure they are referred to as focal or partial seizures and are usually 
named by the origin of the epileptic focus as in temporal lobe epilepsy, while those that 
appear to involve the entire brain at once are called generalized seizures. Finally, 
seizures can be differentiated based on whether the patient loses consciousness during 
the seizure event (complex seizure) or not (simple seizure). These categorizations are 
not mutually exclusive, so one will often describe an epilepsy disorder as complex partial 
seizures of the frontal lobe, for instance. In 1997, the ILAE has classified human 
epilepsies by seizure type as self-limited, continuous, or reflex, and as focal or 
generalized (Engel, 2001). Generalized, self-limited seizures are exemplified by tonic-
clonic seizures, which begin with tonic extension of the limbs and trunk, evolve into 
rhythmic movements (clonus) and terminate spontaneously within a few minutes. 
Absence seizures also are generalized and self limited, characterized by brief episodes 
(about 10 sec) of staring and unconsciousness that can occur more than 100 times per  
day (Panayiotopoulos, 1997). In contrast, focal seizures arise from a focal region of one  
cerebral hemisphere, and their manifestations depend on the extension of the brain 
regions involved. Most seizures are self limited, but continuous seizures, also referred as 
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status epilepticus, sometimes occur. Reflex seizures are rare and are evoked by visual 
stimuli, somatosensory stimuli, thinking, reading, or tooth brushing. The precipitating 
stimulus is specific for each patient. 
The human classification scheme can be used to classify seizures in other species, since 
self-limited, generalized tonic-clonic seizures and status epilepticus occur in many 
species.  
 
1.1.5 Treatments and drugs 
Upon diagnosis (EEG monitoring, video monitoring and magnetoencephalogram testing 
is a typical battery of examinations for diagnosis), the first-line treatment of epilepsy is 
pharmacological intervention. To date there is no cure for epilepsy and current treatment 
options only include lifelong drug therapy and, in a number of difficult cases, surgery may 
be necessary. While the overall goal of antiepileptic drugs is to completely eliminate 
seizures, this goal has not yet been achieved. Current antiepileptic drugs (AEDs) aim at 
symptomatically reduce the frequency and the duration of the seizures. Drug treatment of 
epilepsy began as early as 1857 and mainly involved the use of bromides. Phenobarbital 
was also a popular choice for epilepsy patients early in history. Since then, a large 
number of antiepileptic drugs have been developed for the therapy of various forms of 
epilepsy. No one treatment option works for all types of epilepsy disorders and, therefore, 
the preferred drug treatment of choice depends on a number of different factors such as 
the characteristic pharmacokinetic profile of the various AEDs and on the specific 
biochemical malfunction of the patient (Faught and Pollock, 2001). The most common 
antiepileptic drugs are summarized in Table 1. 
 
 
Antiepileptic drugs are divided into a short list of classes according to their mechanisms 
of action (Howland et al., 2005), which aimed to: -­‐ reduce sodium current (i.e. carbamazepine, lamotrigine, phenytoin)   -­‐ reduce excitatory coupling between neurons (i.e. topiramate)  -­‐ increase inhibitory coupling between neurons (i.e. clonazepam, divalproic acid, 
phenobarbital) 
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DRUG 
COMMON 
NAME 
CHEMICAL 
STRUCTURE 
RECEPTOR 
TARGET COMMON SIDE EFFECTS 
Carbamazepine 
 
Na+-channel 
antagonist; 
possible 
glutamatergic 
inhibition 
Diplopia, headache, dizziness, 
nausea, and drug interactions. 
Gabapentin 
 
Na+-channel 
antagonist; 
Ca2+-channel 
antagonist 
Ataxia, somnolence and 
peripheral edema. 
Lamotrigine 
 
Na+-channel 
antagonist 
Headache, nausea, insomnia, 
dizziness and possible severe, life 
threatening, skin rashes. 
Phenobarbital 
 
GABAA 
receptor 
agonist 
Sedation, decreased cognitive 
function. 
Phenytoin 
 
Na+-channel 
antagonist; 
Ca2+-channel 
antagonist 
Sedation, cosmetic changes (gum 
hypertrophy, hirsutism, acne, and 
facial coarsening), drowsiness, 
dysarthria, tremors, cognitive 
difficulties, and ataxia. 
Topiramate 
 
Na+-channel 
antagonist; 
GABAA 
receptor 
agonist 
Anorexia, paresthesias, 
somnolence, impaired 
concentration, confusion, and 
abnormal thinking. 
Valproate 
 
Na+-channel 
antagonist 
Hair loss and major weight gain. 
Rarely it can cause fatal 
hepatotoxicity and teratogenicity 
(neural tube defects). 
  
Table 1: Most common used antiepileptic drugs in clinic. 
 
These AEDs are clearly intended to reduce the abnormal excessive neural activity of 
epileptic patients. Their effects on neural synchrony, however, still remain unclear and 
more than 30% do not respond to current anticonvulsant drugs (Kwan and Brodie, 2000); 
this percentage has remained unchanged for over twenty years despite the discovery of 
several new anti-epileptic medications. 
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This lack of improvement in efficacy can be attributed to the fact that none of the recently 
discovered medications exhibit a novel mechanism of action. The most commonly 
prescribed medications are Carbamazepine, Valproate or Phenytoin.  
When seizures cannot be controlled pharmacologically, surgery is the most considered 
alternative. Three broad categories of epilepsy can be treated successfully with surgery: 
partial seizures, seizures that begin as partial seizures before spreading to the rest of the 
brain and unilateral multifocal epilepsy with infantile hemiplegia (Bleck, 1987). The most 
common type of surgery for epilepsy is removal of a seizure focus (often called 
topectomy or lesionectomy). Usually, the more well defined the seizure focus the better is 
the post-surgical prognosis (Bleck, 1987). Other types of surgery include loboectomy (i.e. 
temporal lobe resection, reportedly having up to 70-90% success rate, Brodie & 
Schachter, 2000), subpial transection (Morrel et al., 1989), callosotomy, severing the 
bundle of neural connections between the right and left cerebral hemispheres, and 
similar procedures involving the anterior and posterior commissures (Brodie & Schacter, 
2000). The most radical surgical procedure to treat epilepsy is hemispherectomy. 
Other treatment strategies of epilepsy include vagus nerve stimulation, transcranial 
magnetic stimulation and biofeedback.  
An additional line of research is currently investigating development of implantable 
devices that can deliver drugs to specific parts of the brain (Pathan at al., 2009). 
Furthermore, researchers are looking into altering certain environmental and life-style 
factors such as diet, which might alleviate seizure disorders (Korsholm & Law, 2013. 
Unfortunately many patients (about 20%) continue to experience seizures even after 
several treatment attempts, highlighting the need of new innovative therapies to improve 
their threatening condition.  
 
1.1.6 Temporal Lobe Epilepsy 
Temporal lobe epilepsy (TLE) is the most common type of epilepsy in adults, and many 
patients continue to be affected by uncontrolled seizures despite treatment with AEDs 
(Engel et al., 1997). This condition is associated with specific structural lesions in the 
hippocampus (which may be surgically resected in medically intractable cases), leading 
to progressive development of spontaneous recurrent seizures (SRS) from the medial or 
lateral temporal lobe (so called Medial temporal lobe epilepsy or Lateral temporal lobe 
epilepsy).  
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Patients with temporal lobe epilepsy have approximately 2 to 30 seizures per month 
(French et al., 1993). These seizures may be partial, complex or generalized (depending 
on the involvement of one or both emispheres) and are unfortunately unpredictable. They 
start with an aura (King, 1977), during which the patient is still conscious, that is a 
visceral sensation of nausea, pressure, “butterflies” and/or epigastric rising, followed by a 
focal motor seizure and loss of consciousness which begins with motor arrest and staring 
and evolves to oral-alimentary automatisms (e.g., lip smacking, chewing, tooth grinding). 
Focal motor seizures sometimes progress to generalized tonic-clonic seizures. The 
mechanisms that terminate seizures and determine whether focal seizures will become 
generalized are still unknown.  
Most patients with temporal lobe epilepsy have a history of brain injury and up to 2/3 of 
them had febrile seizures. Age at time of the injury is quite variable, but it usually 
happens during childhood (Mathern et al., 2002).  Other precipitating injuries include 
head trauma, brain infections or hypoxia/ischemia (Mathern et al., 1995). Not all these 
precipitating events involve seizures at the time: after recovery from the initial 
precipitating injury, patients usually begin a seizure-free latent period, ranging from 
months to years, when aberrant changes in structure and physiology of the brain tissue 
happen before the development of SRS (Mathern, et al., 2002.). After this time, 
spontaneous, recurrent seizures occur, which typically continue throughout life. 
This seizure-free latent period has been matter of great interest. It has been proposed 
that it is attributable to the time necessary for synaptic reorganization to establish a 
sufficient degree of recurrent excitation to surpass the seizure threshold. During the 
latent period, the hippocampus is undoubtedly the brain region mainly affected by unique 
morphological alterations. The most common lesional abnormality observed in patients 
with TLE is the Hippocampal Sclerosis (HS) (Babb and Brown; 1987), consisting in a 
massive loss and widening of the neurons in the hilus of the dentate gyrus and in the 
CA1 and CA3 layers (Engel, 1989; Ben-Ari and Cossart, 2000), and the mossy fiber 
sprouting, that is the aberrant growth of granule cell axons into the inner molecular layer 
of the dentate gyrus (Sutula et al., 1989; Babb et al., 1991; Isokawa et al., 1993). 
Consequently, a prominent hypothesis states that hippocampal neuronal loss and mossy 
fiber sprouting play a critical role in the genesis and progression of TLE (Lothman and 
Bertram, 1993); nevertheless, lesions also may develop in subregions of the amygdala 
and entorhinal cortex (Bernasconi et al., 2003). 
Even though we know which are the morphological changes in patients with TLE, the 
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mechanisms of epileptogenesis are still unknown. Many hypotheses of temporal lobe 
epileptogenesis focus on the hippocampal dentate gyrus, which is thought to serve as a 
seizure-suppressing filter or gate (Lothman et al., 1991): the dentate gyrus displays 
dramatic lesions, such as loss of hilar neurons (Margerison and Corsellis. 1966) including 
excitatory mossy cells (Babb et al., 1984) and inhibitory interneurons (Maglóczk et al., 
2000). Excitatory dentate granule cells survive but their inhibition is dramatically 
worsened due to loss of inhibitory GABAergic interneurons that normally inhibite the 
granule cells making them hyperexcitable and lowering the seizure threshold (Staley and 
Mody. 1992).  
In addition, loss of mossy cells can also give rise to axon sprouting and synaptogenesis, 
inducing an aberrant positive-feedback circuit between dentate granule cells that 
generates seizures (Nadler et al., 1980). Mossy cells are the predominant neurons in the 
hilus and concentrate their glutamatergic axon terminals in the inner molecular layer of 
the dentate gyrus where they form excitatory synaptic contacts with granule cells 
(Wenzel et al., 1997). Since mossy cells are particularly sensitive to a wide range of 
insults (Buckmaster and Schwartzkroin, 1994), when they die their axon terminals 
degeneration leaves the postsynaptic sites vacant on the proximal dendrites of granule 
cells (Nadler et al., 1980), leading to abnormal granule cell axon reorganization (Laurberg 
and Zimmer, 1981). 
Granule cells then ectopically sprout axon collaterals to invade the inner molecular layer, 
forming synapses that fill the empty synaptic sites. Anatomic evidence from patients with 
temporal lobe epilepsy showed that granule cell axons reorganize to form a positive-
feedback circuit (Zhang and Houser. 1999) and the extent of granule cell axon sprouting 
correlates with the extent of hilar neuron loss (Babb, et al., 1991). 
It would be extremely useful to develop methods to block the aberrant reorganization 
after an epileptogenic injury. Currently such treatments do not exist: prescribed epilepsy 
medications are only seizure-suppressing anti-convulsants and not anti-epileptogenic, 
temporarily treating the symptoms by reducing the probability of seizures, but they do not 
permanently block or reverse the development of epilepsy (Temkin, 2001). Creating 
antiepileptogenic treatments is an important goal of epilepsy research. 
 
1.1.7 Animal models of TLE 
Fundamental questions regarding cause and pathogenesis of epilepsy still persist. In 
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spite of the large diffusion, the study of epilepsy cannot be performed on humans for 
disparate reasons, such as ethical issues, unavailability of controls and high costs of 
human research.  Study of brain tissues obtained with surgery or autopsy can be helpful, 
but is limited in quantity, quality, and experimental versatility, and control tissue is 
frequently unavailable. Moreover, since TLE is the most common form of drug-refractory 
epilepsy, studies on human specimens are usually not very informative and consistent 
because the clinical history of the affected patients is never the same and the results 
could be altered by a prolonged pharmacology therapy. The need of animal models to 
pursue in vivo studies that cannot be done in humans is based on the belief that more 
extensive investigations will provide us a deep knowledge of epilepsy, from the basic 
mechanisms underlying the epileptogenesis to the consequences of the seizures. 
Therefore, laboratory animal models are essential to help identify causes of temporal 
lobe epilepsy and translate such findings into better treatments for patients. 
In particular, animal models of seizures or epilepsy serve a variety of purposes, among 
which: 
-Discover novel AEDs.  
-Evaluate the possible specific efficacies of the compound against different types of 
seizures or epilepsy.  
-Use of specific models of AED-resistant seizures to investigate whether the novel drug 
has advantages towards clinically established AEDs for therapy of difficult-to-treat types 
of seizures or epilepsies.  
-Characterize the preclinical efficacy of novel compounds during chronic administration, 
to evaluate for instance whether drug efficacy changes during prolonged treatment and if 
epileptogenesis alters the adverse effect potential of a given drug. 
-Estimate effective plasma concentrations of new AEDs for first clinical trials.  
Since epilepsy is such a complex pathology, the attempts to accurately model all the 
human aspects of every single disease subtype not always succeeded. Hence, some 
experimental approaches can reproduce only some of the manifestation of epilepsy, 
allowing only the investigation on that symptom and not on the whole complex picture of 
a complete model. In any case, this gives the chance to study an aspect of the disease. 
Several animal models have been developed by application of chemical, electrical or 
damaging insults on a healthy brain to recapitulate the changes in human patients with 
TLE. Among them, electrical kindling of the limbic regions, systemic injections of 
convulsants such as kainic acid (KA) or pilocarpine (Pilo), and genetic models in which 
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human ion channel mutations are expressed, or important regulatory genes for 
interneuron development have been knocked out. Febrile seizures and traumatic brain 
injury are additional seizure models that mimic early onset or acquired epilepsy in adult 
rodents. Electrical kindling creates abnormal brain electrical activities directly by 
providing high frequency electrical stimulation of the hippocampus and its afferent 
pathways (Loscher et al., 1998). KA is a glutamatergic neuron agonist and excitotoxic 
that is specific for AMPA/kainate receptors. When injected systemically or focally into the 
brain, it can cause excitotoxicity in the CA3 region (Neema et al., 2005; Carpentino et al., 
2008). While rats subjected to KA-induced SE will develop spontaneous epileptic 
seizures, many strains of mice do not. 
Pilocarpine is a parasympathomimetic alkaloid that binds to M1 muscarinic receptors, 
altering Ca2+ and K+ currents (Segal, 1988). The increased concentration of intracellular 
Ca2+ allows the release of glutamate from presynaptic termini that, in turn, provokes the 
SE. Once activated, seizures are subsequently maintained by activation of NMDA 
receptors. Glutamate promotes the entrance of Na+ and Ca2+ into the cells by interaction 
with on AMPA/KA receptors, removing the Mg2+ which blockades the NMDA receptor. 
Increased Ca2+ concentration into the postsynaptic cells induces excitotoxic effects and 
cell death. The dose of alkaloid necessary to evoke the SE ranges from 300 to 400 
mg/Kg; this treatment evoke powerful limbic seizures by activating cholinergic neurons in 
the entorhinal cortex. Pilocapine induces seizures within the limbic circuit but is not 
directly neurotoxic. However, it has been shown to induce leakiness in the blood-brain 
barrier and the influx of albumin into the brain may be a cause of neuronal degeneration 
and astrogliosis in this model (Marchi et al., 2010). Due to the excessive excitation to the 
dentate gyrus, hilar inhibitory interneurons, whose function is to keep dentate gyrus 
activity under control, degenerate and lead to further excitation of the limbic circuit 
(Baraban et al., 2009). Moreover, after injection of pilocarpine have been detected high 
levels of serum IL-1β, known to cause sudden rapid changes in excitability of both 
inhibitory and excitatory neurons (Plata-Salamán and Ffrench-Mullen, 1992; Yang et al., 
2005). 
Pilocarpine model is considered one of the best models for severe human TLE. After 
administration of Pilo, rodents exhibit stereotypical behaviors that can be categorized into 
6 classes according to Racine scale (Racine, 1972), recently revised (Veliskova et al., 
2006). As schematized, it uses numbers from 1 to 6 to define seizure classes: the first 
three represent partial seizures, the last three the generalized ones. SRSs begin as 
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partial seizures and become secondary generalized (Table 2). 
 
 
     Classes Features  
1 Staring and mouth clonus 
     P
artial 
2 Automatisms 
3 Monolateral forelimb clonus 
4 Bilateral forelimb clonus 
     G
eneralized 
5 Bilateral forelimb clonus with  
rearing and falling 
6 Tonic-clonic seizures 
 
Table 2: Classes of epileptic seizures according to Racine’s scale classification (Racine, 1972) 
 
Some rodents develop prolonged severe seizures, named status epilepticus (SE), 
characterized by continuous head bobbing and body shake. SE can last from 2 hrs to 12 
hrs. Following SE rodents have a latent seizure-free period, in which they then enter 
post-ictal coma, lasting 1-2 days, before showing spontaneous recurrent seizures 
(SRSs). The length of the latent period varies between animals and techniques utilized to 
detect seizures. By using video-EEG monitoring, a study in mice showed that the latent 
period is two weeks on average, spanning from 4 to 42 days after SE (Cavalheiro, 1997). 
A more recent study established the mean latent period in rats between 5 and 17 days, 
averaging one week (Goffin et al., 2007). During the seizure-free phase, brain networks 
rearrangements occur (Pitkänen and Sutula, 2002). Following the latent period, the 
recurrence of seizures become quite regular, usually clustered in a cycle peaking every 
5-8 days or more with an higher frequency during the day (Arida et al., 1999). In 90% of 
the cases, EEG trace is characterized by a cerebral activity that starts from the 
hippocampus and spreads to the neocortex, usually lasting less than 60 seconds 
(Cavalheiro et al., 1991). Despite SE is routinely pharmacologically stopped by 
administration of anticonvulsant drugs such as diazepam and ketamine, only a 
percentage of animals (ranging from 60 to 70%) survive the treatment (Cavalheiro et al., 
1991; Liu et al., 1994). During the very first days following Pilo-induced SE, treated 
animals might experience some occasional, self-limiting generalized seizures for 1-3 
days (Mazzuferi et al., 2010).  
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1.2 NEUROGENESIS AND ASTROGLIOSIS 
 
1.2.1 Neurogenesis 
Neurogenesis is the process that gives rise to functional neurons from precursors. 
Although experimental studies put in evidence for many decades that neurogenesis 
occurs in the adult mammalian brain (Altman, 1962), the concept has become more 
widely accepted only upon introduction of the thymidine analog bromodeoxyuridine 
(BrdU) in these studies (Christie and Cameron, 2006; Gage, 2002). BrdU is incorporated 
into DNA during synthesis in the S-phase of the cell cycle, allowing the identification of 
cells within the cell cycle or their postmitotic progeny. The administration of BrdU, mostly 
conducted in rats or mice, have been extended also to humans, showing evidence of 
ongoing neurogenesis also in the brain of aged subjects (Eriksson et al., 1998). These 
results pointed out the attention on the opportunities offered from the modulation of 
neurogenesis on a clinical perspective view, from the repairing of neuronal loss due to 
aging, pathologies or injuries to the cell fate control of neural progenitors (Kozorovitskiy 
and Gould, 2003).  
Neurogenesis takes place mostly during embryonic and perinatal stages of mammalian 
life. However, new neurons are born throughout life (at least under physiological 
conditions) into restricted two neurogenic regions: the subventricular zone (SVZ) lining 
the lateral ventricles and the subgranular zone of the dentate gyrus (DG) of the 
hippocampus (Gage, 2000). In humans and rodents, the hippocampus is located in the 
temporal lobes. Principal cells are confined to compacted layers called the dentate gyrus, 
composed of granule cells, and the CA regions composed of pyramidal neurons.  
Even if neural stem cells (NSCs) both originate from SVZ and DG, distinct progenies 
arise from these two niches: cells generated in the SVZ migrate toward the olfactory bulb 
to differentiate into distinct types of olfactory neurons [with the majority being GABAergic 
or dopaminergic neurons and only a few glutamatergic cells (Nissant and Pallotto, 2011)] 
whereas in the DG, newborn neurons don’t migrate long distances and differentiate into 
one neuronal subtype, excitatory glutamatergic granule neurons (Young et al., 2011). It’s 
still unknown if this fate divergence is intrinsically predetermined or is due to external 
signals. Gene expression and protein profiles of NSCs isolated from distinct subregions 
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within the neurogenic areas indicate strong similarities among NSCs within (e.g. isolated 
from dorsal and ventral SVZ) and between neurogenic regions (e.g. comparing SVZ and 
DG). Such profiles could then be compared with the profiles of their progeny at different 
maturation stages. However, this analysis is incomplete because we still lack of reliable 
markers that are specific for different stages of neuronal differentiation; the absence of 
such markers continues to represent one of the major limitations in the field of adult 
neurogenesis (Suhonen et al., 1996).  
To assess the role of extrinsic cues towards fate determination, several studies involving 
transplantation of NSCs from one region into another have been made, showing as 
newborn cells may change their “natural” fate when grafted in a different region, 
indicating a strong influence of extrinsic cues on fate determination (Suhonen et al., 
1996). But these results are controversial since other experiments put in evidence how 
the fate of NSC progeny is critically affected by intrinsic cues (i.e. NSCs isolated along 
the dorsoventral axis of the SVZ generate cells retaining their original site-specific 
behavior even after heterotopic transplantation (Merkle et al., 2007). Certainly additional 
studies are required to analyze the instructive role of the microenvironment and the cell 
autonomous vs. cell non-autonomous determination of NSCs.  
We can distinguish three layers in the dentate gyrus: the molecular layer is the closest to 
the cortex, mainly formed by dendrites and axons; just below there is a structure forming 
a characteristic “U” shaped structure named granule cell layer, formed by the bodies of 
the granule neurons; underneath the granule cell layer lays the hilus, composed of the 
axons of the granule cells and interneurons. Adult newborn neurons of the hippocampus 
develop from stem cells located in the subgranular zone lining the granule cell layer 
(Kriegstein & Alvarez-Buylla, 2009). Here the multipotent neural stem cells undergo 
intermittent cycles of division that originate proliferating precursor cells with a progressive 
limited renewal potential, which then differentiate into various lineages.  
The primary multipotent stem cells of the neurogenic niche, called type 1 cells (or radial 
glia cells), are slowly dividing but they have an unlimited self-renewal capacity and are 
positive for some neural stem cell markers such as Nestin or Sox2 (Seri et al., 2001). 
They project a single process that crosses the granule cell layer and ramifies into the 
molecular layer. Upon division, type 1 cells differentiate into type 2 cells (or non-radial 
precursor cells), which are more proliferative intermediate neuronal progenitor cells with 
only short processes (Suh et al., 2007). We can consider type 2 cells as the transition 
phase between multipotency and lineage specialization. Actually, these cells are further 
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subdivide into type 2a cells, mitotic and multipotent cells which still express some neural 
stem cell markers, and type 2b cells, lineage-committed proliferative neuronal precursors 
which start to express immature neuronal markers (i.e. doublecortin) (Steiner et al., 
2006). Type 2b cells then lead to type 3 cells (or neuroblasts), which also can proliferate 
but don’t express anymore any stem cell markers and give rise to mature neurons 
(Filippov et al., 2003; Fukuda et al., 2003; Kempermann et al., 2004; Zhao et al., 2008). 
Every single stages is finely modulated by signals within the niche: recent experimental 
evidences have enlightened the critical importance of key molecules involved in the 
regulation of neurogenesis both during embryonic development and in adult brain. For 
example, signaling mediated by Bone morphogenetic protein (BMP) and Notch is 
essential to regulate the balance between quiescent and proliferative neural stem cells, 
as well as specific growth factors (i.e. Fibroblast Growth Factors or Brain Derived 
neurotrophic factor) may also play a pivotal role in regulating NSC behavior in the adult 
brain (Palmer et al., 1995; Ables et al., 2010; Lugert et al., 2010; Mira et al., 2010, 
Paradiso et al., 2009). However, the mechanism to which these pathways act together 
and integrate into a common endpoint is still unknown.  
Similar to embryonic and early postnatal development, adult-born neurons are generated 
in excess: about half of them fail to survive and to integrate into pre-existing neural 
networks. The continuous production and elimination of cells in the DG vouch for the 
dynamic ability of the brain to remodel discrete networks throughout the entire lifespan 
(Aasebø et al., 2011). New neurons are specifically selected for integration, a process 
that seems to be activity-dependent (Kempermann et al., 1997; Tashiro et al., 2006). 
However, we still do not know which types of signals are necessary and sufficient to 
enhance the survival and integration of new neurons. Similarly, it remains unclear why 
new neurons show an increased excitability compared with mature neurons.  
In the rat, neurogenesis occurs in the subgranular zone, that lies within the first 50–100 
µm of the granule cell layer, and new neurons are thought to derive from radial glia which 
in turn divide into more differentiated cells that ultimately become dentate gyrus granule 
cells (Seri et al., 2004). Newly born granule cells can functionally integrate into 
hippocampal circuitry (Jessberger and Kempermann, 2003), resembling other granule 
cells both for morphology and for electrophysiological properties (van Praag et al., 2002). 
Even though promising new data show that newborn neurons generated into the DG can 
integrate into the hilus and CA3 region of hippocampus (Toni et al., 2007), further 
experiments will be essential to understand the cellular mechanisms that underlie the 
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function of new neurons in adult brain behavior. 
 
1.2.3 Neurogenesis and epilepsy 
Even though there is to date no proof for the relevance of adult neurogenesis in brain 
diseases, the finding that NSCs persist in the adult brain and constantly generate new 
neurons may represent a novel therapeutic target in a number of neuropsychiatric and 
neurological disorders. Furthermore, NSCs may not only be disease-relevant or a 
therapeutic target in the two neurogenic areas: under certain conditions (such as 
ischemic stroke), it has been shown that new neurons are generated within normally non-
neurogenic areas such as the striatum (Arvidsson et al., 2002).   
The proliferation and integration of newborn cells in adult brain is highly sensitive to 
environmental stimuli (Kempermann et al., 1997) and, in particular, can be strongly 
affected by physiopathological events. For instance, neurogenesis drastically increases 
upon induced epileptic seizures in rodents (Parent et al., 1997; Scharfman et al., 2000). 
However, increasing evidence suggests that aberrant neurogenesis might concur for 
abnormalities both in human and experimental model of TLE, such as mossy fiber 
sprouting, dentate gyrus cells (DGCs) layer dispersion, and the appearance of DGCs in 
ectopic locations or with abnormal hilar basal dendrites (Kron et al., 2010). In contrast, 
other work suggests that newborn DGCs that integrate normally during epileptogenesis 
may serve a compensatory role to restore inhibition (Jakubs et al., 2006). 
Experimental evidences on animal model of epilepsy showed that the most affected 
neural stem cell population by kainic acid-evoked seizures are cell type 1, 2a and 3; the 
administration of proconvulsant drugs wreaks drastic effects on adult neurogenesis and 
on morphology and localization of the newborn cells, with dispersion of granule cell layer 
(Steiner et al., 2008, Jessberger et al., 2005; Parent and Murphy, 2008; Scharfman et al., 
2000, Steiner et al., 2008).   
Interestingly, some attempts addressed to induce neuron production in neocortical areas 
or to reprogram glial cells into neurons have been successful carried out (Magavi et al., 
2000; Heinrich et al., 2010).  
Regarding epilepsy, the increased generation of new functional neurons to replace the 
neuronal loss due to epileptic seizures may exert a therapeutic effect, even though the 
achievement of this goal appears much more difficult than previously anticipated 
(Scharfman, 2004). 
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As discussed before, the dentate gyrus is the primary site in the temporal lobe where the 
majority of neurogenesis is thought to occur in normal adult brain, and the temporal lobe 
is the most epileptogenic region of the brain. The proliferation rate of neuronal progenitor 
cells is not steady but is modifiable by environmental and pathological conditions. In 
particular, neuronal activity exerts a strong influence on proliferation rate: prolonged 
neuronal depolarizations or repetitive discharge significantly increases the neurogenesis 
rate in the dentate gyrus, highlighting the strict relation between seizure activity and 
increased neurogenesis (Bengzon et al., 1997). Indeed, a bilateral increase of 
neurogenesis has been demonstrated in rodents following status epilepticus evoked by 
administration of chemoconvulsivant such as pilocarpine  (Parent et al., 1997) or kainic 
acid (Gray and Sundstrom, 1998), but even after amygdala kindling (Scott et al., 1998) or 
electroconvulsive shock (Madsen et al., 2000). Seizures can also modify the survival of 
new neurons in a severity-dependent manner (Ekdahl et al., 2001).  
 
1.2.4 Astrocytes and epilepsy 
Astrocytes have a prominent role to ensure the central nervous system to work properly 
by regulation of critical transmitter-signaling pathways including c–aminobutyric acid 
(GABA), adenosine, and glutamate through regulation of extracellular neurotransmitter 
levels responsible for fast excitatory and inhibitory signaling in the central nervous 
system. Consequently, these cells have the potential to modulate synaptic transmission, 
neuronal excitability, and the generation of ictal discharges. Failing to maintain the right 
extracellular concentration of these amino acids may results in ruinous effects on 
neuronal survival and functionality (Rothstein et al., 1996). Although it is commonly 
accepted that the main cause of epilepsy is an over-excitation of a brain specific neuronal 
population, the primary involvement of astrocytes in causation of seizure activity 
becomes undeniable. Astrocytosis and microglial activation are indeed well described 
features of temporal lobe epilepsy (TLE), confirmed by several studies that suggest their 
decisive contribution to epileptogenesis (Briellmann et al., 2002; Vessal et al., 2005; 
Kang et al., 2006; Binder et al., 2006). Upon an epileptogenic insult occur, hypertrophied 
astrocytes in the dentate gyrus form an ectopic glial scaffold that promotes the aberrant 
growth of basal dendrites into the hilus (Shapiro et al., 2006). These basal dendrites are 
targeted for synaptogenesis by mossy fibers (Ribak et al., 2000) and contribute to a 
recurrent excitatory circuit that may facilitate seizures (Austin and Buckmaster, 2004). 
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Astrocytes are also involved in metabolism and regulation of neurotransmitter levels. 
Synaptically released glutamate is normally taken up by glial cells and converted in non-
toxic glutamine, essential for neurons as a renewable source of neurotransmitter 
(Meldrum et al., 1999), by glial-specific enzyme glutamine synthetase (Rothstein et al., 
1996). As found in the hippocampus of patients with mesial temporal sclerosis, the 
expression of the astrocyte-specific enzyme glutamine synthetase (GS) is strongly 
decreased, leading to a misregulation of glutamate/glutamine rate. GS converts 
glutamate to glutamine, an essential amino acid supplied to neurons as a renewable 
source of neurotransmitter (such as the chief inhibitory neurotransmitter GABA). Brain-
slice studies showed that selective reactive astrocytosis and the loss of GS leads to a 
reduction of synaptic inhibition (Ortinski et al., 2010), raising the possibility that astrocytes 
can contribute significantly to the genesis of epilepsy. Astrocyte and microglial activation 
are well-described features of temporal lobe epilepsy (TLE), and studies have suggested 
that glial cells may contribute to epileptogenesis (Briellmann et al., 2002; Vessal et al., 
2005; Kang et al., 2006; Binder et al., 2006). Other studies have shown that after 
seizures, hypertrophied astrocytes in the dentate gyrus form an ectopic glial scaffold that 
promotes the aberrant growth of basal dendrites into the hilus (Shapiro et al., 2006). 
These basal dendrites are targeted for synaptogenesis by mossy fibers (Ribak et al., 
2000) and contribute to a recurrent excitatory circuit that may facilitate seizures (Austin 
and Buckmaster, 2004). 
Postmortem studies of patients with temporal lobe epilepsy showed that loss of glutamine 
synthetase is accompanied by reactive astrocytosis with alteration of protein expression 
that eventually leads to a reduced synaptic inhibition and increased spread of excitation 
(Ortinski et al., 2010). When taken together with the observation that astrocytes release 
chemical transmitters, the idea that glial cells might contribute to the generation of 
seizures has got a foothold (Wetherington et al., 2008). There are no unique mechanisms 
for the contribution of astrocytes to epileptogenesis, since they can trigger the neuronal 
hyperactivity in previously normal neurons or just promote the epileptic discharge in 
abnormal neurons or just fail to arrest neuronal hyperactivity (Castiglioni et al., 1990). 
Significant increases of astrocytosis have been detected in several brain foci related with 
seizure generation, leading to the concept that gliotic scar formation is a key feature of 
human epilepsy and, therefore, suggesting a prominent role for glia in epileptogenesis 
(Harris, 1975; Mazzuferri et al., 2010; Bovolenta et al., 2010).  
In addition to exerting inhibitory influences indirectly through the synthesis of neuronal 
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GABA, astrocytes regulate the extracellular concentration of adenosine, a powerful 
endogenous anticonvulsant. An increase in the expression of adenosine kinase, the 
enzyme involved in the conversion of adenosine to AMP, has been registered in 
presence of reactive astrocytes (Boison, 2008); thereupon, a reduction in this 
endogenous anti-seizure is strictly related to reactive astrocytosis. 
Moreover, astrocytes are involved in modulation of neuronal N-methyl-D-aspartate 
(NMDA) receptors expression, contributing to their excitation through the release of 
glutamate and D-serine. Astrocytic Ca2+ signals, which are dampened by some 
anticonvulsants, stimulate the release of glial glutamate, leading to neuronal excitation 
(Tian et al., 2005). Considering the decrease in adenosine- and GABA-dependent 
inhibition that happen during reactive astrocytosis, becomes easy to conceive how these 
events combination might trigger epileptic seizures. 
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1.3 HERPES VIRUSES 
 
1.3.1 Herpersviridae classification 
The Herpesviridae family is a group of enveloped viruses highly dispersed in most animal 
species.  
Members of this family with human tropism are classified in 8 different subtypes:  
Herpes simplex virus Type-1 (HSV-1), Herpes simplex virus type 2 (HSV-2), Varicella 
zoster virus (VZV of HHV-3), Epstein-Barr virus (EBV or HHV-4), Human cytomegalovirus 
(HCMV or HHV-5), Human herpesvirus 6 (HHV-6), Human herpesvirus 7 (HHV-7), 
Human herpesvirus 8 (HHV-8), Kaposi’s sarcoma-associated herpesvirus (KSHV) (P. E. 
Pellett and B. Roizman, 2007). 
All these subtypes share distinct biological properties: firstly, their genomes encode a 
large group of enzymes which participate in nucleic acid metabolism (such as thymidine 
kinase), DNA synthesis (i.e. DNA polymerase and helicase) and protein modification (i.e. 
protein kinase); secondly, viral DNA replication and capsid assembly take place in the 
nucleus, whereas the tegument association and envelope acquisition occur in the 
cytoplasm, as viruses exit the host cell; finally, infectious viruses can either go through a 
lytic lifecycle accompanied by destruction of the host cell or establish a latent state in the 
host cell. The latent genome can be reactivated by various stimuli, entering the lytic life 
cycle and causing disease upon reactivation. Humans are readily infected by these 
viruses and often are positive for five or more of these viruses in their lifetime. On the 
basis of host-cell range, length of replication cycle, cell type where latency is established 
and genomic analysis, Herpesviruses have been classified into three subfamilies: 
Alphaherpesviruses, Betaherpesviruses and Gammaherpesviruses (table 3).  
FAMILY NAME GROWTH CYCLE  AND CYTOPATHOLOGY 
LATENT 
INFECTION 
Alpha-
herpesviruses 
HSV-1 
HSV-2 
VZV 
Short,  
Cytolytic Neurons 
Beta-
herpesviruses 
CMV 
HHV-6 
HHV-7 
Long,  
Cytomegalic Long, 
Lymphoproliferative 
Glands, Kidneys, 
Lymphoid tissue 
Gamma- 
herpesviruses 
EBV 
HHV-8 
Variable, 
Lymphoproliferative Lymphoid tissue 
 
Table 3: Herpesviridiae family classification 
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Members of the Alphaherpesvirus subfamily are characterized by a broad host range, 
relatively short lytic lifecycle, rapid spread in culture, and efficient destruction of infected 
cells. In addition, they encode a similar set of homologous genes arranged in similar 
order and can efficiently invade the peripheral nervous system moving from the infected 
epithelial cells to infect neurons resident in the dorsal root ganglion or cervical ganglion 
via retrograde transport of viral capsids (Frampton et al., 2005). The virus will persists in 
a latent state in the nervous systems of the host for a lifetime where the viral genome 
remains in an epichromosomal state associated with histones without integrating into the 
host genome (Steiner and Kennedy, 1993). 
The Betaherpevirinae have a narrow host range and long replication cycle in infected 
cells. They are able to establish latency in secretory glands, lymphoreticular cells, 
kidneys and other tissues.  
The Gammaherpevirinae generally replicate in lymphoblastoid cells, especially in T or B 
lymphocytes, and also establish latency in lymphoid tissues.  
 
1.3.2 HSV-1 overview 
Viral particles mediate the transfer of the viral genome and accessory proteins from an 
infected host cell through the production of progeny virus or from cell-to-cell spread to a 
noninfected host cell. Since viruses with a DNA genome must find a way to get the DNA 
to the nucleus, viruses use a basic strategy in which the infected cell assists the virus. To 
infect a target cell, a virus particle proceeds through a multistep entry process, tightly 
regulated in time and space. In general, this mechanism occurs via a universal set of 
steps involving attachment, stable binding, and fusion.  
The HSV virion is designed to protect the viral genome from adverse conditions in the 
extracellular environment and to permit cell invasion so that the viral genome can be 
released to the cell nucleus to efficiently express its genes. 
The Herpes Simplex Virus Type-1 virion is composed of four main elements: a linear 
double-stranded DNA encompassed in an electron-opaque core, an icosahedral capsid, 
a large proteinacous space referred as the tegument, and an envelope with glycoprotein 
spikes at the outermost layer of the virion (Fig.1). 
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Fig. 1: Electron microscroscopy picture of HSV-1 virus 
 
1.3.3 HSV-1 DNA genome 
The genome of HSV-1 in a mature virion is a large linear and double stranded DNA (152 
kilo base pair, of which 68% are G/C), and it carries at least 84 protein-encoding open 
reading frames (ORF) organized into a 126 Kb unique long segment (UL) and 26 Kb 
unique short segment (US), tightly packed in a linear form that become circularized after 
the virus reach the nucleus (McGeoch et al., 1988). These regions are flanked by 
inverted repeat sequences, a terminal repeat termed TRL and an internal repeat termed 
IRL  (Perry, 1988) containing sequences required for cleavage and packaging of the 
HSV-1 genome, termed “a” sites (Deiss, 1986).  The US also is flanked by inverted 
repeats termed TRS and IRS (Fig. 2).  
 
 
 
Fig. 2: Schematic representation of HSV-1 genome 
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It has been shown that the L and S units can invert relative to each other and the DNA 
genome produces four linear isomers of equal proportion in infected cells (Hayward et al., 
1975). Moreover, the HSV-1 genome has three lytic origins of replication, two located 
within the US segment  (oriS) and one in the UL segment (oriL). 
The HSV-1 replication is strictly regulated in a sequential manner: three gene classes, 
known as the immediate early genes (α-genes), the early genes (β-genes), and the late 
genes (γ-genes), are coordinately expressed following the transcriptional regulation of 
viral and host cell proteins (Watson et al., 1981). 
The α genes don’t need any viral protein synthesis for their expression but they just 
requires a cis-acting site (alpha TIC; with the consensus  
5'-GyATGnTAATGArATTCyTTGnGGG-3') located in the promoter-regulatory domains of 
the alpha genes; the products of these genes are involved in the transcriptional 
regulation of β- and γ-genes and also can operate a positive and negative feedback 
regulation of α-genes (O’Hare and Hayward, 1985) though the mechanisms regulating 
these processes are not completely understood. 
 
1.3.4 HSV-1 nucleocapsid 
The HSV genome is packed within an icosahedral protein shell, called nucleocapsid or 
simply capsid, which total molecular mass is 0.2 billion daltons. The nucleocapsid 
displays 162 capsomers made up of four viral proteins: VP5, VP26, VP23, and VP19C 
(Zhou et al., 2000). Within the envelope, the nucleocapsid takes up about one third of the 
volume, while the tegument occupies the remaining rest two thirds of the volume. 
Interestingly, the encapsidation and release of viral DNA take place through a portal 
located within the capsid, made up by a dodecamer of the pUL6 protein (Cardone et al. 
2007).  
 
1.3.5 HSV-1 tegument 
The capsid is coated with an amorphous proteinaceous filled space designated as the 
tegument, particularly important since is involved in transcriptional regulation of 
immediate early viral genes and in regulation of host-cell transcription (virion-host-shutoff 
protein) (Dargan et al., 1998). The tegument contains at least 20 viral proteins; some of 
these, such as VP16, are responsible for triggering the viral immediate early gene 
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expression (Campbell et al., 1984). Others contribute to creating a more suitable 
environment for viral replication in infected cells, such the virion-associated host shutoff 
protein (vhs) which degrades cellular mRNA to enhance the efficiency of viral protein 
translation (Kwong and Frenkel, 1989) and the protein encoded by US11, an RNA 
binding protein which inhibits the activation of protein kinase R inducing cellular 
translation arrest in host cells (McKnight et al., 1994). The tegument also includes the 
VP22 protein, that works like a stabilizer for important viral proteins such as gE, gD and 
ICP0 (Duffy et al., 2009) and is involved in viral spread during lytic infection.  
 
1.3.6 HSV-1 envelope 
Through the electron microscope, HSV-1 virions are visualized as pleiomorphic 
membrane-bound particles surrounded by an envelope obtained from the cytoplasmic 
membranes of previously infected cells. the average diameter of a spherical HSV-1 virion 
is 186 nm, which enlarges to 225 nm once spikes on the envelope surface are included. 
The lipid layer of the envelope is seen as a continuous silkily circular surface, around 5 
nm thick (Grunewald et al., 2003).  
The envelope consists of a trilaminar lipid membrane containing multiple viral membrane 
proteins with 9 different glycoproteins embedded on its surface: gB, gC, gD, gE, gG, gH, 
gI, gL and gM.  Among these, only gB, gC, gD, gH, and gL are important for cellular 
attachment, fusion, and internalization of the virus (Cai, et al., 1988). 
About 600-700 glycoprotein spikes have been counted on the surface of the envelope 
(Grunewald K, et al., 2003), non-randomly distributed since they are presented thinly at 
the proximal pole and compactly around the distal pole (Spear et al., 2000). 
 
1.3.7 HSV-1 infection 
HSV-1 enters host cells through a fusion event of the virion envelope with the plasma 
membrane. Fusion activity is triggered by receptor binding at neutral pH, inducing 
irreversible conformational changes that allows for viral fusion (Wittels and Spear, 1991). 
The virus can also spread from cell to cell by inducing the fusion of cellular membranes. 
Viral entry into cells requires at least four viral glycoproteins: gD, gB and the heterodimer 
gH-gL. Initially, gC (WuDunn et al., 1989) and gB (Herold et al., 1994) interact 
independently with glycosaminoglycan (GAG) moieties of cell surface proteoglycans to 
promote the attachment of the virion to the host cell. Following the attachment of the 
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virus to the cell surface, cell entry requires the engagement of glycoprotein gD to any one 
of several entry receptors, to increase the stability of viral attachment and to trigger 
essential fusion events. Interestingly HSV gD can bind to three cellular receptors called 
herpesvirus entry protein A (HveA), nectin-1 (HveC) or 3-O-sulfated heparan sulfate (3-
OS HS) (Montgomery et al., 1996). The binding of gD to nectin-1 induce a conformational 
change in this glycoprotein that enables it to interact with gB and/or the heterodimer gH-
gL (Turner et al., 1998).  
Following the adsorption of HSV-1 to the cell surface, the nucleocapsid is released into 
the cytoplasm along with the surrounding tegument proteins; these can spread into the 
cell in order to modify its environment for viral replication. VP1-2 localizes to the nuclear 
pore along with the capsid, mediating DNA translocation into the nucleus (Jovasevic et 
al., 2008). One of the most studied tegument proteins, VP16, also migrates into the 
nucleus through interaction with a cellular protein HCF-1 (Wysocka and Herr, 2003; 
Hancock et al., 2010). The nucleocapsid migrates towards the nucleus of the host cell 
(Sodeik et al., 1997); this migration rely upon the cellular microtubules and the 
microtubule directed motors dynein and dynactin (Dohner et al., 2002; Sodeik et al., 
1997). HSV-1 genome is subsequently translocated through the capsid portal via the 
nuclear pore complex (Ojala et al., 2000).  
 
1.3.8 IE gene expression  
Before the viral DNA genome reaches the nucleus, it is not associated with any cellular 
histone proteins inside the capsid (Cohen et al., 1980). The viral genome is quickly 
transformed to a circular form once inside the nucleus, where it is deposited with cellular 
nucleosomes. It has been reported that during lytic infection, the chromatinization of 
HSV-1 genome occurred within 3-6h after the infection (Huang et al., 2006). The 
remodelling of viral chromatin by host factors and viral proteins promotes the 
transcription of viral genes. The first class of genes expressed during HSV-1 lytic 
infection are the immediate early genes, named by the initial phase of viral replication. 
The tegument protein VP16 is essential for viral replication since it initiates the IE gene 
expression and turns on viral propagation in host cells, interacting and recruiting some 
transcription factors and chromatin modifiers to the viral immediate early gene promoters. 
VP16 acts through two pathways, recruiting the RNA II polymerase to the IE promoters 
and promoting the active form of viral chromatin. Importantly, VP16 forms a complex with 
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the cellular transcription factor Oct 1 to initiate a cascade of viral gene expression 
(Triezenberg et al., 1988). The IE proteins are the first viral proteins expressed, requiring 
only the virion protein VP16 working in conjunction with the host cell transcriptional 
machinery for their expression. Four of the five IE proteins (ICPO, ICP4, ICP22 and 
ICP27) return to the nucleus after translation and play a role in regulating expression of 
viral and/or cellular genes throughout the course of infection. The fifth IE protein, ICP47, 
blocks antigen presentation and is not known to play a role in virus transcription or 
replication in cell culture. 
 
1.3.9 ICP0  
Infected-cell polypeptide 0 (ICP0) is a RING finger E3 ubiquitin ligase involved in 
inhibiting the host antiviral system, promoting the viral replication and reactivation of 
latency. ICP0 is a 100 kDa protein encoded by the gene α0 located in the inverted repeat 
sequences flanking the unique long sequence of the viral genome (Hagglund and 
Roizman, 2004). ICP0 is extensively processed after translation: it gets phosphorylated 
and nucleotidylylated by viral kinases (Blaho et al., 1993). ICP0’s mechanism of action is 
still not well known, but several studies have shown that it works as a transcriptional 
activator of HSV mRNA synthesis, potentiating the function of ICP4 (Gelman et al., 
1986): combinations of ICP0 and ICP4 are 20-fold more potent at driving mRNA 
synthesis than either ICP0 or ICP4 alone (Gelman, 1986). In addition, ICP0 is essential 
for viral escape to the innate interferon response (Leib et al., 1999) and, due to its 
nuclear localization signal (NLS) domain and its E3 ubiquitin ligase, ICP0 localizes to the 
nucleus early during viral replication accumulating initially at or near pro-myelocytic 
leukemia (PML) nuclear bodies, leading to their dispersion at early phase of infection and 
cotributing to the formation of adjacent, sub-nuclear replication compartments (Maul et 
al., 1996). Recent data have implicated ICP0 in dissociating class II histone deacetylases 
(HDACs) from their target genes, providing a further mechanism for ICPO-mediated 
transcriptional regulation (Poon et al., 2006). As the amount of protein increases, ICP0 
spreads out and fills the nucleus. After viral DNA synthesis, ICP0 is found in the 
cytoplasm (Kawaguchi et al., 1997; Lopez et al., 2001). Late after infection, ICP0 seems 
to shuttle between the nucleus and cytoplasm, and it may linger in the nucleus rather 
than reside in the cytoplasm. Although ICP0 is not essential for viral replication in host 
cells, the ICP0-deletion mutant virus results in a 10-100 fold decrease in viral titer 
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compared to the wild type at low multiplicity of infection in the same cell line since 
synthesis of ICP0 causes drive HSV towards productive replication whereas absence of 
ICP0 produces the opposite effect. Synthesis of ICP0 is sufficient to trigger HSV 
reactivation in trigeminal ganglion neurons and other models of latent HSV infection 
(Harris et al., 1989). 
 
1.3.10 ICP4 
ICP4 is the major transcriptional transactivator of HSV-1, and is required for all post-IE 
gene expression (Dixon and Schaffer, 1980). ICP4 of HSV-1 is a large protein with a 
molecular mass of 175 kDa. ICP4 is uncoded by the two copies of the α4 gene, located in 
the inverted repeat region flanking the short segment (Us) of HSV-1 genome and has 
several functional domains, including the DNA-binding domain, at least one transcription 
activation domain, a dimerization domain, and a nuclear localization signal (Roizman et 
al, 2001). During IE infection, ICP4 is localized to the nucleus, where it exists as 
homodimer, and is immediately recruited to the viral genome (Everett et al., 2004). Later 
during viral DNA replication, ICP4 is found in the replication compartments inside the 
nucleus.  
The structure of ICP4 consists of a DNA binding domain, a nuclear localization domain 
and two transactivation regions (Carrozza and DeLuca, 1996). ICP4 physically interacts 
with host transcriptional factors, such as TATA-binding protein, TFIIB, TFIID, and 
TAF250. These interactions are believed to be crucial for the ability of ICP4 to induce 
viral genes, inducing the transcription from promoters that minimally contain the 
recognizable cis-acting element of ICP4 (Shapira et al., 1987) and functioning as a 
regulatory protein for the activation of E and L gene expression and repressing IE gene 
expression.  ICP4 is necessary for viral growth since it is essential for the transcription of 
viral early and late genes (Watson and Clements, 1980).  
ICP4 increase the transcription of viral genes during viral infection and enhance the 
formation and the activation of transcription initiation complexes with a relatively simple 
set of general transcription factors (Carrozza and DeLuca, 1996). However, it is still not 
well known how ICP4 affects the formation of transcription initiation complexes. 
 
1.3.11 ICP22 
ICP22 is a 68 kDa protein, encoded by the α22 gene in the unique short region of the 
	   35	  
viral genome, containing two nuclear localization signals within its structure (Stelz et al., 
2002).  Although the exact mechanism of repression remains unclear, ICP22 which may 
have multiple functions in viral proliferation but the most important is the transcriptional 
regulation of cellular and viral mRNAs which mediates changes on the host RNA 
polymerase II. This results in the inhibition of the transcription of many cellular and viral 
gene that precedes an increased expression of some late proteins (e.g. USll, UL38 and 
UL41) and the destabilization of host cell cycle proteins (e.g. cyclins A and B), leading to 
cell cycle deregulation and reducing the antiviral response (Orlando et al., 2006).  
 
1.3.12 ICP27 
The fourth IE regulatory protein is ICP27, expressed from the UL54 open-reading frame 
of the UL of HSV. ICP27 is a regulatory phosphoprotein which has a predicted molecular 
mass of 55kDa that becomes 63 after post-transcriptional modifications (Smith et al., 
2005). Like ICP4, ICP27 is required for the productive cycle and activates E and L gene 
expression (Uprichard and Knipe, 1996). ICP27 has been reported to play a number of 
roles in the regulation of gene expression, including stabilizing mRNA, disrupting 
spliceosomes and inhibiting splicing, and transporting viral mRNAs to the cytoplasm 
(Bryant et al., 2001). It has also been shown to shuttle between the nucleus and 
cytoplasm and to bind to RNA lending support to the proposed role for ICP27 in mRNA 
export (Soliman et al., 1997). At early times post-infection, ICP27 is detected diffusely 
throughout the nucleus but it then moves to replication compartments (Mears and Rice 
1998).  
 
1.3.13 ICP47 
ICP47 is the only IE gene that has not been shown to play a role in regulating viral and/or 
cellular gene expression. This 9 kDa protein instead plays a role in modulating the host 
immune response to infection by blocking translocation of antigenic peptides into the 
endoplasmic reticulum (Fruh et al., 1995). ICP47 binds specifically to transporters 
associated with antigen processing (TAP), blocking peptide-binding and translocation by 
TAP as well as subsequent loading of peptides onto MHC class I molecules in the 
endoplasmic reticulum. Therefore, infected cells are masked for immune recognition by 
cytotoxic T-lymphocytes (Ahn et al., 1996). ICP47 is not essential in tissue culture, but is 
essential for neuroinvasiveness in vivo (Burgos et al., 2006). 
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1.3.14 Virus egress 
Two main models have been proposed to explain the egress newborn virion from the cell, 
as it is still unclear how this process occurs. In one model, the enveloped particle fuses 
with the outer nuclear membrane, thus releasing the capsid into the cytoplasm. The 
capsid then buds into the secretory pathway via the Golgi network, where it reacquires an 
envelope and the associated glycoproteins. Evidence for this model comes from electron 
microscopy studies that have shown the clear presence of non-enveloped capsids in the 
cytoplasm (Siminoff and Menefee, 1966). However, it is not known if these capsids 
eventually exit the cell, or if they are an aberration. A most recent model proposes that, 
upon exiting the nuclear membrane, the virion acquires a second envelope. This second 
envelope is lost upon fusion and release into the secretory pathway (Enquist et al., 
1998). From that point on, the two models are similar, with the virion released from a 
secretory vesicle into the extracellular space. 
 
1.3.15 Latency 
Up today, the exact mechanisms of HSV-1 latency are not yet completely understood. 
During a latent infection the virus is in a relative quiescent state where the transcription is 
limited to a single region of the viral genome and only a group of latency-specific RNAs 
are detectable in the nuclei of neuronal infected cells. Only one region of the viral 
genome, known as the LAT locus, is actively transcribed during latency, due to the 
presence of a latency-associated promoter (LAP) that remains active during this phase of 
the infection, resulting in the synthesis of non-messenger RNA molecules of unknown 
function (the latency-associated transcripts, or LATs), which accumulates in the nucleus 
of the latently infected neurons (Farrell et al., 1991). Very recently, the LAT locus has 
been shown to express miRNA molecules that can downregulate expression of lytic viral 
genes (Umbach, et al., 2008). The mechanism of reactivation is still uncertain, although 
several models of reactivation are proposed: the causes of viral reactivation usually result 
from some stimulus that can be linked to stress (physical of psychological) trauma, 
pneumococcal or meningococcal infection, UV irradiation, fever, hormonal changes or 
other unknown causes.  
Upon reactivation, virus travels via anterograde transport from the infected neurons back 
to the epithelium that is innervated by the nerve endings. This is usually the site of 
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primary infection such as the lip or can be to other innervated areas such as the eye. 
This reactivation could lead to the formation of an ulcer caused by the cell to cell spread 
and replication of the virus. This, while relatively benign on most areas of the face, can 
have serious consequences in the eye.  In rare cases virus can move from the peripheral 
nervous system to the central nervous system resulting in encephalitis, meningitis and 
bells palsy all of which, if left untreated, can result in death of the patient. Fortunately this 
rarely occurs and the factors that predispose a person to encephalitis are not known. 
Thus, two of the most important cellular targets in HSV disease are epithelial cells of the 
mucosa (replication and spread), and neurons (for latent infections). 
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1.4 GENE THERAPY 
 
1.4.1 Overview 
Loosely defined, gene therapy is the transfer of genetic material either from a virus, 
naked DNA or RNA, or liposomes to specific cells in order to intercede in cell fate control 
(i.e. restoring protein production that is absent or deficient due to a genetic disorder) and 
to treat a certain disease state.  
With the advent of the human genome project and recent advances in stem cell 
technology, this fairly new field is destined to become the best bet for new treatments of 
life threatening diseases, after the residual technical problems will be overcome. For a 
successful gene therapy is necessary to have a suitable disease model, specificity of 
gene delivery, efficient gene transduction, and limited or null toxicity. The biggest limiting 
step for these criteria is the effective targeting of specific affected cells within a myriad of 
cellular receptors while avoiding or minimizing toxic effects to normal tissue. Recent 
efforts have shown that retargeting of viral vectors is possible through genetic 
modification of the nucleocapsid and glycoprotein coat of different viruses mainly for 
cancer therapy (Kritz et al., 2007; Morizono et al., 2005; Uchida et al., 2012). Removal of 
toxicity is commonly achieved by the deletion or the modification of essential viral gene 
functions (Bozac et al., 2006, Hong et al., 2006). 
Once these processes have been optimized for efficient large-scale manufacture the full 
potential of gene therapy can be realized.  
 
1.4.2 Vectors for gene therapy 
Gene transduction is the process of expressing an ectopic gene in specific cells. The 
vector has the role in delivery of the genetic payload to the target tissue and, also, to 
protect it from degradation mediated by host immune surveillance. Vector mediated gene 
transfer can be carried out by one of two ways either viral or non-viral.  
Most non-viral methods are composed of synthetic carriers such as liposomes, 
polyplexes, nanoparticles, or alternatively naked DNA injection.  
Viruses are naturally derived vehicles that offer the advantage of tissue tropism as well 
as large genetic payload.  
Interesting pre-clinical and clinical studies has shown the potential of genetic therapies 
(Kohn et al., 2003, Cavazzana-Calvo and Fischer, 2007): encouraging results came from 
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clinical trials for the treatment of monogenetic diseases (Bainbridge et al., 2008; Aiuti et 
al., 2009). However, recent studies have shown that other avenues can be explored such 
as chronic pain, bone regeneration, oxidative injury and cancer therapy (Atencio et al., 
2004, Heavner et al., 2007). 
Gene transduction is the process of expressing an ectopic gene in specific cells. The 
vector has to deliver the genetic payload to the target tissue and, also, to protect it from 
degradation mediated by host immune surveillance. Although the basic principle of gene 
therapy is quite simple, successes rely considerably on the development of the gene 
transfer vectors. Over the years, a number of gene transfer vehicles have been 
developed that can roughly be divided into two categories: non-viral and virus-based 
gene delivery systems. Most non-viral gene delivery systems depend on direct delivery of 
genetic information into a target cell and include direct injection of naked DNA or 
encapsulation of DNA with liposomes, polyplexes or nanoparticles. Although these 
delivery systems exhibit low toxicity, gene transfer in general is inefficient and often 
transient (Huebner et al., 1999). Non-viral vectors are promising, but still big challenges 
regarding gene-transfer efficiency need to be engaged (Boulaiz, H., 2005; Rolland, 
2006). For this reason, development of gene therapy elicited greater progresses during 
last years especially using viral vectors, which have been the first choice for clinical trials 
(Edelstein et al. 2004).  
Viral vectors make it possible to dramatically improve the transfer efficiency and to 
control the number of recombinant DNA molecules introduced in the genome of a 
transgenic cell.  
This explains why viruses have had to consistently develop into efficient vehicles for 
gene transfer. Gene therapy based on viruses shows great promises for both basic 
research and therapeutic applications and has been the focus of many institutions and 
each vector system has their own intrinsic limitations and advantages. Several groups all 
over the world are making huge efforts to improve at the best the features of candidate 
virus to get the perfect vector. 
It is important to choose the best vector for each specific application. Several factors 
must be considered when making this decision such as the route of delivery, the duration 
of gene expression, the viral tropism and its toxicity. 
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1.4.3 Retroviruses & Lentiviruses 
Retroviruses are one of the main tool of current gene therapy approaches. Following 
entry into the cell, the viral RNA is reverse transcribed into linear double-stranded DNA 
and transported to the nucleus, where it becomes integrated into the host genome. In 
retroviral/lentiviral vectors, essential viral genes are replaced by the gene of interest, 
which is flanked by the virus long terminal repeats (LTR) and packaging signal. Vector 
production utilises packaging cell lines that express the deleted viral genes from separate 
plasmids to minimise the possibility of generating replication-competent virus through 
recombination. Retroviral vectors derived from Moloney murine leukemia virus (MoMLV) 
have limited applications as delivery vectors to the nervous system, due to their inability 
to deliver genes to non-dividing cells and thus, post-mitotic neurons. They have, 
however, been extensively used for ex vivo transplantation strategies and delivery to 
neural precursors.  
The majority of retroviral vectors are based on the betaretrovirus Moloney murine 
leukemia virus (MoMLV). The MoMLV genome encodes for three essential genes: gag, 
pol, and env. The env gene is required to produce transmembrane subunits for the 
binding to cell surface receptors of the target cell. Once inside the cell, the viral RNA is 
reverse transcribed into linear double-stranded DNA by the pol gene and subsequently 
transported to the nucleus for integration into the host genome. All that is required for 
viral replication are the 3’ end and 5’ LTRs, which contain the sites of DNA transcription 
initiation and polyadenylation. These sites are essential for production of progeny viral 
genomes and viral mRNA. A packaging signal termed psi is also located near the 5’ 
repeat sequence which directs incorporation of viral DNA into the capsid. As the viral 
DNA is packaged, the gag gene directly binds to the viral RNA to promote packaging into 
the virion.  
Retroviral vectors can either be replication-competent or replication-defective. In 
retroviral replication-defective vectors, the three essential genes just described above are 
deleted and replaced by the gene of interest, which is flanked by LTRs and packaging 
signal.  These viruses are capable of infecting their target cells and delivering their viral 
payload, but then fail to continue the typical lytic pathway that leads to cell lysis and 
death. In this case, for retroviral-vector production are needed packaging cell lines that 
express the deleted viral genes from separate plasmids to minimize the possibility of 
generating replication-competent virus through recombination: typically the propagation 
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take place in murine based cell lines that provide the missing essential genes in trans. 
These cell lines have been developed to complement for env, gag, and pol genes on 
separate plasmids to reduce the possibility of generating replication competent retroviral 
vectors (Markowitz et al., 1988).  
The primary limitation to the development of this system for gene therapy involves the 
requirement of actively dividing cells for transduction: systems based on simple 
retroviruses cannot deliver genes to quiescent cells because a complex of a retrovirus 
provirus with internal viral proteins is incapable of entering the cell nucleus with the intact 
cell membrane. Hence, infection of quiescent cells with simple retroviruses is aberrant 
and does not lead to provirus integration in the genome of an infected cell. As a result, 
non-dividing cells such as neurons are very resistant to infection and transduction by 
retroviruses. The main drawback to this system of gene transfer is the issue of insertional 
mutagenesis due to integration into the host genome might lead to cancer or leukemia 
(Herzog and Arruda, 2003). Despites these limitations, retrovirus-based systems are now 
most widely used to deliver various genes to higher animal and human cells in vitro and 
in vivo, since their stable integration in the infected cell genome can achieve high 
efficiency of transduction and long-term expression. In addition, they have been used in a 
number of FDA-approved clinical trials (Cavazzana-Calvo, et al., 2000). 
Compared to retroviruses, lentiviral-based vectors have the big advantage to produce 
long-term transgene expression by integration into the genome of both dividing and non-
dividing cells, including neurons and induce a minimal inflammatory response when 
introduced into the brain (Brooks et al., 2002). However, the use of these vectors don’t 
reduce the risk of insertional mutagenesis by activation of cellular proto-oncogenes, even 
though this risk is lower for neurons then glial cells, which retain a mitotic competence. 
The viral safety could be increased by directing integration to specific target sites through 
the use of viral integrase fused with a sequence-specific DNA-binding protein (Tan et al., 
2004) or through the use of integration-defective LV vectors (Saenz et al., 2004). The 
complex genome and replication cycle of lentiviruses have made the development of 
vectors and stable packaging cell lines difficult. Moreover, the restricted host range, low 
titres and pathogenic characteristics of HIV-1 have limited its use. 
 
1.4.4 Adenovirus 
Adenoviruses are the largest non-enveloped icosohedral viruses containing double-
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stranded DNA that causes endemic and epidemic respiratory and intestinal infections in 
humans. The virions bind to the coxsackie-adenovirus receptor and integrins on the 
plasma membrane and enter the cell by receptor-mediated endocytosis (Harrison, 2010). 
The acidification of the endosome allow the nucleocapsid release into the cytoplasm and 
the linear DNA enters the nucleus through the nuclear pore, where it remains in an 
episomal form. The adenoviral genome is a linear, double-stranded DNA (dsDNA), 
varying from 26 to 40 kb in length, depending on the subtype. (Campos and Barry, 2007). 
This linear form is organized into a compact, nucleosome-like structure within the viral 
capsid and is known to have inverted terminal repeat (ITR) sequences (103 base pairs in 
length) on each end of the strand (Douglas, 2007). The viral genome has two major 
transcription regions, termed the early region and the late region, and two inverted 
terminal repeats at both end of the strand. Gene expression proceeds in a cascade 
fashion, with activation of early genes followed by the onset of viral DNA replication and 
subsequently expression of late genes, leading to the production of infectious viral 
particles.  
Adenoviruses, in particular Human adenovirus serotypes 5 (Ad5), have been attractive 
candidate for use as a vector in basic studies and gene therapy (Morgan and Anderson, 
1993; Crystal, 1995), since their genome is relatively easy to manipulate by recombinant 
DNA techniques, the viral particle is fairly stable and they can be grown to high titer 
(Kanegae et al., 1994). Moreover, they have a broad host range and a variety of different 
cell-type specificity, independently from cell division. As opposed to lentiviruses, 
adenoviral DNA does not integrate into the genome and is not replicated during cell 
division. This is a double-edged sword, since it limits their use just for transient 
expression assays, although adenoviral vectors are occasionally used in in vitro 
experiments. Adenoviruses are able to host moderate DNA inserts (up to 8 kb) but some 
viral proteins are expressed after administration into the host and, being one of the most 
common human pathogen, in vivo delivery may be hampered by prior host immune 
response. 
 
1.4.5 HSV-based vectors 
Due to their permissive characteristics, HSV-1, HCMV and EBV are the mostly chosen 
herpes virus subtypes for the production gene delivery vectors. However, the ability to 
infect a broad host range, the natural neuronal tropism and especially the wide 
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knowledge of its biology have made HSV-1 the first choice for the development of new 
HSV-based viral vectors. 
As mentioned before, we can distinguish two serotypes of HSV, HSV-1 and HSV-2. 
Lesions caused by HSV-1 strains cannot be distinguished from those caused by HSV-2 
but there are distinct genetic and biological differences between members of the two 
serotypes. For example, although both HSV-1 and HSV-2 can infect either oral or genital 
sites, HSV-1 is more likely to reactivate frequently from oral sites and HSV-2 is more 
likely to reactivate from genital sites (Lafferty et al., 1987). The most common 
manifestations of HSV infection are mucocutaneous lesions, commonly called cold sores 
or fever blisters if they occur on or near the lips.  
One advantage of using HSV-1 as viral vector is the availability of several animal models 
that support HSV-1 infection and latency include the mouse, rat, hamster, guinea pig, 
rabbit, dog, and cat.  
A variety of HSV-1 vectors have been developed for use as gene transfer vehicles. The 
main differences are in the number of genes mutated or deleted in the host strain.  
 
1.4.6 Wild-type HSV-1 vectors 
Wild-type HSV-1 induces encephalitis at very low titers when injected intracranially. Thus, 
these vectors are unlikely to be useful for direct intracranial injection. One potential use of 
vectors based upon wild-type strains is that they are transported to the central nervous 
tissues when injected peripherally (Deshmane et al., 1995), similar to a natural infection.  
However, since attenuated HSV-1 strains can also reach the nervous system after 
peripheral injection (Coffin et al., 1996; Marshall et al., 2000; Perez et al., 2004), it is not 
likely that vectors based upon wildtype strains will be suitable for in vivo applications. 
Some non-neurotropic viral vectors can be transported to the CNS after peripheral 
inoculation, but the efficiency compared to HSV-1 has not been examined (Azzouz et al., 
2004; Wong et al., 2004). 
 
1.4.7 Replication defective vectors 
Expression of viral genes is generally toxic to cells, as the central purpose of viral gene 
expression is to redirect cellular activities towards replication of the virus. This applies to 
HSV-1 (Lilley et al., 2001). For example, the function of the HSV-1 vhs gene is to prevent 
expression of host genes (Smiley, 2004), which has an obvious negative effect on an 
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infected cell. This has obvious effects on the health of an infected cell. 
However, an ideal gene transfer vector will not be cytotoxic. Thus, studies have been 
carried out to determine the most effective way to prevent viral gene expression in order 
to limit toxicity. The herpesviruses share a common mode of control of gene expression 
where genes are expression in a temporal order. 
Immediate-early genes are the first to be expressed and one of their primary functions is 
to transactivate expression of other genes. Thus, one strategy to block expression of 
most viral genes is to mutate these genes, thus preventing the transactivation of all other 
genes (Glorioso and Fink, 2004). 
Each of the five immediate-early genes (ICP 0, ICP 4, ICP 22, ICP 27, ICP 47) has been 
mutated in the various HSV -1 vector strains created to date (Chiocca et al., 1990; Goins 
et al., 2001; Howard et al., 1998; Huard et al., 1997; Krisky et al., 1998; Lilley et al., 
2001). One or more immediate early genes are usually deleted. The immediate-early 
genes are either essential for replication in vitro, or their deletion can result in lower titers 
(the exception being ICP47, which is only required for in vivo replication). In order to be 
able to produce these vectors, complementing cell lines have been created in order to 
provide the necessary viral genes in trans.  
 
1.4.8 Replication defective vectors 
Viral gene expression is generally toxic to cells, since the virus aims at redirect cellular 
activities towards its own replication preventing the expression of essential genes of the 
infected cells (Smiley, 2004). 
However, an ideal gene transfer vector must not be cytotoxic. Thus, studies have been 
carried out to determine the most effective way to prevent viral gene expression in order 
to limit toxicity.  
Gene expression in HSV is activated in a specific temporal order (Honess and Roizman, 
1974). Since immediate-early genes are the first to be expressed and one of their primary 
functions is to transactivate expression of other genes, their inhibition could be the best 
way to prevent the transactivation of all other genes (Glorioso and Fink, 2004). 
Each of the five immediate-early genes has been deleted or mutated in the various HSV -
1 vector strains created to date (Chiocca et al., 1990; Dobson et al., 1990; Goins et al., 
2001; Howard et al., 1998; Huard et al., 1997; Krisky et al., 1998; Lilley et al., 2001; 
Puskovic et al., 2004). The deletion of these genes make the virus unable to replicate in 
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vitro in “regular” cell lines. To overcome this problem, complementing cell lines have 
been created in order to provide the necessary viral genes in trans making possible to 
get viral titers comparable to wild-type or replication attenuated vectors (DeLuca et al., 
1985; Samaniego et al., 1995; Marconi et al., 1996). The deletion of viral genes make 
possible the insertion of larger transgene into the viral genome of this replication-
defective vectors. The drawback of this system is the possibility for the virus of 
reacquiring the complementing viral genes inserted in trans in the complementing cell 
lines by recombination with the homology sequences cloned in the cell genome reverting 
to a replication competent virus after several passages in vitro; these virus stocks need to 
be periodically screened to check for wild-type revertants. However, as many of these 
vectors have been deleted for different essential genes, there are only very few 
probability of complete reversion to wild-type. 
 
1.4.9 Replication attenuated vectors 
The HSV genes can be categorized in essential or non essential for viral replication. 
Essential genes are required to produce new infectious viral particles in permissive cell 
culture infections. Non essential genes are only required for optimum lytic replication or 
affect the natural life cycle of the virus in vivo, contributing to host range, pathogenesis, 
or latency. HSV-1 needs about half of its genes for replication in vitro. However, many 
more genes are required for replication in vivo (i.e. thymidine kinase, ICP6, ICP 34.5); 
these genes have been identified to attenuate the ability of the virus to replicate in 
animals, while preserving the ability to replicate to high titers in cultured cells (Lilley et al., 
2001). Since these viruses don’t need to be grown on complementing cell lines, the 
probability of reversion to wild-type is low. 
 
1.4.10 Amplicons & BAC 
For several years, HSV vectors have been routinely generated through extremely tedious 
and long processes depending on rare recombination events in susceptible eukaryotic 
cells and the co-transfection of these cells with HSV DNA and a plasmid containing 
exogenous sequences flanked by viral sequences homologous to the insertion site.  This 
process allows the deletion or mutation of the gene of interest in the virus genome, but 
unfortunately the deletion of essential viral genes is not always possible because of the 
strong selection for progeny viruses that efficiently replicate in vitro and can results in 
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compensatory mutations on the viral genome after several virus passages. These 
problems have been partially solved with the creation of transcomplementing cell lines 
that compensate for the absence of the deleted viral genes; this solution works well but 
sometimes is not feasible because of the high toxicity of HSV proteins for the transduced 
cells.  
The solution to overcome all these obstacles was to mantain and modify the HSV 
genomes in bacteria, taking advantage of the accuracy of the bacterial polymerase for 
clonal maintenance of viral sequences and of the absence of selective pressure since the 
viral promoters cannot be activated in bacteria: the entire viral genome can actually be 
carried as an episome in prokaryotic cells, where it can be easily manipulated by 
prokaryotic genetic techniques and then transfected into eukaryotic cells to produce virus 
particles. 
Amplicon vectors are HSV-1 virions carrying a concatemeric DNA plasmid instead of the 
viral genome but which don’t differ from wild type HSV-1 regarding the structural, 
immunological and host range points of view. The HSV amplicon plasmid is a standard 
Escherichia coli plasmid containing the bare minimum of viral sequence, the HSV-1 
packaging sequence, or pac sequence (Hershey & Chase, 1952), and an HSV-1 origin of 
replication, the oriS sequence (McGeoch et al., 1986). This allows for up to 150kb DNA 
of foreign DNA to be incorporated. It typically also house a bacterial origin of replication 
for propagation in E. coli, a marker gene, and transgenes of interest. 
Thanks to the ability to package very large transgenic sequences, amplicons can be used 
to deliver complete DNA genomes, or DNA sequences that regulate chromatin structure 
and function or subnuclear localization. This may be useful to design improved gene 
therapy vectors having advantages such as prolonged, physiological and tissue-specific 
expression, generation of multiple splice variants from primary genomic transcripts, or 
synthesis of the full set of proteins required to assemble complex structures as well as 
metabolic or signalling pathways. 
The use of amplicons as vector gene transfer take the advantage from the fact that they 
carry no virus genes and consequently do not induce synthesis of virus proteins and 
strongly reduces the risk of reactivation, complementation or recombination with latent 
HSV-1 genomes. Therefore, these vectors are fully nontoxic for the infected cells and 
nonpathogenic for the inoculated organisms. Moreover, they have the ability to infect a 
wide variety of cell type and they are not particular easy to manipulate for vector 
construction.  Classically, amplicon vectors were prepared in cells transfected with the 
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amplicon plasmid and superinfected with helper HSV-1, which supplied the full set of 
proteins required to amplify and package the amplicon DNA into HSV-1 particles. As the 
helper virus used was generally a replication-defective mutant of HSV-1, the amplicon 
stocks were produced in transcomplementing cell lines (Geller et al., 1990). However, the 
use of defective HSV-1 as helper resulted in the production of helper-contaminated 
vector stocks, and the contaminant helper particles, even if defective, induced significant 
cytotoxicity and inflammatory responses (Johnson et al., 1992) therefore preventing their 
use in gene therapy of vaccination protocols. To overcome these obstacles, different 
helper systems that produce essentially helperfree vector stocks have been recently 
developed. The first of these systems was based on the cotransfection of amplicon 
plasmids with a set of five overlapping cosmids that supplied the full-set of transacting 
HSV-1 functions required to build amplicon vectors. These cosmids however lacked the 
pac sequences, thus avoiding packaging of the helper virus genomes that could emerge 
following homologous recombination between the cosmids. As a consequence, these 
cosmids allowed producing amplicon vectors with only very low levels of contamination 
with helper particles. 
However, the amplicon could be packaged into virus using a helper-virus free method. A 
limitation of herpes amplicons packaged by either method is the inability to transcribe a 
transgene for an extended duration and the difficulty to prepare in high amounts than 
recombinant-defective vectors. In vivo studies show that HSV amplicons delivered to the 
central nervous system (CNS) can express their transgene from weeks to months 
depending on the promoter and expression is typically limited to a small number of cells 
(Jln et al., 1996; Kaplltt et al., 1994; Brooks et al., 2000). 
Sometimes may happen that viral sequences inserted in high copy plasmids are toxic 
even for bacteria; this problem has been circumvented by use of low copy plasmids, like 
bacterial artificial chromosomes (BACs).  
These DNA constructs have a huge capacity (up to 300 kbp) for the cloning of 
exogenous genetic sequences and they can be faithfully replicated in E. coli facilitated by 
components encoded in the minimal fertility factor replicon (mini-F) included in the 
backbone of the BAC. A typical BAC vector is about 10 kilobase pairs long and its 
replication initiates at the origin of replication S (oriS) and it is regulated by the repE and 
repF gene products encoded in the mini-F, necessary for BAC replication, and by genes 
to control the rate of replication in order to limit the copy number to one or two BACs per 
bacterial cell, such as parA and parB. In addition, two loxP sites are often included at 
	   48	  
both ends of the BAC sequence so that the BAC vector can be excised out when 
recombinant viruses are generated (see discussion below). Moreover, many BAC vectors 
harbor a variety of expression cassettes that allow visualization of BAC-containing 
sequences in transfected cells selection in mammalian cells (such as GFP, beta-
galactosidase, antibiotic resistance genes, or metabolic genes). Recent advances in 
bacterial artificial chromosome (BAC) technology have enabled cloning of the whole HSV 
genome as a BAC plasmid and subsequent manipulation in E. coli (Stavropoulos et al., 
1998; Tanaka et al., 2003).  
Due to the big size of HSV genome, the manipulation of BAC-cloned HSV DNA with 
conventional methods (restriction enzyme digestion or ligation) is almost impossible. To 
overcome this limitation, severeal techniques have been adapted to create new 
possibilities for the targeted mutagenesis of the viral genome in E. coli, such site-specific 
or homologous recombination and transposon integration (Horsburgh et al., 1999; White 
et al., 2003). This technology arouses new possibilities for the targeted mutagenesis of 
the viral genome (Brune et al., 2000; Wagner et al., 2002). To reduce the possibility of 
harmful effects for bacterial sequences on eukaryotic cells and potential transmission 
between bacteria and man, some herpesvirus BAC clones have been constructed 
cloning the BAC sequences between 2 loxP sites, allowing its removal by Cre 
recombinase so that the BAC vector can be excised out when recombinant viruses are 
generated  (Tanaka et al., 2003). 
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1.5 LIM-HOMEODOMAIN PROTEINS  
 
1.5.1 Lhx-protein overview 
The LIM homeobox genes are widely expressed in various developmental and 
physiological processes including embryogenesis, development of central nerve system 
(CNS) and endocrine regulation. LIM-homeodomain (LIM-HD) proteins are important in 
CNS development (Hunter and Rhodes, 2005) and are one of the subfamilies of 
homeobox-containing genes found to be essential in eukaryotes (Kadrmas and Beckerle, 
2004) for many developmental processes and organogenesis (Hunter and Rhodes, 
2005). LIM-HD proteins are composed of two LIM domains located at N-terminal, and a 
DNA-binding homeodomain at C-terminal (Hobert and Ruvkun, 1998; Hobert and 
Westphal, 2000; Kadrmas and Beckerle, 2004). LIM domain is a zinc-binding domain 
(Michelsen et al., 1993; Archer et al., 1994) consists of approximately 55 amino acids 
with 8 highly conserved, cysteine and histidine-rich residues. Each LIM domain 
coordinates two zinc ions, the first four highly conserved residues bind to the first zinc ion 
while the other four binds to the second zinc ion to form zinc-finger structure (Kadrmas 
and Beckerle, 2004). This tandem zinc-finger topology of LIM domain can be linked to 
other protein targets for various functions (Agulnick et al., 1996; Breen et al., 1998; 
Dawid et al., 1998; Matthews and Visvader, 2003; Matthews et al., 2008).  
 
1.5.2 LIM-homeodomain protein 2 (Lhx2) 
Lhx2, a subfamily member of LIM homeobox genes, was originally identified in pre-B cell 
lines (Xu et al., 1993).  
Lhx2 plays a pivotal role in embryogenesis, as Lhx2 -/- mouse embryos develop liver 
hypoplasia and die at embryo day E15–E17 (Wandzioch et al., 2004). Lhx2 is also 
required for the development of eye, forebrain, and erythrocyte (Porter et al., 1997) and 
interacts with the thyroid stimulating hormone b-subunit (TSHb) promoter, enhancing its 
expression (Kim et al., 2007). 
One of the most important roles played by Lhx2 at the very early step of embryogenesis 
is to ensure the proper patterning of telencephalon by regulating a crucial boundary in the 
early cortical neuroepithelium. In Lhx2 -/- mouse, the cortical primordium that should give 
rise to hippocampus and cortex in the embryo is replaced by alternative cortical hem and 
anti-hem (Wnt- and Bmp-rich signaling centers that are normally restricted to the medial 
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extreme of the dorsal telencephalon), resulting in an expanded and mislocated cortical 
hem (Bulchand et al., 2001). During these early developmental stages, coordinated 
signalling at key boundaries between compartments finely regulates brain development. 
We can distinguish three distinct structures of the telencephalon involved in forebrain 
arrangement: the thalamic eminence, the cortical hem and the septum. Lhx2 plays a 
fundamental role in regulating both size and location of this dorsal signaling center 
structure and, moreover, to maintain neuroepithelial stem cells in a proliferative state 
(Roy et al., 2013). 
In mouse forebrain hem system, Lhx2 expression is significantly downregulated after 
E10.5 to allow the structures the proper acquirement of their identity (Mangale et al., 
2008). However, it has been demonstrated that Lhx2 expression is not just limited to the 
early embryonic neuroepithelium but continues in the telencephalic ventricular zone even 
after E10.5, when remains strongly expressed in the hippocampal ventricular zone with 
the ongoing hippocampal neurogenesis (Bulchand, 2003).  During these midlate 
gestation phases, the progenitor cells of the CNS give rise to neurons and, further on in 
time, glial cells (Miller and Gauthier, 2007).  Although we still don’t know which are 
exactly the molecular pathways beyond this cell fate switch, experimental analysis 
identified in Notch signaling one of the most important actors involved in this process, 
since it is essential at early stages to keep the undifferentiated state of telencephalic 
progenitors (Mizutani and Saito 2005) and, later, to direct astrogliogenesis through 
activation the transcription factor Nfia, which is necessary and sufficient for astrocytic cell 
fate (Ge et al., 2002; Piper et al., 2010). Even though Notch signaling is active from early 
stages in the telencephalic ventricular zone, astrocytes are not generated during the 
neurogenic phase. In a recent study has been identified in Lhx2 a major role in 
repressing the astrogliogenesis selectively in the hippocampus by repression of the 
GFAP promoter, target of Nfia, by breaking the Notch-Nfia pathway to prevent premature 
gliogenesis until neurogenesis is complete (Subramanian et al., 2011).  
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2. MATERIALS AND METHODS 
 
2.1 Cell lines  
U2OS Human Osteosarcoma (HTB-96) and HEK 293T/17 Human Epithelial Kidney 
(CRL-11268) cell lines were purchased from ATCC (Manassas, VA) whereas primary 
Mouse Embryo Fibroblasts were purchased from Millipore (PMEF-CFL). U2OS-ICP4 
complementing cell line has been generated (and kindly donated) by Yoshitaka Myagawa 
through lentiviral transduction of ICP4 HSV-1 gene into U2OS cells, allowing the stable 
expression of the transgene. All these cells were maintained at 37°C with 5% CO2. All 
these cells were grown in Dulbecco’s Modified Minimum Essential Medium (DMEM, 
HyClone) supplemented with 10% Fetal Bovine Serum (FBS, Sigma), 2 mM L-glutamine 
(Cellgro), 100 U/mL Penicillin (Cellgro), and 100 µg/ml Streptomycin (Cellgro). 
Undifferentiated mouse ES-D3 cells, generously donated by Thomas E. Smithgall, were 
maintained on a feeder cell layer of mitomycin C-treated mouse embryonic fibroblast 
(PMEF-CFL, Millipore) in Dulbecco’s Modified Minimum Essential Medium (DMEM, 
Gibco), supplemented with 15% knockout serum replacement (KSR, Gibco), 1 mmol/L 
glutamine (Gibco), 0.1 mmol/L β-mercaptoethanol (Gibco), 100 mM/L nonessential amino 
acids (Sigma), 100 mg/ml penicillin and 100 mg/ml streptomycin (Sigma). To maintain the 
pluripotent status, 1000 U/ml recombinant mouse leukemia inhibitory factor (mLIF, 
Chemicon) has been added to the culture medium. Medium was replaced daily until cells 
reach confluence and they were dissociated using TrypLE Express (Gibco). To make the 
feeder layer, mouse embryonic fibroblasts (MEF) were cultured at 37°C and 5% CO2 in 
DMEM + 10% FBS; at approximately 80% confluence, the cells were incubated with 10 
µg/ml mitomycin C (Sigma) for 2.5 h and washed three times with PBS. After this 
treatment, about 1x106 inactivated MEF were plated in 6cmø petri dishes coated with 
0.1% gelatin (Sigma).  
 
2.2 DNA restriction digest and purification from agarose gel  
Plasmids, BAC DNAs and PCR products were digested with restriction enzymes (NEB), 
according to rre’s instructions. The DNA fragments were run on a 1% agarose gel 
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supplemented with 0.001% Ethidium Bromide. Gel purification have been done using the 
MiniElute Gel extraction kit (QIAGEN), according to the manufacturer’s instructions. 
 
2.3 Ligation of DNA fragments and transformation of competent 
bacteria  
Linearized DNA fragments were ligated together (generally at a 1:10 backbone/insert 
ratio) through overnight incubation with T4 DNA ligase (NEB), at 16° C. 
 
2.4 PCR analysis 
Routine PCR for detection of an amplification product or estimation of a product size was 
performed using Go-Taq (Promega) according to the manufacturer’s instructions.  
DNA fragments for subcloning were amplified by Polymerase Chain Reaction (PCR) 
using either High Fidelity Accuprime PFX DNA Polymerase (Invitrogen). 
  
2.5 Chemical transformation of competent bacteria cells  
DNA ligation products (about 10 ng) were chemically transformed into DH10β competent 
bacteria (NEB) through the following steps: a single aliquot of bacteria (50 µl) was placed 
on ice for 30 minutes with the ligated DNA before receive heat shock (30 seconds in a 
water bath at 42° C); the tubes were immediately placed on ice for 5 minutes and 
incubated for 1 hour at 37°C with shaking at ~225 rpm upon be added with 900ul of SOC 
or Luria-Bertani (LB) broth (1% NaCl, 1% Bacto-Trypton, 0.5% Yeast-Extract, 0.02% 
NaOH). About 100 ul of the transformation mix were plated on LB-agar plates (1% NaCl, 
1% Bacto-Trypton, 0.5% Yeast-Extract, 0.02% NaOH, 1.5% agar) containing the 
appropriate selection drug and incubated overnight at 37°C. 
 
2.6 DNA extraction for screening of transformed bacteria colonies  
Transformed bacteria colonies grown on agar plates were picked, expanded overnight in 
LB broth plus the appropriate selection drug and processed to extract plasmid DNA using 
the QIAprep Spin Miniprep Kit (QIAGEN), according the manufacturer’s instructions. 
Quantification of DNA was performed using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies). 
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2.7 Gateway® recombination 
The Invitrogen Gateway® technology employs in vitro site-directed recombination to 
clone a DNA fragment from an entry vector to a donor vector, while maintaining both its 
orientation and the open reading frame. This reaction exploit the LR recombination 
between an attL containing entry clone and an attR containing estimation vector, 
exchanging the region between L sites in the entry vector with the region between R sites 
in the destination vector, giving rise to an attB-containing Expression cloneLR reactions 
were performed in 10 µl, adding 100ng of entry plasmid (containing the transgene flanked 
by attL sites), 1ug of destination DNA vector (with attR sequences) and 1 µl of LR 
Clonase II enzyme mix (Invitrogen), enough to achieve an efficient recombination. 
Recombination reactions were incubated for 1h at room temperature and followed by 
Proteinase K treatment (15 min at 37°C) to inactivate the enzyme before transformation. 
Transformation of expression vectors was performed using 1–2 µl of recombination 
reaction and 40 µl of electrocompetent bacteria (ElectroMAX™ DH10B™ T1 Phage-
Resistant Competent Cells, NEB). 
 
2.8 Electroporation 
The transformation of the BAC requires electroporation. Electrocompetent bacteria 
(ElectroMAX™ DH10B™ T1 Phage-Resistant Competent Cells, NEB) were thawed on 
ice for 5–10 min. For a single transformation, 1 aliquot (50 µl) of bacterial suspension 
was mixed in a cold transformation cuvette with 3–5 µl of the ligation product 
(approximately 10 ng of BAC DNA) using a Biorad GenePulserXcell electroporator 
(Voltage 1650 V, Capacitance 25 uF, Resistance 150 Ω, Cuvette 1 mm). Immediately 
after the electroporation, 1ml of SOC-medium was added and this suspension was 
transferred to an Eppendorf tube. The cells were incubated on a rotor at 37°C for 1 h; 
100 µl of this solution were plated on an agar plate containing the chloramphenicol 
selection and grown at 37°C over night. 
 
2.9 BAC minipreps and midipreps 
Following electroporation and selection on agar plates, single BAC-transformed bacteria 
colonies were picked and BAC–DNA extracted following the “Miniprep-Alkaline Lysis for 
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BACs” protocol adapted from Untergasser’s Lab 
(http://untergasser.de/lab/protocols/miniprep_alkaline_lysis_for_bacs_v1_0.htm).  
The BAC-DNA was then checked for correct manipulation using both diagnostic PCR and 
FIGE (Field Inversion Gel Electrophoresis) analysis. Positive clones were furthermore 
propagated using Midipreps kit (Promega), according to manufacturer’s instructions. 
 
 
2.10 Transfection of BAC-DNA into U2OS-ICP4 to generate JΔβββ4 and 
JΔΝΙ4 viruses 
BAC HSV-1 DNAs were transfected into U2OS-ICP4 cells to ensure the ability of the 
BAC-DNA to produce virus. On the day before transfection, cells were plated in a 6 
multiwell plate at a density of 1.2x106 cells/well. 24 h later 80% confluent cells were 
transfected with 30 µl of BAC HSV-1 DNA using Lipofectamine LTX (Invitrogen) following 
the manufacturer’s instructions. Cells were incubated at 37°C in 5% CO2 in 
DMEM+10%FBS until viral plaques formation and spreading, observed by fluorescence 
microscopy for mCherry expression. Fluorescent pictures of transfected cells were taken 
using a Nikon Diaphot fluorescent microscope. 
 
2.11 Viral titration in plaques forming units (p.f.u/ml)  
Titration of viral supernatant was performed through infection of a 48 well of either U2OS-
ICP4 with serial 10-fold dilutions of viral supernatant. The day before infection, cells were 
plated as a monolayer on a 48 well dish at a density of 1.8x105cells/well and incubate at 
37°C overnight or until monolayer is confluent (triplicates were used for statistical 
analysis). At this point cells were infected with serial 10-fold dilutions of viral supernatant 
in 120 µl of serum-free media and incubated at 37°C in 5% CO2, shaking multiwell plates 
20-30' to ensure that the virus is spread evenly over the entire monolayer. 3h after the 
infection each 120 µl of growth media plus 5% methylcellulose (MeOH) were added to 
each well. The infected cells were maintained at 33°C in 5% CO2 until plaques formation. 
Since HSV-1 infected cells strongly express mCherry, 3-4 days after infection was 
possible to detect red expanding plaques made by dying cells. Plaques counting has 
been done by fluorescence microscope; the titer results were then calculated in p.f.u /ml 
(plaque forming units per ml of viral preparation).  
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2.12 Infection to test viral growth  
The day before infection, U2OS-ICP4 cells were plated as a 60% confluent monolayer. 
24 h later 100% confluent wells were infected at an established multiplicity of infection 
(MOI) in serum free media and incubated at 37°C in 5% CO2. 2 h after the infection each 
well was overlaid with DMEM plus 10% FBS and maintained at 33°C in 5% CO2 a 
condition that does not interfere with viral growth but stops cells from becoming over-
confluent in the plate. At different time-points after initial infection, viral supernatant was 
collected and titered to quantify viral yield.  
 
2.13 High scale viral production  
Viruses were propagated on U2OS-ICP4 cells plated in T150 tissue culture flasks. In 
order to get high titer stocks, about 20 T150 flasks per virus have been used. 24 h before 
infection, U2OS-ICP4 were plated as a 50% confluent monolayer in order to have about 
90-100% confluent cells the day after. The amount of virus for infection were established 
by calibrating the multiplicity of infection (MOI, between 0.01 and 0.05), in serum free 
media; the infected cells were incubated at 33°C in 5% CO2.  
4-5 days after infection, supernatant was collected and separated from cellular debris by 
centrifugation at 3000 revolutions per minute (rpm) for 10 minutes, followed by filtration 
through a 0.8 µm Versapor filtering membrane (PALL Corporation). The virus was then 
concentrated by 19500 rpm centrifugation for 45’ and the viral pellet resuspended in 
about 250µl Phosphate-Buffered-Saline (PBS) 1X supplemented with 10% glycerol by 
slow overnight rotation at 4°C. The resulting concentrated virus was divided in 10/20 µl 
aliquots and stored at -80°C. The day after, one aliquot was used for titration. 
 
2.14 Immunofluorescence of adherent cells 
Cells for immunofluorescence labelling were cultured at sub-confluence in 6- or 12-wells. 
Cells were washed from supernatant and fixed for 30’ at RT. Upon permeabilization of 
membranes (0.1% Triton X-100, 10’, RT), cells were incubated with blocking solution 
(10% horse serum in PBS) for 1h and consequently incubated O/N at 4°C with Lhx2 
primary antibody (goat polyclonal, santa cruz, 1:100). The day after, upon 3x washing in 
PBS, cells were incubated with secondary antibody (488 donkey anti-goat, Invitrogen, 
1:1000 or 594 rabbit anti-goat, Sigma, 1:2000). 
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2.15 Western blot  
To extract proteins, adherent cells were washed from their supernatant and incubated on 
ice with pre-chilled RIPA buffer for 10’. Cells were then scraped from the bottom of the 
well, moved to pre-chilled tube and sonicated 3 x 15’’. Debris were removed upon 15’ of 
centrifugation at 4oC; supernatant was used to calculate the amount of proteins through 
Bio Rad® protein assay, according to manufacturer’s instructions. Upon polymerization of 
polyacrylamide separating and stacking gel, 6X protein loading buffer to protein samples 
was added and then boiled at 100°C for 5’. 20µg of protein samples were loaded on each 
lane of stacking gel and run on Tris running buffer (110 V for ~1-2 hr or until the loading 
buffer reached the bottom edge of separating gel). Proteins were transferred onto a 
PVDF membrane for 90’ at 200 mA using SD Semi-dry Transblot Apparatus (Bio-Rad). 
The blotted membrane was incubated in blocking buffer (5% dry milk in PBS) for 1h at 
RT to reduce unspecific binding and finally incubated O/N at 4°C with anti-Lhx2 primary 
antibody (goat polyclonal, 1:200, diluted in blocking buffer). A horseradish peroxidase-
conjugated antibody (donkey anti-goat, 1:6000) was then added, and secondary 
antibodies were detected through autoradiography using enhanced chemioluminescence 
(ECL Plus, General Electric Healthcare, Milwaukee, WI). 
 
2.16 Viruses 
Both the JΔβββ4 and JΔΝΙ4- HSV vectors have been generated by engineering of the 
bacterial artificial chromosome (BAC) containing the HSV-1 genome from the strain 
KOS (KB), donated to our lab by Dr. D.A. Leib (Gierasch et al., 2006). As discussed 
before in section 1.4.10, the advent of recombinant approaches to manipulate BAC DNAs 
have dramatically increased the possibilities to generate novel HSV-based vectors, 
taking advantage from the wide versatility of biological features of bacteria, in which the 
BACs autonomously can propagate.  
The Leib’s BAC-DNA construct contains the LacZ reporter gene under the control of the 
SV40 promoter and the sequence encoding the chloramphenicol resistance protein, 
which allows the selection of bacteria transformed with this BAC. 
In this construct the BAC sequences are located between the UL37 and UL38 intergenic 
regions of HSV-1 genome, flanked by loxP recombination sites that allow their excision 
by Cre recombination (Sternberg and Hamilton, 1981), in order to remove any residual 
bacterial sequence and, therefore, to avoid potential negative effects of on viral 
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replication and on cellular health.  
Important modifications of this backbone have been made by Dr Yoshitaka Miyagawa 
(see section). 
 
 
2.17 Primary cell cultures 
To establish primary neuronal cultures, sterilized glass coverslip were specifically treated 
for cell attachment. All steps were done in sterile hood. 
The day before the experiment, upon immersion for 15’ in absolute ethanol, 12 mm ⌀ 
glass coverslips were placed under UV light for further 15’ and, eventually, quickly 
passed through the flame before been individually put into the central wells of a 24 
multiwell plate. 
Hence, the sterilized coverslips were double coated: firstly, 200ul of 1mg/ml Poly-L-
Ornithine solution (Sigma) was added in each well containing the coverslip and let it 
incubate for 1h at R/T; after washing (2X with sterile ddH2O) and drying, 200ul of 
10ug/ml Laminin solution (Sigma) was further added in the same wells. The multiwell was 
then moved in the incubator at 37C for an O/N coating. 
C57BL newborn mice pups were sacrificed at postnatal day 1 (P1). Hippocampi were 
carefully separated from the rest of brain tissue and washed 3X with Hanks Balanced 
Salt Solution (HBSS, Sigma). To achieve their disassociation, brain tissues were 
incubated for 30’ at 37C in a solution of HBSS with 2mg/ml of the proteinase Papain 
(Sigma). The enzymatic reaction was stopped by washing cell pellet with Neurobasal 
(Gibco) + 2% FBS (Gibco), 10ul/ml Hepes (Sigma), 10ul/ml Na+-Pyruvate (Sigma), 2ul/ml 
Penicillin-Streptomycin (Gibco) and 2% FBS (Gibco). The disassociation was 
mechanically completed by manual pipetting with a glass pasteur pipette and pelleted 
down for 10’ at 500rpm. The pellet was resuspended with Neurobasal (Gibco) 
supplemented with 2% FBS (Gibco), 10ul/ml Hepes (Sigma), 10ul/ml Na+-Pyruvate 
(Sigma), 2ul/ml Penicillin-Streptomycin (Gibco) and 2,5 ul/ml L-Glutamine (Gibco). To get 
single cells, the resuspended solution was passing through a 25G needle and a 70um 
cell strainer and, eventually, seeded on previously coated glass coverslips (~5x105 
cells/well). 
The day after, the medium was replaced with Neurobasal (Gibco) supplemented with 
20ul/ml B27 (Gibco), 10ul/ml Hepes (Sigma), 10ul/ml Na+-Pyruvate (Sigma), 2ul/ml 
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Penicillin-Streptomycin (Gibco) and 2,5 ul/ml L-Glutamine (Gibco). 
 
2.18 Animals 
Newborn C57BL (P1) were used for in vitro experiments. Male Sprague-Dawley rats 
(240–280 g; Harlan Italy) were used for in vivo infusion of the vectors. All procedures 
were carried out in accordance with guidelines by the European Community and national 
laws and policies. 
 
2.19 Pilocarpine model and HSV infusion 
Male Sprague-Dawley rats (280 g, Harlan Laboratories) were injected with methyl-
scopolamine (1 mg/kg) 30 minutes before the pilocarpine administration (370 mg/kg). All 
the animals that experienced 2 hours of status epilepticus (SE) were infused 3 days after 
pilocarpine with HSV vectors. Under ketamine and xylazine anesthesia (87 mg/kg 
ketamine, 13 mg/kg xylazine), a borosilicate glass needle connected to a perfusion pump 
was stereotactically implanted in the CA1 sector of dorsal hippocampus, using the 
following coordinates (calculated from bregma): AP (anterior-posterior) -1.7; ML (Medial-
Lateral) -1.7; DV (Dorsal-Ventral) +3.2. A total of 1x106 pfu of vector were injected in a 
volume of 2 ul at a flow rate of 0.1 ul/min. The animals were sacrificed 12 days after SE 
(to verify the virus toxicity) and 28 days after SE (that is 25 days after infusion of the 
vectors). Control animals were vehicle-injected or naïve rats. 
 
2.20 Fixation Procedure 
At different time points, anesthetized animals were sacrificed by decapitation and brain 
tissue was immediately collected and frozen. By criostatic microtome (Leica), 20 µm 
coronal sections were cut and subsequently fixed in paraformaldehyde solution, that 
stabilizes cell structures by introducing covalent crosslinks between proteins. The 
protocol used was the following: 
- 30’ in paraformaldehyde 4% solution (prepared in PBS) 
- 10’ in PBS 3X 
- 10’ in PBS 1X 
When the slices were not immediately processed, they were dehydrated through a series 
of graded alcohol baths of increasing concentration (5’ in EtOH 80%, 5’ in EtOH 95%, 5’ 
in EtOH 100%) and finally stored at -80oC. 
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2.21 Hematoxilin and Eosin staining 
Frozen coronal sections (20 µm thick) were cut at the level of the dorsal hippocampus 
(plate 45, Paxinos and Franklin, 2001) and mounted onto polarized slides (Superfrost 
slides,Diapath). 
The frozen brains were subjected to standard histological procedures and stained with 
hematoxilin and eosin to accurately identify the regions of virus injection.  
 
2.22 Fluoro-Jade C and NeuroTrace staining 
Damaged neurons were then detected using the Fluoro-Jade C (FJ) (Schmued and 
Hopkins. 2000), on coronal sections cut at the level of the dorsal hippocampus (Paxinos 
and Franklin 2004). NeuroTrace 594 red fluorescent (NT; Molecular Probes, Inc., 
Eugene, OR, USA) staining has been performed after FJ staining, to identify 
degenerating neurons. After rehydration in 0.1 M PBS, (pH 7.4), sections were treated 
with PBS plus 0.1% Triton X-100 10 min, washed twice for 5 min in PBS then stained by 
NT (1:100), for 20 min at room temperature. Sections were washed in PBS plus 0.1% 
Triton X-100, twice with PBS, then let stand for 2 h at room temperature in PBS. 
 
2.23 GFAP immunofluorescence and Neurotrace staining 
After a PBS wash, frozen coronal sections were preincubated with PBS containing 0.3% 
Triton X-100 for 10 min. After two rinses in PBS, they were blocked for 30 min in a 
solution of PBS containing 5% bovine serum albumin (BSA) and 5% normal goat serum. 
Finally, sections were incubated overnight at 4°C with the primary antibodies, anti-GFAP 
(rabbit polyclonal; 1:100; Sigma). The next day, sections were rinsed twice with PBS and 
preincubated with PBS containing 0.3% Triton X-100 for 30 min. Then, they were rinsed 
with PBS again and then incubated for 3 h at room temperature with a secondary 
antibody mixture containing goat anti-rabbit, Alexa 594-conjugate (1:500; Life 
Technologies-Invitrogen). Finally, samples were washed three times with PBS, then they 
were stained by NT (1:100), for 20 min at room temperature. Sections were washed in 
PBS plus 0.1% Triton X-100, twice with PBS, then let stand for 2 h at room temperature 
in PBS. Coverslips were mounted using anti-fading Gel/Mount water based media 
(Biomeda). The specificity of immunolabeling was verified in all experiments by controls 
in which the primary antibody was omitted. 
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3.RESULTS 
 
 
 
3.1 Lhx2 cDNA cloning into pENTR1A® plasmid 
Lhx2 human cDNA (NCBI Reference mRNA Sequence: NM_004789.3), kindly donated 
from Elena Cattaneo’s lab, was cloned in PCR4-TOPO® plasmid. The cDNA was firstly 
cut out from the original plasmid with EcoRI restriction enzyme and then ligated to the 
linearized pENTR1A® plasmid, cut as well with EcoRI. Before ligation, 5´ phosphate 
groups were removed from linearized pENTR1A by treatment with Alkaline Phosphatase 
(CIP), to prevent simply recircularising during the ligation step. 
 
Fig. 4: Schematic representation of pENTR-Lhx2 generation.  
 
The importance of cloning Lhx2 gene into pENTR1A plasmid conferred the possibility to 
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easily move the transgene from this entry vector to any destination vector endowed with 
the Gateway Cassette (see section…). 
The resultant pENTR-Lhx2 plasmid was transformed into competent E.Coli; several 
bacterial colonies grew after plating these transformed bacteria on agar dishes with 
kanamycin selection, predicting the incorporation of kanamycin-resistance gene and the 
removal of ccdB gene (encoding for a lethal bacterial toxin, essential to avoid 
background) from original pENTR1A. 
To check if the cloning was actually successful, it has been done a diagnostic digestion 
using SalI restriction enzyme that should cut once the “empty” pENTR1A and twice the 
pENTR-Lhx2. Every screened clone showed the expected digestion pattern after gel 
running of DNA fragments (Fig. 5), confirming that the gene inserted into the entry 
plasmid and, importantly, with the correct orientation. 
 
 
Fig 5. Diagnostic restriction digestion of pENTR-Lhx2 with SalI, followed by DNA sequencing, verified that 
the Lhx2 gene was cloned into pENTR1A plasmid correctly. 
 
 
3.2 Construction of the fusion gene Lhx2-T2A-eGFP 
To check Lhx2 transgene expression in living cells, a fusion gene has been created by 
insertion of the enhanced green fluorescent protein (eGFP) gene in-frame with Lhx2 
gene, separated by the viral 2A oligopeptide (T2A) that mediates ribosomal skipping 
(Ryan et al., 1981, Donnelly et al., 2001). As a result, the Lhx2 and eGFP genes might be 
efficiently co-expressed from the same promoter but translated separated, making eGFP 
expression a useful marker for Lhx2 for both in vitro and in vivo studies. Three 
consecutive PCR reactions were used to generate the Lhx2-T2A-eGFP cassette. Lucia 
Mazzacurati kindly donated the BAC-DNA in which she inserted the T2A-eGFP cassette, 
which served as DNA template for the first PCR reaction. This reaction was run using an 
upper 5’-tailed primer (Lhx2endΔSTOP-T2A-F), complementary for the first nucleotides of 
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T2A but carrying a non-complementary sequences at its 5' ends, corresponding to the 
final part of Lhx2 gene without its STOP codon; the lower primer (eGFPend_XbaI-
EcoRV-R) annealed to the end of eGFP gene, and it has as well a non-complementary 
sequence corresponding to XbaI and EcoRV restriction sites, introduced to facilitate the 
following cloning. This reaction produced a 0.8Kb amplicon. For the parallel PCR 
reaction, I used a forward primer (Lhx2_preSalI-F) that anneal just before the unique SalI 
site of Lhx2 gene (nt 1004) and a reverse primer (Lhx2endΔSTOP-R) complementary to 
the end of Lhx2 gene, but not to the STOP codon that was so deleted (the deletion of 
STOP codon is essential to keep the RNA polymerase transcription until the end of eGFP 
gene). The size of the amplicon generated with the latter reaction was 0.25Kb. 
 
  
 
Fig. 6: Schematic representation of Lhx2-T2A-eGFP generation. Two partially overlapping amplicons were 
generated by independent PCRs. These two fragment were then linked together through an overlap PCR.  
 
 
The two resultant amplicons were purified from gels and finally linked together through an 
overlap PCR, by using two of the four primers involved in the previous PCR 
(Lhx2_preSalI-F and Lhx2endΔSTOP-R). The DNA fragment SalI_Lhx2end-T2A-
eGFP_XbaI-EcoRV has been finally got (1 Kb) and it was then cloned in the pENTR-
Lhx2 plasmid (conveniently deleted of SalI restriction site present in polylinker site) 
through digestion with SalI and XbaI and following ligation.  
Upon bacteria transformation and DNA purification, SalI-XbaI diagnostic digestion 
confirmed the successful cloning for 5 of 6 Kan-resistance screened growing bacteria, 
(Fig. 7). DNA sequencing further confirmed the accuracy of this cloning. 
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Fig. 7: Restriction pattern of pENTR-Lhx2_ΔSalI-T2A-eGFP after double restriction digestion with SalI and 
XbaI confirmed the successful cloning of the fusion gene Lhx2_ΔSalI-T2A-eGFP into pENTR1A plasmid 
 
 
 
 
 
3.3 Construction of the expression plasmid pcDNA-DEST_Lhx2 and 
pcDNA-DEST_Lhx2-T2A-eGFP 
To confirm the ability to express the eGFP protein, the Lhx2-T2A-eGFP construct was 
cloned into the expression plasmid pcDNA-DEST, conveniently engineered by Yoshitaka 
Miyagawa with the introduction of the Gateway cassette, which allows the insertion of 
transgenes deriving from an entry vector in just one step, through LR recombination. (Fig. 
8). 
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Fig. 8: Schematic representation of Lhx2 cloning by LR reaction into the expression plasmid pcDNA-DEST. 
 
This reaction replaced the ccdB gene of original pcDNA-DEST with the Lhx2-T2A-eGFP, 
guaranteeing the growth of only recombinant bacterial colonies upon transformation. In 
parallel, another LR recombination was run to insert the only Lhx2 gene into the same 
pcDNA-DEST. Ampicillin-resistant colonies were screened for correct insertion of 
transgenes by diagnostic digestion, again with SalI and XbaI (Fig. 9) 
 
 
Fig. 9: Restriction pattern of pcDNA-DEST_LHX2_T2A_eGFP and pcDNA-DEST_LHX2 upon double 
digestion with SalI and XbaI  
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Both the pcDNA-DEST-Lhx2 and pcDNA-DEST-Lhx2_T2A_eGFP were afterwards 
transfected in HEK293T cells, to demonstrate the in vitro capability for Lhx2 and eGFP 
expression. pcDNA-DEST alone was transfected as a control. 24h after transfection, cells 
were fixed and labeled through indirect immunofluorescence (Fig. 10) 
 
Fig. 10: Immunofluorescence on HEK293T 24h after transfection with pcDNA-DEST, pcDNA-DEST_Lhx2, 
pcDNA-DEST_Lhx2_T2A_eGFP. Cells transfected with both the recombinant expression plasmids pcDNA-
DEST_Lhx2 and pcDNA-DEST_Lhx2_T2A_eGFP are positive for Lhx2 upon immunofluorescence. 
Moreover, the newly generated fusion protein Lhx2_T2A_eGFP cloned in this expression plasmid could 
efficiently express both Lhx2 and eGFP protein. 
 
Immunofluorescence analysis confirmed the expression of Lhx2 protein from both 
backbones and, moreover, the co-expression of Lhx2 and eGFP in HEK293T cells 
transfected with pcDNA-DEST-Lhx2_T2A_eGFP. In the latter case, eGFP fluorescence 
looks higher then Lhx2 labeling; this could be due to a differential fluorescence emission. 
The lysates of HEK293T transfected cells was collected to further check Lhx2 
expression, this time by Western Blot analysis. As shown in Fig 11, from both plasmids 
Lhx2 is strongly expressed. 
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Fig. 11: Western blot analysis of HEK293T lysates 24h upon transfection with pcDNA-DEST, pcDNA-
DEST_Lhx2, pcDNA-DEST_Lhx2_T2A_eGFP. 20mg of protein were load in each lane. Last lane is loaded 
with the lysate of untransfected HEK293T cells. Both the pcDNA-DEST_Lhx2 and pcDNA-
DEST_Lhx2_T2A_eGFP strongly express Lhx2 protein. This latter showed an additional higher band, 
probably due to a residual uncut Lhx2-eGFP protein. 
 
 
3.4 Generation and characterization of JΔβββ4-Lhx2 and JΔΝΙ-Lhx2 
viruses 
Once verified the ability of hLhx2 cDNA to successfully encode for Lhx2 protein, Lhx2 
cDNA could finally be cloned into the HSV-1 BAC-DNA. Important modification of HSV-1 
genome have been made by Yoshitaka Miyagawa, to make the virus unable to replicate 
in non-complementing cells and to remove or, at least, dramatically drop its 
toxicity anyhow keeping a stable transgene expression (Fig. 12). The oldest version, 
named JΔβββ4, has been deleted of the immediate early (IE) genes encoding for ICP4 
and ICP47 proteins; in addition, ICP0, ICP22 and ICP27 IE genes have been converted 
to early genes by replacement of their original promoters with a promoter controlling the 
expression of early genes, in order to allow their expression only in case of ICP4 
expression in complementing cell lines. Three additional and undoubtedly not 
less important variation of this backbone have been made: 1) cloning the gene for 
the fluorescent protein mCherry, driven by the ubiquitin promoter, to constitutively 
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express this marker protein for the detection of HSV-1 occurred infection in target cells; 
2) introduction of the Gateway cassette, that have been strategically inserted for a rapid 
and efficient cloning of any gene into this BAC DNA (placed downstream the strong 
and constitutively express promoter EF1α); 3) the double mutation on gB protein 
(D285N/A594T), which has been demonstrated to enhance the viral infectiveness 
(Uchida et al., 2010). 
 
Fig. 12: Schematic representation of JΔβββ4 and JΔΝΙ BAC-DNAs. The only characteristic differentiating 
the JΔΝΙ from the JΔβββ4 (from which the first one is derived) is the deletion of the ICP0 immediate early 
gene.   
 
The JΔβββ4 vector, however, may exert some toxic effect in vitro or in vivo, making it 
useless for particular assays. To reduce residual viral toxicity, a newer HSV-1 vector has 
been generated: this novel recombinant virus, called JΔΝΙ, has been engineered to have 
only one but essential difference to its predecessor JΔβββ4 (from which has been 
derived), that is the deletion of ICP0 gene (unpublished data). 
Both of them were engineered to carry the gateway cassette between UL3 and UL4 
region of HSV-1 genome, allowing a fast and efficient recombination with any DNA 
fragment previously cloned into an Entry Vector. 
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Fig.13: Schematic representation of Lhx2 cloning by LR reaction into the HSV-1 BAC DNA and resultant 
recombinant vectors 
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Following LR reaction, BAC DNAs were transformed in electrocompetent bacteria to 
achieve their propagation; only the clones that successfully incorporated the recombinant 
BAC DNA might form colonies. 
Bacteria transformed with both JΔβββ4-Lhx2 and JΔΝΙ-Lhx2 BAC DNAs gave rise to 
several colonies after growing O/N on LB-agar plates supplemented with the selector 
drug chloramphenicol (CM). Single colonies were picked with a sterile tip and transferred 
into tubes containing LB broth + CM for propagation. Additionally, single bacterial 
colonies previously transformed with the parental JΔβββ4 and JΔΝΙ were picked and 
propagated, to serve as negative controls for following assays. BAC-DNAs were purified 
by BAC minipreps and overnight digested with BglII. The presence of a BglII restriction 
site in the Lhx2 cDNA (at nt 175) produced an extra DNA fragment for both JΔβββ4-Lhx2 
and JΔΝΙ-Lhx2 backbones if compared to their parental JΔβββ4 and JΔΝΙ. This was 
confirmed upon FIGE gel analysis of BAC-DNA digestions (Fig. 14). 
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Fig. 14: Diagnostic FIGE digest (left pictures) of JΔNI, JΔNI-Lhx2, JΔβββ4, JΔβββ4-Lhx2 BAC-DNAs with 
BglII and predicted digestion patterns resulting from Serial Cloner® software (right pictures) with same 
restriction enzyme. BglII BAC digestion generated one extra band of 4,2-Kb in both JΔNI-Lhx2 and JΔβββ4-
Lhx2 backbones compared to their parentals, predicting Lhx2 insertion; moreover, both digests showed the 
expected shift of the DNA fragment containing the site of insertion from 11.5-Kb to 7.1-Kb in JΔΝΙ-Lhx2 
digest and from 14.7-Kb to 10.4-Kb in the JΔβββ4-Lhx2 digest, without any changes in other bands. 
 
 
To confirm the positive result coming from diagnostic digestion and the correct insertion 
of the Lhx2 gene, a diagnostic PCR was run. The DNA templates were the same BAC 
DNAs used for FIGE analysis. A couple of primers has been selected that should 
generate a PCR amplicon only in case Lhx2 was cloned into the destination vector with 
the right orientation: the forward primer annealed at nt 671 of Lhx2 gene and the reverse 
primer annealed on UL4 region, giving rise to a 1.2kb PCR product (Fig. 15). 
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Fig. 15: Diagnostic PCR on recombinant BAC DNAs. Clear differences between the parental and the 
recombinant backbones confirmed the successful cloning of Lhx2 cDNA in both the JΔΝΙ and JΔβββ4 BAC 
DNAs. In particular, the PCR on JΔΝΙ-Lhx2 and JΔβββ4-Lhx2 produced a strong band of expected size 
(1.2kb) after gel running, while a series of not specific bands appeared on the lane loaded with the PCR 
products generated from parental backbones JΔΝΙ and JΔβββ4, indicating the absence of Lhx2 gene 
inside. 
 
To test if the virus could efficiently generate replicating viral particles in complementing 
cell line, JΔΝΙ-Lhx2 and JΔβββ4-Lhx2 BAC DNAs were transfected in U2OS-ICP4 cells, 
seeded in 6 multiwell plate. Recombinant virus can be actually reconstituted by 
transfection of purified virus BAC DNA into susceptible eukaryotic cells. Upon uptake of 
the virus genome into transfected cells HSV-1 proteins start to be expressed, initiating 
the replication. Since ICP4 IE gene (essential for viral replication) have been deleted 
from both viral vectors, the expression in trans of this protein mediated by U2OS-ICP4 
can compensate its missing. However, JΔΝΙ-Lhx2 backbone is additionally missing of 
ICP0 IE gene; although not essential for viral replication, ICP0 confers a significant 
advantage for the growth of the virus. Experimental analysis showed that U2OS cells 
could functionally substitute for ICP0. This makes U2OS-ICP4 cells an ideal tool even for 
JΔΝΙ-based vectors propagation. Indeed, U2OS-ICP4 cells transfected with whether 
JΔβββ4-Lhx2 or JΔΝΙ-Lhx2 can both form plaques clearly visible 3 days post BAC-
transfection with fluorescence microscope, as shown in Fig. 16. 
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Fig. 16: U2OS-ICP4 cells 3 days post transfection with JΔβββ4-Lhx2 and JΔΝΙ-Lhx2 BAC DNAs. Both 
viruses could form plaques even though, as expected, viral growth is faster for JΔβββ4-based vector, due 
to the presence of ICP0 gene into the viral backbone. 
 
 
Generally, after BAC-transfection viral growth is rather slower than usual, since a 
percentage of viral particles generated are not able to spread and infect other cells. 
Indeed, after transfection were necessary 7 days to collect the virus: at this point, every 
cell was infected and most of them underwent cytolysis, releasing virions in the growing 
medium. However, several cells were still attached on the well bottom; to collect as much 
as possible virus, these cells were scraped out from their adhesion surface and sonicated 
in their own supernatant to free the virus still trapped inside cells. This procedure must be 
done only when the purpose is to collect as much virus as possible for its propagation, 
since the massive cytolysis mediated by sonication also free a big amount of cellular 
debris in the medium, making the virus preparation too “dirty”. To reduce the cellular 
contaminants, the sonicated supernatant was spun down at 3000 rpm for 10 minutes and 
passed through a 0.8um filter. This viral preparation was used to propagate the amount 
of virus by infection of U2OS-ICP4 cells, seeded in 10cm ø petri dishes at M.O.I. of 0.1. 
after 3 days from infection with both JΔβββ4-Lhx2 and JΔΝΙ-Lhx2, a great percentage of 
U2OS-ICP4 cell was mCherry positive (Fig. 17), meaning that both these viruses can 
efficiently infect and spread in U2OS-ICP4 cell monolayer. 
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 JΔNI-Lhx2                                           JΔβββ4-Lhx2 
 
Fig. 17: U2OS-ICP4 cells 3 days post infection with JΔΝΙ-Lhx2 and JΔβββ4-Lhx2.  Both the viruses rapidly 
form spreading plaques. The kinetic of propagation of JΔβββ4-Lhx2 virus is visible faster then the JΔΝΙ-
Lhx2 one, due to additional presence of ICP0 gene into its genome. 
 
 
Upon virus collection from 10cm ø petri dishes, viral propagation was scaled up by 
infection of U2OS-ICP4 cells seeded and brought to confluency in T150 flasks. 
JΔβββ4-Lhx2 virus was propagated in 15 T150 flasks confluent with U2OS-ICP4 cells. On 
the other hand, JΔΝΙ-Lhx2 virus (that, missing ICP0, grow slower) was propagated into 
Corning® CellBIND® Surface CellSTACK® cell culture 10 chambers, a very useful tool to 
greatly scale-up cell cultures and, in this case, viral production. Indeed, after titration of 
purified virus, the amount of JΔβββ4-Lhx2 virus got from 15 T150 flasks was about 1x108 
pfu (resuspended in 250ul of PBS + 10% glycerol, for a concentration equal to 4x108 
pfu/ml) 10 times less of JΔΝΙ-Lhx2 virus purified from 10 chambers (1x109 pfu in 1ml of 
PBS + 10% glycerol). 
To test whether JΔβββ4-Lhx2 and JΔΝΙ-Lhx2 viruses were able to express Lhx2 protein, 
confluent U2OS-ICP4 cells were infected at M.O.I. 0.1 to perform an 
immunofluorescence against Lhx2 protein 24h after infection. As shown in Fig. 18, 
U2OS-ICP4 cells infected with both viruses were positive for Lhx2 after 
immunofluorescence, 24h after infection. 
  
	   74	  
 
    
 
  mCherry                               Lhx2  
 
Fig. 18: Immunofluorescence on U2OS-ICP4 infected cells. Infection was performed at MOI 0.1 and cells 
were processed 24h after infection. Both JΔΝΙ-Lhx2 and JΔβββ4-Lhx2 infected cells are positive after Lhx2 
staining, confirming that the two viruses could express Lhx2 protein after infection of this complementing 
cell line. 
 
 
 
These data were further confirmed by western blot analysis: lysates from U2OS-ICP4 
infected cells were collected 24h after infection at M.O.I. 0.1 (same conditions as above); 
the samples were loaded onto an SDS-polyacrylamide gel and run under standard 
conditions. Interestingly, the band corresponding to Lhx2 protein in JΔΝΙ-Lhx2 infected 
cell lysate appeared stronger then the one revealed in JΔβββ4-Lhx2 lysate. This might be 
due to the greater toxicity evoked by JΔβββ4-based vector (extensively demonstrated in 
Glorioso’s lab in previous studies, unpublished data) on U2OS-ICP4 cells: cell death lead 
to protein degradation and, as a consequence, Lhx2 protein levels might decrease (Fig. 
19) 
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Fig. 19: Western Blot analysis on U2OS-ICP4 lysates 24h upon infection (MOI 0.1). 20 µg of protein were 
loaded on each lane. The band corresponding to Lhx2 appeared in both lanes corresponding to cells 
infected with JΔΝΙ-Lhx2 and JΔβββ4-Lhx2 infected cells. The differential intensity of the two bands may 
indicate the higher toxicity evoked by the JΔβββ4-Lhx2 viral backbone. 
 
 
 
 
However, we didn’t know if the complementation of these cells for ICP4 could affect the 
transgene expression. Hence an immunofluorescence against Lhx2 were performed on 
regular U2OS cells 24h post-infection with JΔΝΙ-Lhx2 and JΔβββ4-Lhx2, this time using 
M.O.I. 1. Consistently with previous results, even in this case we got the positive signal 
for Lhx2 protein on U2OS cells infected with both viral vectors (Fig. 20).  
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                                   mCherry                   Lhx2 
 
Fig. 20: Immunofluorescence staining of Lhx2 on U2OS infected cells, 24h post-infection with JΔβββ4, 
JΔβββ4-Lhx2, JΔΝΙ,  JΔNI-Lhx2 at MOI1. Lhx2 positive U2OS cells were detected upon infection with both 
JΔNI-Lhx2 and JΔβββ4-Lhx2  viruses, even though this latter produced a stronger signal, vouching for a 
major transgene expression 
 
 
Moreover, from this analysis we can undoubtedly infer that both these vectors are not 
able to form plaques in U2OS gathering that no mutation potentially reverting the viral 
phenotype occurred, keeping both viruses replicative-incompetent in infected non-
complementing cell-lines. 
As discussed above, U2OS cells can partially complement for the deletion of ICP0. To 
assess if this endogenous complementation could affect the levels of transgene, another 
cell type must be used for infection. Hence, Mouse Embryonic Fibroblasts (MEFs) were 
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infected at M.O.I. 10; 24h post-infection, cell lysates were collected and analyzed through 
western blot. Unexpectedly, only cells infected with JΔΝΙ-Lhx2 revealed the clear band of 
Lhx2 protein. Again, this result enhances that JΔβββ4-based virus is dramatically more 
toxic then JΔΝΙ-based vectors, at least in vitro. Actually, according to their morphology, 
as soon as 24h after the infection, MEFs infected with JΔβββ4-based viruses looked 
visibly suffering if compared to those infected with the JΔΝΙ-based vectors.  
 
 
Fig. 21: Western Blot analysis on mouse embryonic fibroblasts lysate,s 24h upon infection at MOI 10 with 
JΔΝΙ-GFP, JΔNI-Lhx2, JΔβββ4-GFP and JΔβββ4-Lhx2. 20 µg of protein lysates were loaded on each lane. 
Only the lysate of MEF infected with JΔNI-Lhx2 revealed the band of Lhx2 protein. The absence of any 
band for JΔβββ4-Lhx2 infected MEF is probably due to the high toxicity elicited by this vector on fibroblasts. 
 
 
Both these viruses were used to test their infectivity and transgene expression on mouse 
Embryonic Stem Cells (mESCs). mESCs were initially cultured on MEF-inactivated 
feeder layer to facilitate the maintaining of their indifferentiated state and then, 3 days 
before infection, moved on a feeder-free culture to minimize MEF contaminations (Fig. 
22) 
	   78	  
 
Fig. 22: Feeder-free culture of mouse embryonic stem cells showing healthy and indifferentiated colonies 
 
24h after infection, cells were fixed and stained by immunofluorescence against Lhx2. 
Again, Lhx2 expression looks higher on mESCs infected with JΔβββ4-Lhx2 virus, even 
though we can detect Lhx2-positive cells also upon infection with the JΔΝΙ-Lhx2 vector 
(Fig. 23). Interestingly, uninfected cells showed few Lhx2-positive cells, confirming the 
very early role of this transcription factor.  
 
Fig. 23: Immunofluorescence staining of Lhx2 on mouse embryonic stem cells infected with JΔΝΙ-Lhx2 and 
JΔβββ4-Lhx2. Uninfected cells showed rare Lhx2-positive cells (upper row, picture took at higher 
magnificence) confirming the early role of this transcription factor.  
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To assess whether these two viral backbones may exert toxicity on mESCs, we let them 
to aggregate on embryoid bodies after infection. mESCs were infected in suspension at 
M.O.I. 10 by rotating the tube at 37C. Uninfected cells were exposed at the same 
conditions to serve as negative control. After 3h of viral exposure, mESCs were pelleted 
down and the virus was removed. Cells were then resuspended on mESC medium 
without LIF (to trigger the differentiation program) and plated on 96mw plate (round wells) 
opportunely coated with Pluronic F127 (Sigma) to avoid the attachment on well surface. 
Cells were allowed to hang (37°C, 5% CO2), kept undisturbed for five days; at day 5, 
pictures were taken at fluorescence microscope (Fig. 24).  
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Fig. 24: Embryoid bodies (EBs) formation 5 days upon infection of mESCs (MOI10) with JΔβββ4, JΔβββ4-
Lhx2, JΔΝΙ,  JΔNI-Lhx2 viruses. JΔβββ4-infection couldn’t allow the generation of EBs, killing mESCs 
before during the first days upon infection 
 
From these images we can clearly point out how JΔβββ4-based viruses are particularly 
toxic for mESCs, strongly affecting cellular health and inhibiting embryoid bodies 
formation. On the other hand, mESCs infected with JΔΝΙ-based viruses gave rise to 
healthy and growing embryoid bodies, showing several mCherry-positive cells 5 days 
after infection and even later, meaning that this backbone is dramatically less toxic then 
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its previous version, at least concerning mESCs. 
 
3.5 in vitro infection of primary cultures of neurons and astrocytes 
from JΔβββ4- and JΔΝΙ-based HSV-1 vectors 
The final in vitro investigation was carried out on primary neuronal and astroglial cell 
cultures derived from P1 mice pups, since the target of this work is indeed the cellular 
population residing in central nervous system. This experiment held a crucial relevance 
for our purposes because we didn’t have any indication about JΔβββ4- and JΔΝΙ-based 
HSV-1 viral effects on cells of CNS. 
Distinct primary cell cultures of neurons and astrocytes were made from the same P1 
mice brood. Five days after cell plating, both neurons and astrocytes were infected at 
M.O.I. 1, 10 and 50 with JΔβββ4-eGFP and JΔΝΙ-eGFP viruses to check infectivity and 
transgene expression in living cells. Likewise it has been done for Lhx2 cloning, eGFP 
gene has been inserted into both HSV-1 recombinant BAC-DNAs through LR-reaction, 
inserting the transgene into the Gateway cassette between UL3 and UL4 with 
EF1α promoter to drive its expression (Miyagawa et al., unpublished data).  
24h post-infection, several neurons and astrocytes infected with both vectors were 
mCherry-positive, even at the lowest M.O.I.; many but not all these cells showed eGFP 
expression, even though the intensity profile of eGFP emission appeared lower 
compared to mCherry. To increase the eGFP signal, 72h post-infection primary neurons 
and astrocytes were fixed and respectively fluorescence immunostained for MAP2 
(neuronal marker) or GFAP (astrocyte marker) and co-labeled with an antibody against 
the eGFP protein. From this assay we could clearly detect eGFP expression in both 
neurons and astrocytes 3 days after infection with either JΔβββ4- and JΔΝΙ-derived 
vectors, suggesting that both of them could actually infect rodent neurons and astrocytes 
with a quite good transgene expression during the early infection stages (Fig. 25).  
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Fig 25: Immunofluorescence staining of primary cultures of neurons and astrocytes, 72h upon infection 
with JΔβββ4-eGFP and JΔΝΙ-eGFP viruses. Both MAP2-positive neurons and GFAP-positive astrocytes 
colocalize with eGFP viral protein. 
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3.6 In vivo inoculation of HSV-1 based vectors 
The encouraging results got in vitro turned our attention on in vivo administration of the 
two viral vectors. 
The viral preparation was directly injected in the hippocampus of adult rats through a 
single stereotaxical inoculation; anesthetized animals were sacrificed by decapitation and 
brain tissue was collected and frozen immediately. 
36 rats were included for these in vivo studies.  
We decided to split the animals in 2 indipendent groups: 
 
1) “Naïve group”, which included 15 rats that didn’t receive any treatment before 
inoculation of JΔβββ4 and JΔΝΙ viruses. This group was constituted to assess whether 
HSV-1-based vectors are able to exert their infectivity even in vivo and, most importantly, 
if the infection might be accompanied by relevant toxicity. The animals of this group were 
subdivided as following: 
5 rats inoculated with just the vehicle solution (PBS+10%glycerol) 
5 rats inoculated with 1x106 pfu in 2 µl of PBS+10%glycerol of JΔβββ4 vector 
5 rats inoculated with 1x106 pfu in 2 µl of PBS+10%glycerol of JΔΝΙ vector 
These animals were sacrificied at day 12 post-infection (Fig. 26a). 
 
2) “Pilocarpine group”, including animal models of epilepsy previously treated with the 
proconvulsivant drug pilocarpine.  With this group we wanted to investigate whether Lhx2 
overexpression mediated by JΔβββ4-Lhx2 and JΔΝΙ-Lhx2 vectors could influence the 
ratio neurons:astrocytes and have a disease-modifying effect changing the severity and 
the number of seizures per day.  
20 animals were subjected to pilocarpine treatment; unfortunately, 7 of them died during 
status epilepticus, so we eventually got 3 animals for vector type (including relative 
controls). Animals belonging to this group were sacrificied 28 days post infection. During 
the last week, they were monitored 24/24h to assay the number and the severity of 
seizures (Fig 26b). 
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Fig. 26: Schematic	  diagram	  of	  in	  vivo	  experiments	  in	  both	  naïve	  (a)	  and	  pilocarpine	  (b)	  groups.	   
 
Ex vivo experiments were conducted on 20µm brain slices were, cut by criostatic 
microtome. 
First analysis was aimed to disclose the presence of viral infection into hippocampus of 
naïve animal group. Since every viral vector has been engineered to constitutively 
express mCherry upon infection, with fluorescence microscope we sought the presence 
of red fluorescence protein on hippocampus of infected animals. Interestingly, we could 
detect red signal in both JΔΝΙ- and JΔβββ4-injected brains (Fig. 27). 
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Fig. 27: 20 µm coronal frozen sections brain slices of naïve group of animals, counterstained with DAPI. 
First panel (a-c.1) shows the brain of a sham-animal injected with the vehicle solution (PBS+10%glycerol). 
Second panel (d-i) shows the brain of an animal injected with JΔβββ4 virus: mCherry signal is detected 
around the injection site (d-f, for higher magnification see d.1-f.1); moving to a more posterior level of the 
injection site (g-i) the expression of mCherry is still strong. Last panel (l-q) shows the brain of an animal 
injected with JΔΝΙ virus. mCherry expression is detectable in the injection site (i-n) even though is not 
considerably extended (for higher magnification see i.1-n.1); some red spots are visible in a more posterior 
level (o-q). 
 
 
 
3.7 Naïve group: hematoxilin-eosin staining of coronal brain slices  
To evaluate from a macroscopic point of view the ongoing damage evoked by viral 
injection, brain slices of naïve animals were stained with hematoxylin and eosin. Beside 
its usefulness to determine the integrity of the tissue, this staining give us some important 
indications regarding the accumulation and infiltration by cells of the immune system. The 
first evidence we could find out from these assay is the absence of either a strong 
immune response or extended tissue damage in proximity of the viral inoculation site. 
Even in this case we can detect some differences between the behavior of the two HSV-
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1 vectors: JΔβββ4-based virus evoked a bigger infiltration of ectopic cells around the spot 
of injection, if compared to his counterpart JΔΝΙ virus. This result is consistent with the 
previous in vitro data, confirming the differential toxicity exerted by the two vectors even 
though it seems to be restricted to the inoculation site (Fig. 28). 
 
 
 
Fig. 28: Hematoxylin-eosin staining of coronal frozen brain slice of naïve group of animals. Both 
hippocampi have been included in these pictures. a) sham animal, injected with the vehicle. b) JΔβββ4-
virus injected brain. c) JΔΝI-virus injected brain. 
 
 
3.8 Naïve group: Fluro-Jade staining of coronal brain slices 
To investigate the eventual neuronal degeneration in the injected brains, we further 
stained the brain slices with Fluoro Jade, a fluorochrome particularly useful for our 
purposes since it labels degenerating neurons in ex vivo samples of central nervous 
system. However, we couldn’t detect any positive signal 12 days post infection on slice 
brain of naïve group. We could just observe some positive cells in proximity of the 
injection site on the cortex surface, due certainly to mechanic injury caused by the glass 
needle (Fig. 29). We could then assess that after 12 days from infection, both viruses 
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don’t cause any neuronal degeneration. 
 
Fig. 29: Fluoro Jade staining of JΔβββ4 (a-c) and JΔΝΙ (d-f) injected brains. No positive cells were detected 
after infection with both viruses 12 days after infection. We can see just some positive cell on cortical 
surface (g-i), due to the mechanical damage caused by the entry of the needle. 
 
 
3.9 Effects on SE-Induced Astrocytosis and outcome of pathology  
Once was stated that both JΔβββ4 and JΔΝΙ viruses can efficiently infect cells of CNS 
upon injection in rat hippocampus,  our attention turned on the effective target of this 
study, the animal models of epilepsy. Both the HSV-1 based vectors were tested on the 
pilocarpine SE–induced astrogliosis and epileptogenesis. In this epilepsy model, the 
pharmacologically evoked status epilepticus produces intense neuronal damage and, 
after a latent period of about 2 weeks, spontaneous seizures occur (Pitkanen et al., 
2006). In the present experimental series, pilocarpine (370 mg/kg i.p.) rapidly induced a 
robust convulsive SE that was interrupted after 2 hours through administration of the 
anticonvulsant diazepam (10 mg/kg i.p.). According to Racine seizures scale observation 
(Racine, 1972), the severity of SE in the different animals was indistinguishable. This 
drug treatment caused damage in several brain areas: in particular hippocampal damage 
closely resembled human hippocampal sclerosis and was invariably remarkable 
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(Lehmann et al., 2000; Poirier et al., 2000; Paradiso et al., 2009). 
Three days after SE, these lesioned animals were randomly assigned to five groups: the 
first two group were injected with the JΔΝΙ-LHX2 and JΔβββ4-Lhx2, respectively; other 
two groups were injected with the relative control vectors (JΔβββ4 and JΔΝΙ); and, finally, 
the last group was not treated at all. Since no significant differences were observed 
between these latter three groups in any of the parameters examined, they have been 
pooled together for subsequent analysis and collectively termed ‘‘control’’. 
Viral vectors were stereotactically injected into the rat brain (a area between the 
molecular layer of DG and the radial layer of CA1 of the right hippocampus), three days 
after SE. At this time point, the pilocarpine-lesioned brain reacted to the injury by a strong 
increasing of cell proliferation, in an attempt to repair the neuronal loss. However, most of 
these cells differentiate into reactive astrocytes, giving rise to an epileptiform tissue and, 
consequently, eliciting epilepsy. 
Animals were killed 28 days post SE (25 days after viral injection). During the last week, 
they were accurately video-monitored 24/24h to assay the number and the severity of the 
seizures for each subgroup (Fig. 26b).  
To evaluate the pathology, the various experimental subgroups were compared to 
assess eventual differences in astrocytes:neurons ratio by cell staining with GFAP 
(astrocytic marker) and NeuroTrace (neuronal marker). The density of GFAP-positive 
cells in the entire hippocampus was significantly increased in pilocarpine-treated animals 
compared with naïve controls, an indication of reactive astrocytosis (Garzillo and Mello, 
2002). Interestingly, in the subgroup of animals treated with both the vectors expressing 
Lhx2, the density of GFAP-positive cells appeared to be decreased in comparison with 
the control, as shown in Fig. 30. An intriguing data emerging from this analysis is the 
tangible differences in astrocytic density between the hippocampi injected with JΔΝΙ-Lhx2 
or JΔβββ4-Lhx2: for these latter, the astrocyte number is indeed much smaller than the 
JΔΝΙ-Lhx2 subgroup in particular in the radial layer of CA1, a region mostly affected by 
astrocytosis after pilocarpine treatment (Becq et al., 2005; Parent et al., 1997; Parent et 
al., 2006). In the DG, instead, the difference with control in the number of astrocytes 
seemed smaller, probably because that area it’s too far from the injection site. 
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Fig. 30: Immunofluorescence staining of astrocytes (GFAP, green) and neurons (NeuroTrace, red), on 
coronal frozen brain slices of pilocarpine-group of animals, 25 days upon viral injection. Upper panel shows 
the CA1 region (where injection has been performed), lower panel the dentate gyrus. 
 
The decreased reactive astrocytosis may imply a reduced hyperexcitability of the brain 
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and, consequently, a lower susceptibility to develop seizures. We then finally went to 
investigate if this beneficial effect could ameliorate the outcome of the pathology in terms 
of SRSs. We performed behavioral analyses during the last week of life of all the 
subgroup of animals, when the occurrence, severity, and duration of spontaneous 
recurrant seizures (SRSs) were recorded. As expected, all non vector-injected 
pilocarpine-treated rats exhibited, on average, about 3 spontaneous generalized seizures 
per day. Administration of the control vectors did not modify this pattern. Even the 
animals treated with the JΔΝΙ-Lhx2 vector displayed a similar SRSs pattern. In contrast, 
rats injected with the JΔβββ4-Lhx2 vector showed an important improvement, with an 
average reduction of the seizures in the measure of 65% (Table 4)  	  
        Control JΔΝΙ-Lhx2 JΔβββ4-Lhx2 
Seizures 
 per day  
(average) 
3,5 3,2 1,1 
	  
Table 4: Average of seizures per day of pilocarpine group of animals. 	  
Thus, the hippocampal injection of JΔβββ4-Lhx2 vector after the establishment of 
hippocampal sclerosis by pilocarpine treatment might provide both astrocytosis decrease 
and reduction of SRSs.  	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4. DISCUSSION 	  
Epilepsy is most commonly treated with anti-epileptic drugs (AEDs). However, the 
pharmacological treatment is not a cure for epilepsy, but it just aims to try stop seizures. 
None of the AEDs developed up today can indeed prevent the progression of 
symptomatic epilepsies resulting from a known brain insult (i.e. head trauma, prolonged 
febrile seizures, brain infection, brain tumors, episode of status epilepticus, stroke). 
Moreover, AEDs have been demonstrated partially or totally ineffective to control 
seizures for more then 30% of patients; last option for the pharmacoresistant patient is 
usually the surgical resection of the epileptic focus, operation that could distress the 
person even more.  
It is therefore necessary to identify novel strategies to meet this relevant clinical demand, 
preventing the development of disease or, at least, improving the clinical picture for 
millions of patients worldwide affected from this invalidating pathology. 
Last years have been marked by a fluctuating but, after all, increased enthusiasm around 
gene therapy, an emerging new field of medical research that ambitiously promises to 
cure a wide range of untreatable diseases, including epilepsy. Novel approaches of gene 
therapy are constantly emerging, prompted by encouraging results from a variety of pre-
clinical and clinical studies. Several strategies have been explored to achieve the highest 
efficiency for gene transfer while minimizing side effects, but the challenge to set up final 
tools for an efficient and safe gene delivery is still open. The most employed approach for 
gene delivery to the target cells take advantage of genetically engineered non-toxic viral 
vectors. To date, the systems which best couple high efficiency at transducing cells with 
transgene long-term expression are based on retroviral and lentiviral vectors. However, 
although these vectors can be considered highly useful tools for genetic analysis and 
pre-clinical studies, the hazardous drawbacks deriving from viral DNA insertion into the 
host genome are seriously limiting the access to clinical trials.  
Thus far, gene therapy attempts to treat symptomatic epilepsies took advantage of 
recombinant adeno-associated or herpes simplex viruses. These latter strongly burst into 
the gene therapy scene by offering unique features that support their development as the 
best candidate viral vectors especially for targeting the nervous system. HSV is a highly 
infectious, naturally neurotropic virus with the largest cloning capacity among all other 
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viruses, able to establish life-long latency in neurons without any integration into the host 
genome, thus eliminating every possibility of insertional mutagenesis. HSV vectors could 
become the first choice for future approaches of gene therapy if residual drawbacks that 
still limit their use (such as toxicity and level/duration of transgene expression) will be 
overcome.  
Riding this wave, we addressed our study on novel vectors based on Herpes Simplex 
Virus-1 for epilepsy treatment. In this work I have shown data on in vitro and in vivo 
testing of the first and the second generation of two HSV-1 recombinant vectors both 
generated by Dr. Yoshitaka Miyagawa in Glorioso’s lab at University of Pittsburgh 
(unpublished data). Through recombinational cloning, I inserted the gene encoding for 
the transcription factor Lhx2 into both backbones (kindly shared by Dr. Miyagawa).  
The decision to pick this gene for epilepsy gene therapy relies upon the characteristics of 
the Lhx2 protein, involved in the regulation of a wide range of processes from early 
embryogenesis to adult tissue homeostasis, including neural patterning of the central 
nervous system. Although its essential role as a “selector gene” for cerebralcortical fate 
during the very early stages of embryogenesis has been extensively demonstrated, 
recent experimental evidences have extended this view to a “novel” function for Lhx2 in 
the modulation of active neurogenesis in the post-natal central nervous system. In 
particular, Lhx2 could ensure a proper neurogenesis by inhibiting astrogliogenesis 
selectively in the hippocampus, preventing premature astrocyte formation (Subramanian 
et al., 2011). Because epileptogenesis is associated with loss of neurons and reactive 
astrogliogenesis, the key roles played by Lhx2 in neural specification of the adult 
hippocampus make it appealing for a gene therapy approach addressed to 
antiepileptogenic treatments. This was the rational of this thesis: targeting Lhx2 gene in 
specific hippocampal regions during brain remodelling after evoked status epilepticus 
might change the astrocytes-to-neurons ratio by increasing newborn neurons and not 
reactive glial cells. This intervention could potentially ameliorate the outcome of the 
disease, possibly preventing the aberrant transformation of injured brain tissue after an 
epileptogenic insult. Time of intervention is critical, since the goal is to interfere with the 
complex molecular and cellular modifications entailing the plastic reorganization of 
lesioned brain architecture during the time between the precipitating event and the first 
spontaneous seizure. In this seizure-free time, the injured brain reacts to the loss of 
pyramidal neurons by increasing the production of newborn cells in an attempt to restore 
the pre-existing cellular network. However, not all the newborn neurons will properly 
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integrate in the pre-existing circuits: some of them might adopt an ectopic localization, 
potentially giving rise to a new aberrant network triggering spontaneous discharges. 
Moreover, accumulating evidence suggest that a central role in the epileptiform 
transformation may be played by astrocytes. While astrocytes are essential to maintain 
the homeostasis of healthy brain tissue through diverse mechanisms, high proliferating 
reactive astrocytes usually take place near degenerating neurons upon severe brain 
injury. The altered pattern of gene expression and morphology of these newborn glial 
cells might lead to abnormal brain signals, promoting seizure development. 
The aim of this work was to test the infection effectiveness of the novel Herpes-Simplex 
Virus 1-based vectors, to investigate about their toxicity and transgene expression 
through in vitro and in vivo assays and, further, to evaluate the outcome of the pathology 
after Lhx2 delivery in the hippocampus of animal models of epilepsy with HSV-1 based 
vectors.  
Both the HSV-1 vectors used in this work have been engineered to be replication-
incompetent by deletion of immediate early genes essential to replication. The first 
version, named JΔβββ4, is deleted for the immediate early genes ICP4 and ICP47; the 
other IE genes ICP0, ICP22 and ICP27 have been converted to β genes, driven from 
promoters of early genes. Thus, this vector does not express any viral functions but can 
be produced in complementing U2OS cells engineered to express ICP4 in trans. 
However, since a leaky expression of the βICP0 has been detected in human fibroblasts 
infected with the JΔβββ4 virus along with cytotoxicity, from this backbone the second 
generation vector, named JΔNI, has been derived by deletion of the ICP0 IE gene 
(Miyagawa et al., unpublished data). 
To establish which, between the JΔβββ4 and JΔNI backbones, best meets our need, we 
decided to test both of them for in vitro and in vivo studies. 
As expected, all in vitro experiments confirmed that cells infected with the JΔβββ4 vectors 
resulted in greater transgene expression if compared to JΔNI. However, this differential 
transgene expression was also correlated with highest toxicity of JΔβββ4 vector, 
highlighting how ICP0 function can strongly make the difference even when placed under 
the control of a weaker promoter. Nevertheless, even though the lack of ICP0 in JΔNI 
vectors significantly reduces the toxicity compared to its parental version, the effects on 
transgene expression are not detrimental: all cells infected in vitro with the JΔNI virus can 
indeed express detectable levels of transgene without showing strong signs of toxicity.  
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These results where consistent even upon infection of primary cultures of murine 
neurons and astrocytes, both cultures efficiently infected by the JΔβββ4  and the JΔNI 
vector along with a good transgene expression. 
Encouraged by promising in vitro results, we decided to test these novel HSV-1 based 
vectors also in vivo. Even if several efforts have been made to find a good strategy to 
cross the blood-brain barrier after non-invasive peripheral administration of the vectors in 
the blood, these approaches still present several drawbacks that do not allow 
replacement of the “classical” stereotactical injection into the brain.  
JΔβββ4  and JΔNI were then directly inoculated in the right hippocampus of rats, divided 
in two groups: the first one (naïve group) was established to assess the efficiency of in 
vivo infection and the possible toxicity evoked by the two viral backbones, the second 
one (pilocarpine group) was designed to get indications about potential effects of 
hippocampal Lhx2 delivery in on  animal models of epilepsy. 
Since both JΔβββ4 and JΔNI viral vectors have been engineered to express mCherry in 
infected cells, I could detect red signal in both JΔNI- and JΔβββ4-injected brains, in 
confirmation that are both able to efficiently infect CNS cells not only in vitro but also in 
vivo. As expected, the JΔβββ4 virus elicited a more extended infection or, at least, a 
stronger mCherry expression upon infection, confirming the central importance of ICP0 
also in vivo. 
Interestingly, even though the surgical procedure for injection could per se induce an 
immune cellular response with infiltration of blood cells into the brain through breaking of 
the blood-brain barrier, we did not detect a strong response mediated by host immune 
system nor a relevant cellular toxicity evoked by the two vectors 12 days after viral 
injection.  
Finally, we investigated the consequences of Lhx2 gene delivery through JΔβββ4 and 
JΔNI on the lesioned hippocampi of pilocarpine-treated rats. Interestingly, Lhx2 delivery 
with both backbones seemed to be effective in decreasing the density of reactive 
astrocytes, usually substantially enhanced upon induced status epilepticus as shown by 
the lesioned-uninfected control brain. The most evident data resulting from these 
analyses is the substantial differences in astrocytosis between hippocampi injected with 
the JΔNI-Lhx2 and those injected with the JΔβββ4-Lhx2: these latter displayed a strong 
reduction in astrocyte number. The decreased reactive astrocytosis may imply a reduced 
hyperexcitability of the brain and, consequently, a lower susceptibility to seizures. 
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These ex vivo data were strengthened by analysis of the outcome of the pathology in 
terms of spontaneous recurrent seizures. Even though animals injected with the JΔNI-
Lhx2 vector displayed a similar SRSs pattern of control subgroup, rats injected with the 
JΔβββ4-Lhx2 vector displayed a significant improvement of the clinical picture, 
undergoing an dramatic reduction of SRSs (about 65% compared to the control group). 
In conclusion, the JΔβββ4 and JΔNI-based vectors may be useful tools for differential 
purposes: while for in vitro applications the JΔNI vector has been demonstrated to be the 
best compromise between transgene expression and low toxicity effects, for in vivo gene 
transfer it result almost ineffective; in contrast the JΔβββ4 vector has exactly the opposite 
features, too toxic for in vitro approaches but much more effective for in vivo gene 
delivery. Moreover, the in vivo data from this thesis confirmed our hypothesis on the 
potential therapeutic effects of Lhx2 protein delivered into the hippocampus of an animal 
model of epilepsy before SRSs, supporting this approach for the prevention of epilepsy. 
This thesis reported initial data of an ongoing study. Several new generation vectors 
have been already generated to further improve transgene expression and to completely 
remove any residual toxicity. These new vectors could represent the “final tools” for gene 
transfer both in vitro and in vivo, in particular in the central nervous system, allowing the 
efficient delivery of several candidate genes we want to test for gene therapy of epilepsy, 
first of all Lhx2. 
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Increased excitability in tat-transgenic mice: role of tat in HIV-
related neurological disorders. 
Zucchini S, Pittaluga A, Brocca-Cofano E, Summa M, Fabris M, Michele RD, Bonaccorsi 
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Abstract 
HIV-1 associated neurocognitive disorders (HAND) are a major complication of 
HIV-1 infection. The mechanism(s) underlying HAND are not completely 
understood but, based on in vitro studies, the HIV-1 Tat protein may play an 
important role. In this study, the effect of prolonged exposure to endogenously 
produced Tat in the brain was investigated using a tat-transgenic (TT) mouse 
model constitutively expressing the HIV-1 tat gene. We found that stimulus-evoked 
glutamate exocytosis in the hippocampus and cortex was significantly increased in 
TT as compared with wild-type control (CC) mice, while GABA exocytosis was 
unchanged in the hippocampus and decreased in the cortex. This suggests that 
Tat generates a latent hyper-excitability state, which favor the detrimental effects 
of neurotoxic and/or excitotoxic agents. To challenge this idea, TT mice were 
tested for susceptibility to kainate-induced seizures and neurodegeneration, and 
found to exhibit significantly greater responses to the convulsant agent than CC 
mice. These results support the concept that constitutive expression of tat in the 
brain generates a latent excitatory state, which may increase the negative effects 
of damaging insults. These events may play a key role in the development of 
HAND.	  	  	   http://www.sciencedirect.com/science/article/pii/S0969996113000661	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Abstract 
Bradykinin (BK) and its receptors (B1 and B2) may exert a role in the 
pathophysiology of certain CNS diseases, including epilepsy. In healthy tissues, 
B2 receptors are constitutively and widely expressed and B1 receptors are absent 
or expressed at very low levels, but both receptors, particularly B1, are up-
regulated under many pathological conditions. Available data support the notion 
that up-regulation of B1 receptors in brain areas like amygdala, hippocampus and 
enthorinal cortex favors the development and maintenance of an epileptic 
condition. The role of B2 receptors, instead, is still unclear. In this study, we used 
two different models to investigate the susceptibility to seizures of B1 knockout 
(KO) and B2 KO mice. We found that B1KO are more susceptible to seizures 
compared with wild-type (WT) mice, and that this depends on B2 receptors, in that 
i) B2 receptors are overexpressed in limbic areas of B1 KO mice, including the 
hippocampus and the piriform cortex; ii) hippocampal slices prepared from B1 KO 
mice are more excitable than those prepared form WT controls, and this 
phenomenon is B2 receptor-dependent, being abolished by B2 antagonists; iii) 
kainate seizure severity is attenuated by pretreatment with a non-peptide B2 
antagonist in WT and (more effectively) in B1 KO mice. These data highlight the 
possibility that B2 receptors may have a role in the responsiveness to 
epileptogenic insults and/or in the early period of epileptogenesis, that is, in the 
onset of the molecular and cellular events that lead to the transformation of a 
normal brain into epileptic.  	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Abstract 
The pharmacological treatment of temporal lobe epilepsy (TLE), the most common 
epileptic syndrome in adults, is still unsatisfactory, as one third of the patients are 
or become refractory to antiepileptic agents. It is thought that the disease may 
undergo a progressive evolution, which may affect the sensitivity to drugs. TLE 
has been shown to be associated with a dysfunction of the inhibitory signaling 
mediated by GABAA receptors. In particular, the repetitive activation of GABAA 
receptors produces a use-dependent decrease (rundown) of the evoked currents 
(IGABA), which is markedly enhanced in the hippocampus and cortex of drug-
resistant TLE patients. This phenomenon has been also observed in the 
pilocarpine model of TLE, where the increased IGABA rundown is observed in the 
hippocampus at the time of the first spontaneous seizure, then extends to the 
cortex and remains constant in the chronic phase of the disease. Here, we 
examined the pharmacological modulation of IGABA in the natural history of 
experimental TLE. We focused on the antiepileptic agent levetiracetam and on the 
neurotrophin BDNF, which were previously reported to attenuate TLE-induced 
increased rundown in the chronic human tissue. In the pilocarpine model, BDNF 
displayed a paramount effect, decreasing rundown in the hippocampus at the time 
of the first seizure, as well as in the hippocampus and cortex in the chronic period. 
In contrast, levetiracetam did not affect rundown in the hippocampus, but 
attenuated it in the cortex. Interestingly, this effect of levetiracetam was also 
observed on the still unaltered rundown observed in the cortex at the time of the 
first spontaneous seizure.  These data suggest that the sensitivity of GABAA 
receptors to pharmacological interventions undergoes changes during the natural 
history of TLE, implicating that the timing of treatment may highly affect the 
therapeutic outcome. 	  
	   100	  
5. BIBLIOGRAPHY 	   	  	  
1. Aasebo, I. E., S. Blankvoort, and A. Tashiro. 2011. Critical maturational period of new 
neurons in adult dentate gyrus for their involvement in memory formation. Eur J Neurosci 
33:1094-100. 
2. Ables, J. L., N. A. Decarolis, M. A. Johnson, P. D. Rivera, Z. Gao, D. C. Cooper, F. 
Radtke, J. Hsieh, and A. J. Eisch. 2010. Notch1 is required for maintenance of the 
reservoir of adult hippocampal stem cells. J Neurosci 30:10484-92. 
3. Adelow, C., E. Andell, P. Amark, T. Andersson, E. Hellebro, A. Ahlbom, and T. 
Tomson. 2009. Newly diagnosed single unprovoked seizures and epilepsy in 
Stockholm, Sweden: First report from the Stockholm Incidence Registry of Epilepsy 
(SIRE). Epilepsia 50:1094-101. 
4. Agulnick, A. D., M. Taira, J. J. Breen, T. Tanaka, I. B. Dawid, and H. Westphal. 1996. 
Interactions of the LIM-domain-binding factor Ldb1 with LIM homeodomain proteins. 
Nature 384:270-2. 
5. Ahn, K., T. H. Meyer, S. Uebel, P. Sempe, H. Djaballah, Y. Yang, P. A. Peterson, K. 
Fruh, and R. Tampe. 1996. Molecular mechanism and species specificity of TAP 
inhibition by herpes simplex virus ICP47. EMBO J 15:3247-55. 
6. Aiuti, A., F. Cattaneo, S. Galimberti, U. Benninghoff, B. Cassani, L. Callegaro, S. 
Scaramuzza, G. Andolfi, M. Mirolo, I. Brigida, A. Tabucchi, F. Carlucci, M. Eibl, M. 
Aker, S. Slavin, H. Al-Mousa, A. Al Ghonaium, A. Ferster, A. Duppenthaler, L. 
Notarangelo, U. Wintergerst, R. H. Buckley, M. Bregni, S. Marktel, M. G. Valsecchi, 
P. Rossi, F. Ciceri, R. Miniero, C. Bordignon, and M. G. Roncarolo. 2009. Gene 
therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 
360:447-58. 
7. Archer, V. E., J. Breton, I. Sanchez-Garcia, H. Osada, A. Forster, A. J. Thomson, 
and T. H. Rabbitts. 1994. Cysteine-rich LIM domains of LIM-homeodomain and LIM-
only proteins contain zinc but not iron. Proc Natl Acad Sci U S A 91:316-20. 
8. Arida, R. M., F. A. Scorza, C. A. Peres, and E. A. Cavalheiro. 1999. The course of 
untreated seizures in the pilocarpine model of epilepsy. Epilepsy Res 34:99-107. 
9. Arvidsson, A., T. Collin, D. Kirik, Z. Kokaia, and O. Lindvall. 2002. Neuronal 
replacement from endogenous precursors in the adult brain after stroke. Nat Med 8:963-
70. 
10. Atencio, I. A., Z. Chen, Q. H. Nguyen, B. Faha, and D. C. Maneval. 2004. p21WAF-
1/Cip-1 gene therapy as an adjunct to glaucoma filtration surgery. Curr Opin Mol Ther 
6:624-8. 
11. Austin, J. E., and P. S. Buckmaster. 2004. Recurrent excitation of granule cells with 
basal dendrites and low interneuron density and inhibitory postsynaptic current 
frequency in the dentate gyrus of macaque monkeys. J Comp Neurol 476:205-18. 
12. Azzouz, M., S. M. Kingsman, and N. D. Mazarakis. 2004. Lentiviral vectors for treating 
and modeling human CNS disorders. J Gene Med 6:951-62. 
13. Babb, T. L., W. R. Kupfer, J. K. Pretorius, P. H. Crandall, and M. F. Levesque. 1991. 
Synaptic reorganization by mossy fibers in human epileptic fascia dentata. Neuroscience 
42:351-63. 
14. Bainbridge, J. W., A. J. Smith, S. S. Barker, S. Robbie, R. Henderson, K. Balaggan, 
A. Viswanathan, G. E. Holder, A. Stockman, N. Tyler, S. Petersen-Jones, S. S. 
Bhattacharya, A. J. Thrasher, F. W. Fitzke, B. J. Carter, G. S. Rubin, A. T. Moore, 
and R. R. Ali. 2008. Effect of gene therapy on visual function in Leber's congenital 
amaurosis. N Engl J Med 358:2231-9. 
15. Baraban, S. C., D. G. Southwell, R. C. Estrada, D. L. Jones, J. Y. Sebe, C. Alfaro-
	   101	  
Cervello, J. M. Garcia-Verdugo, J. L. Rubenstein, and A. Alvarez-Buylla. 2009. 
Reduction of seizures by transplantation of cortical GABAergic interneuron precursors 
into Kv1.1 mutant mice. Proc Natl Acad Sci U S A 106:15472-7. 
16. Becq, H., I. Jorquera, Y. Ben-Ari, S. Weiss, and A. Represa. 2005. Differential 
properties of dentate gyrus and CA1 neural precursors. J Neurobiol 62:243-61. 
17. Ben-Ari, Y. 2001. Cell death and synaptic reorganizations produced by seizures. 
Epilepsia 42 Suppl 3:5-7. 
18. Ben-Ari, Y., and R. Cossart. 2000. Kainate, a double agent that generates seizures: 
two decades of progress. Trends Neurosci 23:580-7. 
19. Bengzon, J., Z. Kokaia, E. Elmer, A. Nanobashvili, M. Kokaia, and O. Lindvall. 1997. 
Apoptosis and proliferation of dentate gyrus neurons after single and intermittent limbic 
seizures. Proc Natl Acad Sci U S A 94:10432-7. 
20. Berger, H. 1929.  Uber das elektrenkephalogramm des menschen. . Arch. f. Psychiat. 
87. 
21. Berger, M. F., G. Badis, A. R. Gehrke, S. Talukder, A. A. Philippakis, L. Pena-
Castillo, T. M. Alleyne, S. Mnaimneh, O. B. Botvinnik, E. T. Chan, F. Khalid, W. 
Zhang, D. Newburger, S. A. Jaeger, Q. D. Morris, M. L. Bulyk, and T. R. Hughes. 
2008. Variation in homeodomain DNA binding revealed by high-resolution analysis of 
sequence preferences. Cell 133:1266-76. 
22. Bernasconi, N., A. Bernasconi, Z. Caramanos, S. B. Antel, F. Andermann, and D. L. 
Arnold. 2003. Mesial temporal damage in temporal lobe epilepsy: a volumetric MRI 
study of the hippocampus, amygdala and parahippocampal region. Brain 126:462-9. 
23. Binder, D. K., and C. Steinhauser. 2006. Functional changes in astroglial cells in 
epilepsy. Glia 54:358-68. 
24. Blaho, J. A., C. Mitchell, and B. Roizman. 1993. Guanylylation and adenylylation of the 
alpha regulatory proteins of herpes simplex virus require a viral beta or gamma function. 
J Virol 67:3891-900. 
25. Boison, D. 2008. The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol 
84:249-62. 
26. Boulaiz, H., J. A. Marchal, J. Prados, C. Melguizo, and A. Aranega. 2005. Non-viral 
and viral vectors for gene therapy. Cell Mol Biol (Noisy-le-grand) 51:3-22. 
27. Bovolenta, R., S. Zucchini, B. Paradiso, D. Rodi, F. Merigo, G. Navarro Mora, F. 
Osculati, E. Berto, P. Marconi, A. Marzola, P. F. Fabene, and M. Simonato. 2010. 
Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated 
neuroinflammation and reduces spontaneous recurrent seizures. J Neuroinflammation 
7:81. 
28. Bozac, A., E. Berto, F. Vasquez, P. Grandi, A. Caputo, R. Manservigi, B. Ensoli, and 
P. Marconi. 2006. Expression of human immunodeficiency virus type 1 tat from a 
replication-deficient herpes simplex type 1 vector induces antigen-specific T cell 
responses. Vaccine 24:7148-58. 
29. Briellmann, R. S., R. M. Kalnins, S. F. Berkovic, and G. D. Jackson. 2002. 
Hippocampal pathology in refractory temporal lobe epilepsy: T2-weighted signal change 
reflects dentate gliosis. Neurology 58:265-71. 
30. Brooks, A. I., D. A. Cory-Slechta, W. J. Bowers, S. L. Murg, and H. J. Federoff. 
2000. Enhanced learning in mice parallels vector-mediated nerve growth factor 
expression in hippocampus. Hum Gene Ther 11:2341-52. 
31. Brooks, A. I., C. S. Stein, S. M. Hughes, J. Heth, P. M. McCray, Jr., S. L. Sauter, J. 
C. Johnston, D. A. Cory-Slechta, H. J. Federoff, and B. L. Davidson. 2002. 
Functional correction of established central nervous system deficits in an animal model 
of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc 
Natl Acad Sci U S A 99:6216-21. 
32. Bryant, H. E., S. E. Wadd, A. I. Lamond, S. J. Silverstein, and J. B. Clements. 2001. 
	   102	  
Herpes simplex virus IE63 (ICP27) protein interacts with spliceosome-associated protein 
145 and inhibits splicing prior to the first catalytic step. J Virol 75:4376-85. 
33. Buckmaster, P. S., and P. A. Schwartzkroin. 1994. Hippocampal mossy cell function: 
a speculative view. Hippocampus 4:393-402. 
34. Bulchand, S., E. A. Grove, F. D. Porter, and S. Tole. 2001. LIM-homeodomain gene 
Lhx2 regulates the formation of the cortical hem. Mech Dev 100:165-75. 
35. Bulchand, S., L. Subramanian, and S. Tole. 2003. Dynamic spatiotemporal expression 
of LIM genes and cofactors in the embryonic and postnatal cerebral cortex. Dev Dyn 
226:460-9. 
36. Burgos, J. S., E. Serrano-Saiz, I. Sastre, and F. Valdivieso. 2006. ICP47 mediates 
viral neuroinvasiveness by induction of TAP protein following intravenous inoculation of 
herpes simplex virus type 1 in mice. J Neurovirol 12:420-7. 
37. Cai, W. H., B. Gu, and S. Person. 1988. Role of glycoprotein B of herpes simplex virus 
type 1 in viral entry and cell fusion. J Virol 62:2596-604. 
38. Cameron, H. A., and R. D. McKay. 2001. Adult neurogenesis produces a large pool of 
new granule cells in the dentate gyrus. J Comp Neurol 435:406-17. 
39. Campbell, M. E., J. W. Palfreyman, and C. M. Preston. 1984. Identification of herpes 
simplex virus DNA sequences which encode a trans-acting polypeptide responsible for 
stimulation of immediate early transcription. J Mol Biol 180:1-19. 
40. Campos, S. K., and M. A. Barry. 2007. Current advances and future challenges in 
Adenoviral vector biology and targeting. Curr Gene Ther 7:189-204. 
41. Cardone, G., D. C. Winkler, B. L. Trus, N. Cheng, J. E. Heuser, W. W. Newcomb, J. 
C. Brown, and A. C. Steven. 2007. Visualization of the herpes simplex virus portal in 
situ by cryo-electron tomography. Virology 361:426-34. 
42. Carpentino, J. E., N. W. Hartman, L. B. Grabel, and J. R. Naegele. 2008. Region-
specific differentiation of embryonic stem cell-derived neural progenitor transplants into 
the adult mouse hippocampus following seizures. J Neurosci Res 86:512-24. 
43. Carrozza, M. J., and N. A. DeLuca. 1996. Interaction of the viral activator protein ICP4 
with TFIID through TAF250. Mol Cell Biol 16:3085-93. 
44. Castiglioni, A. J., S. L. Peterson, E. L. Sanabria, and E. Tiffany-Castiglioni. 1990. 
Structural changes in astrocytes induced by seizures in a mode of temporal lobe 
epilepsy. J Neurosci Res 26:334-41. 
45. Cavalheiro, E. A. 1995. The pilocarpine model of epilepsy. Ital J Neurol Sci 16:33-7. 
46. Cavalheiro, E. A., J. P. Leite, Z. A. Bortolotto, W. A. Turski, C. Ikonomidou, and L. 
Turski. 1991. Long-term effects of pilocarpine in rats: structural damage of the brain 
triggers kindling and spontaneous recurrent seizures. Epilepsia 32:778-82. 
47. Cavazzana-Calvo, M., and A. Fischer. 2007. Gene therapy for severe combined 
immunodeficiency: are we there yet? J Clin Invest 117:1456-65. 
48. Cavazzana-Calvo, M., S. Hacein-Bey, G. de Saint Basile, F. Gross, E. Yvon, P. 
Nusbaum, F. Selz, C. Hue, S. Certain, J. L. Casanova, P. Bousso, F. L. Deist, and A. 
Fischer. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 
disease. Science 288:669-72. 
49. Chiocca, E. A., B. B. Choi, W. Z. Cai, N. A. DeLuca, P. A. Schaffer, M. DiFiglia, X. O. 
Breakefield, and R. L. Martuza. 1990. Transfer and expression of the lacZ gene in rat 
brain neurons mediated by herpes simplex virus mutants. New Biol 2:739-46. 
50. Christie, B. R., and H. A. Cameron. 2006. Neurogenesis in the adult hippocampus. 
Hippocampus 16:199-207. 
51. Coffin, R. S., M. K. Howard, D. V. Cumming, C. M. Dollery, J. McEwan, D. M. Yellon, 
M. S. Marber, A. R. MacLean, S. M. Brown, and D. S. Latchman. 1996. Gene delivery 
to the heart in vivo and to cardiac myocytes and vascular smooth muscle cells in vitro 
using herpes virus vectors. Gene Ther 3:560-6. 
52. Cohen, G. H., M. Ponce de Leon, H. Diggelmann, W. C. Lawrence, S. K. Vernon, 
	   103	  
and R. J. Eisenberg. 1980. Structural analysis of the capsid polypeptides of herpes 
simplex virus types 1 and 2. J Virol 34:521-31. 
53. Crystal, R. G. 1995. Transfer of genes to humans: early lessons and obstacles to 
success. Science 270:404-10. 
54. Dargan, D. J., J. D. Aitken, and J. H. Subak-Sharpe. 1988. The effect of triterpenoid 
compounds on uninfected and herpes simplex virus-infected cells in culture. III. 
Ultrastructural study of virion maturation. J Gen Virol 69 ( Pt 2):439-44. 
55. Dawid, I. B., J. J. Breen, and R. Toyama. 1998. LIM domains: multiple roles as 
adapters and functional modifiers in protein interactions. Trends Genet 14:156-62. 
56. Deiss, L. P., J. Chou, and N. Frenkel. 1986. Functional domains within the a sequence 
involved in the cleavage-packaging of herpes simplex virus DNA. J Virol 59:605-18. 
57. DeLuca, N. A., A. M. McCarthy, and P. A. Schaffer. 1985. Isolation and 
characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding 
immediate-early regulatory protein ICP4. J Virol 56:558-70. 
58. Deshmane, S. L., B. Raengsakulrach, J. F. Berson, and N. W. Fraser. 1995. The 
replicating intermediates of herpes simplex virus type 1 DNA are relatively short. J 
Neurovirol 1:165-76. 
59. Dixon, R. A., and P. A. Schaffer. 1980. Fine-structure mapping and functional analysis 
of temperature-sensitive mutants in the gene encoding the herpes simplex virus type 1 
immediate early protein VP175. J Virol 36:189-203. 
60. Dobson, A. T., T. P. Margolis, F. Sedarati, J. G. Stevens, and L. T. Feldman. 1990. A 
latent, nonpathogenic HSV-1-derived vector stably expresses beta-galactosidase in 
mouse neurons. Neuron 5:353-60. 
61. Dohner, K., A. Wolfstein, U. Prank, C. Echeverri, D. Dujardin, R. Vallee, and B. 
Sodeik. 2002. Function of dynein and dynactin in herpes simplex virus capsid transport. 
Mol Biol Cell 13:2795-809. 
62. Douglas, J. T. 2007. Adenoviral vectors for gene therapy. Mol Biotechnol 36:71-80. 
63. Duffy, C., E. F. Mbong, and J. D. Baines. 2009. VP22 of herpes simplex virus 1 
promotes protein synthesis at late times in infection and accumulation of a subset of viral 
mRNAs at early times in infection. J Virol 83:1009-17. 
64. Edelstein, M. L., M. R. Abedi, J. Wixon, and R. M. Edelstein. 2004. Gene therapy 
clinical trials worldwide 1989-2004-an overview. J Gene Med 6:597-602. 
65. Ekdahl, C. T., P. Mohapel, E. Elmer, and O. Lindvall. 2001. Caspase inhibitors 
increase short-term survival of progenitor-cell progeny in the adult rat dentate gyrus 
following status epilepticus. Eur J Neurosci 14:937-45. 
66. Engel, J., Jr., T. L. Babb, and P. H. Crandall. 1989. Surgical treatment of epilepsy: 
opportunities for research into basic mechanisms of human brain function. Acta 
Neurochir Suppl (Wien) 46:3-8. 
67. Engel, J., Jr., and E. International League Against. 2001. A proposed diagnostic 
scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task 
Force on Classification and Terminology. Epilepsia 42:796-803. 
68. Enquist, L. W., P. J. Husak, B. W. Banfield, and G. A. Smith. 1998. Infection and 
spread of alphaherpesviruses in the nervous system. Adv Virus Res 51:237-347. 
69. Eriksson, P. S., E. Perfilieva, T. Bjork-Eriksson, A. M. Alborn, C. Nordborg, D. A. 
Peterson, and F. H. Gage. 1998. Neurogenesis in the adult human hippocampus. Nat 
Med 4:1313-7. 
70. Everett, R. D., G. Sourvinos, C. Leiper, J. B. Clements, and A. Orr. 2004. Formation 
of nuclear foci of the herpes simplex virus type 1 regulatory protein ICP4 at early times of 
infection: localization, dynamics, recruitment of ICP27, and evidence for the de novo 
induction of ND10-like complexes. J Virol 78:1903-17. 
71. Farrell, M. J., A. T. Dobson, and L. T. Feldman. 1991. Herpes simplex virus latency-
associated transcript is a stable intron. Proc Natl Acad Sci U S A 88:790-4. 
	   104	  
72. Filippov, V., G. Kronenberg, T. Pivneva, K. Reuter, B. Steiner, L. P. Wang, M. 
Yamaguchi, H. Kettenmann, and G. Kempermann. 2003. Subpopulation of nestin-
expressing progenitor cells in the adult murine hippocampus shows electrophysiological 
and morphological characteristics of astrocytes. Mol Cell Neurosci 23:373-82. 
73. Fisher, R. S. 1989. Animal models of the epilepsies. Brain Res Brain Res Rev 14:245-
78. 
74. Fisher, R. S., W. van Emde Boas, W. Blume, C. Elger, P. Genton, P. Lee, and J. 
Engel, Jr. 2005. Epileptic seizures and epilepsy: definitions proposed by the 
International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy 
(IBE). Epilepsia 46:470-2. 
75. Foucher, I., M. L. Montesinos, M. Volovitch, A. Prochiantz, and A. Trembleau. 2003. 
Joint regulation of the MAP1B promoter by HNF3beta/Foxa2 and Engrailed is the result 
of a highly conserved mechanism for direct interaction of homeoproteins and Fox 
transcription factors. Development 130:1867-76. 
76. Frampton, A. R., Jr., W. F. Goins, K. Nakano, E. A. Burton, and J. C. Glorioso. 2005. 
HSV trafficking and development of gene therapy vectors with applications in the 
nervous system. Gene Ther 12:891-901. 
77. French, J. A., P. D. Williamson, V. M. Thadani, T. M. Darcey, R. H. Mattson, S. S. 
Spencer, and D. D. Spencer. 1993. Characteristics of medial temporal lobe epilepsy: I. 
Results of history and physical examination. Ann Neurol 34:774-80. 
78. Freyd, G., S. K. Kim, and H. R. Horvitz. 1990. Novel cysteine-rich motif and 
homeodomain in the product of the Caenorhabditis elegans cell lineage gene lin-11. 
Nature 344:876-9. 
79. Fruh, K., K. Ahn, H. Djaballah, P. Sempe, P. M. van Endert, R. Tampe, P. A. 
Peterson, and Y. Yang. 1995. A viral inhibitor of peptide transporters for antigen 
presentation. Nature 375:415-8. 
80. Fukuda, S., F. Kato, Y. Tozuka, M. Yamaguchi, Y. Miyamoto, and T. Hisatsune. 
2003. Two distinct subpopulations of nestin-positive cells in adult mouse dentate gyrus. J 
Neurosci 23:9357-66. 
81. Gage, F. H. 2000. Mammalian neural stem cells. Science 287:1433-8. 
82. Gage, F. H. 2002. Neurogenesis in the adult brain. J Neurosci 22:612-3. 
83. Galceran, J., E. M. Miyashita-Lin, E. Devaney, J. L. Rubenstein, and R. Grosschedl. 
2000. Hippocampus development and generation of dentate gyrus granule cells is 
regulated by LEF1. Development 127:469-82. 
84. Ge, S., E. L. Goh, K. A. Sailor, Y. Kitabatake, G. L. Ming, and H. Song. 2006. GABA 
regulates synaptic integration of newly generated neurons in the adult brain. Nature 
439:589-93. 
85. Geller, A. I., K. Keyomarsi, J. Bryan, and A. B. Pardee. 1990. An efficient deletion 
mutant packaging system for defective herpes simplex virus vectors: potential 
applications to human gene therapy and neuronal physiology. Proc Natl Acad Sci U S A 
87:8950-4. 
86. Gelman, I. H., and S. Silverstein. 1986. Co-ordinate regulation of herpes simplex virus 
gene expression is mediated by the functional interaction of two immediate early gene 
products. J Mol Biol 191:395-409. 
87. Glorioso, J. C., and D. J. Fink. 2004. Herpes vector-mediated gene transfer in 
treatment of diseases of the nervous system. Annu Rev Microbiol 58:253-71. 
88. Goffin, K., J. Nissinen, K. Van Laere, and A. Pitkanen. 2007. Cyclicity of spontaneous 
recurrent seizures in pilocarpine model of temporal lobe epilepsy in rat. Exp Neurol 
205:501-5. 
89. Goins, W. F., N. Yoshimura, M. W. Phelan, T. Yokoyama, M. O. Fraser, H. Ozawa, N. 
J. Bennett, W. C. de Groat, J. C. Glorioso, and M. B. Chancellor. 2001. Herpes 
simplex virus mediated nerve growth factor expression in bladder and afferent neurons: 
	   105	  
potential treatment for diabetic bladder dysfunction. J Urol 165:1748-54. 
90. Gray, W. P., and L. E. Sundstrom. 1998. Kainic acid increases the proliferation of 
granule cell progenitors in the dentate gyrus of the adult rat. Brain Res 790:52-9. 
91. Grunewald, K., P. Desai, D. C. Winkler, J. B. Heymann, D. M. Belnap, W. 
Baumeister, and A. C. Steven. 2003. Three-dimensional structure of herpes simplex 
virus from cryo-electron tomography. Science 302:1396-8. 
92. Hagglund, R., and B. Roizman. 2004. Role of ICP0 in the strategy of conquest of the 
host cell by herpes simplex virus 1. J Virol 78:2169-78. 
93. Hancock, M. H., A. R. Cliffe, D. M. Knipe, and J. R. Smiley. 2010. Herpes simplex 
virus VP16, but not ICP0, is required to reduce histone occupancy and enhance histone 
acetylation on viral genomes in U2OS osteosarcoma cells. J Virol 84:1366-75. 
94. Harris, A. B. 1975. Cortical neuroglia in experimental epilepsy. Exp Neurol 49:691-715. 
95. Harris, R. A., R. D. Everett, X. X. Zhu, S. Silverstein, and C. M. Preston. 1989. 
Herpes simplex virus type 1 immediate-early protein Vmw110 reactivates latent herpes 
simplex virus type 2 in an in vitro latency system. J Virol 63:3513-5. 
96. Hayward, G. S., R. J. Jacob, S. C. Wadsworth, and B. Roizman. 1975. Anatomy of 
herpes simplex virus DNA: evidence for four populations of molecules that differ in the 
relative orientations of their long and short components. Proc Natl Acad Sci U S A 
72:4243-7. 
97. Heavner, S. B., A. D. Rubin, K. Fung, M. Old, N. D. Hogikyan, and E. L. Feldman. 
2007. Dysfunction of the recurrent laryngeal nerve and the potential of gene therapy. 
Ann Otol Rhinol Laryngol 116:441-8. 
98. Heinrich, C., R. Blum, S. Gascon, G. Masserdotti, P. Tripathi, R. Sanchez, S. Tiedt, 
T. Schroeder, M. Gotz, and B. Berninger. 2010. Directing astroglia from the cerebral 
cortex into subtype specific functional neurons. PLoS Biol 8:e1000373. 
99. Herold, B. C., R. J. Visalli, N. Susmarski, C. R. Brandt, and P. G. Spear. 1994. 
Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface 
heparan sulphate and glycoprotein B. J Gen Virol 75 ( Pt 6):1211-22. 
100. Hershey, A. D., and M. Chase. 1952. Independent functions of viral protein and nucleic 
acid in growth of bacteriophage. J Gen Physiol 36:39-56. 
101. Herzog, R. W., and V. R. Arruda. 2003. Update on gene therapy for hereditary 
hematological disorders. Expert Rev Cardiovasc Ther 1:215-32. 
102. Hobert, O., and G. Ruvkun. 1998. A common theme for LIM homeobox gene function 
across phylogeny? Biological Bulletin 195:377-380. 
103. Hobert, O., and H. Westphal. 2000. Functions of LIM-homeobox genes. Trends in 
Genetics 16:75-83. 
104. Hong, C. S., W. F. Goins, J. R. Goss, E. A. Burton, and J. C. Glorioso. 2006. Herpes 
simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of 
Alzheimer's disease-related amyloid-beta peptide in vivo. Gene Ther 13:1068-79. 
105. Horsburgh, B. C., M. M. Hubinette, D. Qiang, M. L. MacDonald, and F. Tufaro. 1999. 
Allele replacement: an application that permits rapid manipulation of herpes simplex 
virus type 1 genomes. Gene Ther 6:922-30. 
106. Howard, M. K., T. Kershaw, B. Gibb, N. Storey, A. R. MacLean, B. Y. Zeng, B. C. 
Tel, P. Jenner, S. M. Brown, C. J. Woolf, P. N. Anderson, R. S. Coffin, and D. S. 
Latchman. 1998. High efficiency gene transfer to the central nervous system of rodents 
and primates using herpes virus vectors lacking functional ICP27 and ICP34.5. Gene 
Ther 5:1137-47. 
107. Huang, J., J. R. Kent, B. Placek, K. A. Whelan, C. M. Hollow, P. Y. Zeng, N. W. 
Fraser, and S. L. Berger. 2006. Trimethylation of histone H3 lysine 4 by Set1 in the lytic 
infection of human herpes simplex virus 1. J Virol 80:5740-6. 
108. Huard, J., G. Akkaraju, S. C. Watkins, M. Pike-Cavalcoli, and J. C. Glorioso. 1997. 
LacZ gene transfer to skeletal muscle using a replication-defective herpes simplex virus 
	   106	  
type 1 mutant vector. Hum Gene Ther 8:439-52. 
109. Huebner, S., B. J. Battersby, R. Grimm, and G. Cevc. 1999. Lipid-DNA complex 
formation: reorganization and rupture of lipid vesicles in the presence of DNA as 
observed by cryoelectron microscopy. Biophys J 76:3158-66. 
110. Hughlings-Jackson, J. 1888. On a particular variety of epilepsy (" intellectual aura"), 
one case with symptoms of organic brain disease. . Brain 11. 
111. Isokawa, M., M. F. Levesque, T. L. Babb, and J. Engel, Jr. 1993. Single mossy fiber 
axonal systems of human dentate granule cells studied in hippocampal slices from 
patients with temporal lobe epilepsy. J Neurosci 13:1511-22. 
112. Jakubs, K., A. Nanobashvili, S. Bonde, C. T. Ekdahl, Z. Kokaia, M. Kokaia, and O. 
Lindvall. 2006. Environment matters: synaptic properties of neurons born in the epileptic 
adult brain develop to reduce excitability. Neuron 52:1047-59. 
113. Jessberger, S., and G. Kempermann. 2003. Adult-born hippocampal neurons mature 
into activity-dependent responsiveness. Eur J Neurosci 18:2707-12. 
114. Jessberger, S., B. Romer, H. Babu, and G. Kempermann. 2005. Seizures induce 
proliferation and dispersion of doublecortin-positive hippocampal progenitor cells. Exp 
Neurol 196:342-51. 
115. Jin, B. K., M. Belloni, B. Conti, H. J. Federoff, R. Starr, J. H. Son, H. Baker, and T. 
H. Joh. 1996. Prolonged in vivo gene expression driven by a tyrosine hydroxylase 
promoter in a defective herpes simplex virus amplicon vector. Hum Gene Ther 7:2015-
24. 
116. Johnson, P. A., A. Miyanohara, F. Levine, T. Cahill, and T. Friedmann. 1992. 
Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1. J Virol 
66:2952-65. 
117. Jovasevic, V., L. Liang, and B. Roizman. 2008. Proteolytic cleavage of VP1-2 is 
required for release of herpes simplex virus 1 DNA into the nucleus. J Virol 82:3311-9. 
118. Kanegae, Y., M. Makimura, and I. Saito. 1994. A simple and efficient method for 
purification of infectious recombinant adenovirus. Jpn J Med Sci Biol 47:157-66. 
119. Kang, T. C., D. S. Kim, S. E. Kwak, J. E. Kim, M. H. Won, D. W. Kim, S. Y. Choi, and 
O. S. Kwon. 2006. Epileptogenic roles of astroglial death and regeneration in the 
dentate gyrus of experimental temporal lobe epilepsy. Glia 54:258-71. 
120. Kaplitt, M. G., A. D. Kwong, S. P. Kleopoulos, C. V. Mobbs, S. D. Rabkin, and D. W. 
Pfaff. 1994. Preproenkephalin promoter yields region-specific and long-term expression 
in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. 
Proc Natl Acad Sci U S A 91:8979-83. 
121. Kawaguchi, Y., C. Van Sant, and B. Roizman. 1997. Herpes simplex virus 1 alpha 
regulatory protein ICP0 interacts with and stabilizes the cell cycle regulator cyclin D3. J 
Virol 71:7328-36. 
122. Kempermann, G., S. Jessberger, B. Steiner, and G. Kronenberg. 2004. Milestones 
of neuronal development in the adult hippocampus. Trends Neurosci 27:447-52. 
123. Kempermann, G., H. G. Kuhn, and F. H. Gage. 1997. More hippocampal neurons in 
adult mice living in an enriched environment. Nature 386:493-5. 
124. Kim, K. K., S. B. Song, K. I. Kang, M. Rhee, and K. E. Kim. 2007. Activation of the 
thyroid-stimulating hormone beta-subunit gene by LIM homeodomain transcription factor 
Lhx2. Endocrinology 148:3468-76. 
125. Kohn, D. B., M. Sadelain, and J. C. Glorioso. 2003. Occurrence of leukaemia following 
gene therapy of X-linked SCID. Nat Rev Cancer 3:477-88. 
126. Korsholm, K., and I. Law. 2013. Effects of a ketogenic diet on brain metabolism in 
epilepsy. Clin Nucl Med 38:38-9. 
127. Kozorovitskiy, Y., and E. Gould. 2003. Adult neurogenesis: a mechanism for brain 
repair? J Clin Exp Neuropsychol 25:721-32. 
128. Kriegstein, A., and A. Alvarez-Buylla. 2009. The glial nature of embryonic and adult 
	   107	  
neural stem cells. Annu Rev Neurosci 32:149-84. 
129. Krisky, D. M., P. C. Marconi, T. J. Oligino, R. J. Rouse, D. J. Fink, J. B. Cohen, S. C. 
Watkins, and J. C. Glorioso. 1998. Development of herpes simplex virus replication-
defective multigene vectors for combination gene therapy applications. Gene Ther 
5:1517-30. 
130. Kritz, A. B., C. G. Nicol, K. L. Dishart, R. Nelson, S. Holbeck, D. J. Von Seggern, L. 
M. Work, J. H. McVey, S. A. Nicklin, and A. H. Baker. 2007. Adenovirus 5 fibers 
mutated at the putative HSPG-binding site show restricted retargeting with targeting 
peptides in the HI loop. Mol Ther 15:741-9. 
131. Kuhn, H. G., H. Dickinson-Anson, and F. H. Gage. 1996. Neurogenesis in the dentate 
gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J 
Neurosci 16:2027-33. 
132. Kwan, P., and M. J. Brodie. 2000. Early identification of refractory epilepsy. N Engl J 
Med 342:314-9. 
133. Kwong, A. D., and N. Frenkel. 1989. The herpes simplex virus virion host shutoff 
function. J Virol 63:4834-9. 
134. Laurberg, S., and J. Zimmer. 1981. Lesion-induced sprouting of hippocampal mossy 
fiber collaterals to the fascia dentata in developing and adult rats. J Comp Neurol 
200:433-59. 
135. Lee, S. M., S. Tole, E. Grove, and A. P. McMahon. 2000. A local Wnt-3a signal is 
required for development of the mammalian hippocampus. Development 127:457-67. 
136. Lehmann, T. N., S. Gabriel, R. Kovacs, A. Eilers, A. Kivi, K. Schulze, W. R. 
Lanksch, H. J. Meencke, and U. Heinemann. 2000. Alterations of neuronal 
connectivity in area CA1 of hippocampal slices from temporal lobe epilepsy patients and 
from pilocarpine-treated epileptic rats. Epilepsia 41 Suppl 6:S190-4. 
137. Leib, D. A., T. E. Harrison, K. M. Laslo, M. A. Machalek, N. J. Moorman, and H. W. 
Virgin. 1999. Interferons regulate the phenotype of wild-type and mutant herpes simplex 
viruses in vivo. J Exp Med 189:663-72. 
138. Li, P. M., J. Reichert, G. Freyd, H. R. Horvitz, and C. T. Walsh. 1991. The LIM region 
of a presumptive Caenorhabditis elegans transcription factor is an iron-sulfur- and zinc-
containing metallodomain. Proc Natl Acad Sci U S A 88:9210-3. 
139. Lilley, C. E., R. H. Branston, and R. S. Coffin. 2001. Herpes simplex virus vectors for 
the nervous system. Curr Gene Ther 1:339-58. 
140. Lilley, C. E., F. Groutsi, Z. Han, J. A. Palmer, P. N. Anderson, D. S. Latchman, and 
R. S. Coffin. 2001. Multiple immediate-early gene-deficient herpes simplex virus vectors 
allowing efficient gene delivery to neurons in culture and widespread gene delivery to the 
central nervous system in vivo. J Virol 75:4343-56. 
141. Lopez, M., F. Cocchi, E. Avitabile, A. Leclerc, J. Adelaide, G. Campadelli-Fiume, 
and P. Dubreuil. 2001. Novel, soluble isoform of the herpes simplex virus (HSV) 
receptor nectin1 (or PRR1-HIgR-HveC) modulates positively and negatively susceptibility 
to HSV infection. J Virol 75:5684-91. 
142. Loscher, W. 1997. Animal models of intractable epilepsy. Prog Neurobiol 53:239-58. 
143. Loscher, W., U. Ebert, H. Lehmann, C. Rosenthal, and G. Nikkhah. 1998. Seizure 
suppression in kindling epilepsy by grafts of fetal GABAergic neurons in rat substantia 
nigra. J Neurosci Res 51:196-209. 
144. Lothman, E. W., and E. H. Bertram, 3rd. 1993. Epileptogenic effects of status 
epilepticus. Epilepsia 34 Suppl 1:S59-70. 
145. Lothman, E. W., E. H. Bertram, 3rd, and J. L. Stringer. 1991. Functional anatomy of 
hippocampal seizures. Prog Neurobiol 37:1-82. 
146. Lowenstein, L. F. 2004. Recent research and views on shaking baby syndrome. Int J 
Psychiatry Med 34:131-41. 
147. Lugert, S., O. Basak, P. Knuckles, U. Haussler, K. Fabel, M. Gotz, C. A. Haas, G. 
	   108	  
Kempermann, V. Taylor, and C. Giachino. 2010. Quiescent and active hippocampal 
neural stem cells with distinct morphologies respond selectively to physiological and 
pathological stimuli and aging. Cell Stem Cell 6:445-56. 
148. Madsen, T. M., A. Treschow, J. Bengzon, T. G. Bolwig, O. Lindvall, and A. 
Tingstrom. 2000. Increased neurogenesis in a model of electroconvulsive therapy. Biol 
Psychiatry 47:1043-9. 
149. Magavi, S. S., B. R. Leavitt, and J. D. Macklis. 2000. Induction of neurogenesis in the 
neocortex of adult mice. Nature 405:951-5. 
150. Magloczky, Z., L. Wittner, Z. Borhegyi, P. Halasz, J. Vajda, S. Czirjak, and T. F. 
Freund. 2000. Changes in the distribution and connectivity of interneurons in the 
epileptic human dentate gyrus. Neuroscience 96:7-25. 
151. Mangale, V. S., K. E. Hirokawa, P. R. Satyaki, N. Gokulchandran, S. Chikbire, L. 
Subramanian, A. S. Shetty, B. Martynoga, J. Paul, M. V. Mai, Y. Li, L. A. Flanagan, 
S. Tole, and E. S. Monuki. 2008. Lhx2 selector activity specifies cortical identity and 
suppresses hippocampal organizer fate. Science 319:304-9. 
152. Marchi, N., Q. Teng, C. Ghosh, Q. Fan, M. T. Nguyen, N. K. Desai, H. Bawa, P. 
Rasmussen, T. K. Masaryk, and D. Janigro. 2010. Blood-brain barrier damage, but not 
parenchymal white blood cells, is a hallmark of seizure activity. Brain Res 1353:176-86. 
153. Marconi, P., D. Krisky, T. Oligino, P. L. Poliani, R. Ramakrishnan, W. F. Goins, D. J. 
Fink, and J. C. Glorioso. 1996. Replication-defective herpes simplex virus vectors for 
gene transfer in vivo. Proc Natl Acad Sci U S A 93:11319-20. 
154. Margerison, J. H., and J. A. Corsellis. 1966. Epilepsy and the temporal lobes. A 
clinical, electroencephalographic and neuropathological study of the brain in epilepsy, 
with particular reference to the temporal lobes. Brain 89:499-530. 
155. Markowitz, D., S. Goff, and A. Bank. 1988. A safe packaging line for gene transfer: 
separating viral genes on two different plasmids. J Virol 62:1120-4. 
156. Marshall, K. R., R. H. Lachmann, S. Efstathiou, A. Rinaldi, and C. M. Preston. 2000. 
Long-term transgene expression in mice infected with a herpes simplex virus type 1 
mutant severely impaired for immediate-early gene expression. J Virol 74:956-64. 
157. Mathern, G. W., P. D. Adelson, L. D. Cahan, and J. P. Leite. 2002. Hippocampal 
neuron damage in human epilepsy: Meyer's hypothesis revisited. Prog Brain Res 
135:237-51. 
158. Matthews, J. M., M. Bhati, V. J. Craig, J. E. Deane, C. Jeffries, C. Lee, A. L. 
Nancarrow, D. P. Ryan, and M. Sunde. 2008. Competition between LIM-binding 
domains. Biochem Soc Trans 36:1393-7. 
159. Matthews, J. M., and J. E. Visvader. 2003. LIM-domain-binding protein 1: a 
multifunctional cofactor that interacts with diverse proteins. EMBO Rep 4:1132-7. 
160. Maul, G. G., A. M. Ishov, and R. D. Everett. 1996. Nuclear domain 10 as preexisting 
potential replication start sites of herpes simplex virus type-1. Virology 217:67-75. 
161. Mazzuferi, M., E. Palma, K. Martinello, F. Maiolino, C. Roseti, S. Fucile, P. F. 
Fabene, F. Schio, M. Pellitteri, G. Sperk, R. Miledi, F. Eusebi, and M. Simonato. 
2010. Enhancement of GABA(A)-current run-down in the hippocampus occurs at the first 
spontaneous seizure in a model of temporal lobe epilepsy. Proc Natl Acad Sci U S A 
107:3180-5. 
162. McGeoch, D. J., A. Dolan, S. Donald, and D. H. Brauer. 1986. Complete DNA 
sequence of the short repeat region in the genome of herpes simplex virus type 1. 
Nucleic Acids Res 14:1727-45. 
163. McKnight, S. L., R. C. Kingsbury, A. Spence, and M. Smith. 1984. The distal 
transcription signals of the herpesvirus tk gene share a common hexanucleotide control 
sequence. Cell 37:253-62. 
164. Mears, W. E., and S. A. Rice. 1998. The herpes simplex virus immediate-early protein 
ICP27 shuttles between nucleus and cytoplasm. Virology 242:128-37. 
	   109	  
165. Meldrum, B. S., M. T. Akbar, and A. G. Chapman. 1999. Glutamate receptors and 
transporters in genetic and acquired models of epilepsy. Epilepsy Res 36:189-204. 
166. Merkle, F. T., Z. Mirzadeh, and A. Alvarez-Buylla. 2007. Mosaic organization of neural 
stem cells in the adult brain. Science 317:381-4. 
167. Michelsen, J. W., K. L. Schmeichel, M. C. Beckerle, and D. R. Winge. 1993. The LIM 
motif defines a specific zinc-binding protein domain. Proc Natl Acad Sci U S A 90:4404-
8. 
168. Miller, F. D., and A. S. Gauthier. 2007. Timing is everything: making neurons versus 
glia in the developing cortex. Neuron 54:357-69. 
169. Minoo, P., L. Hu, Y. Xing, N. L. Zhu, H. Chen, M. Li, Z. Borok, and C. Li. 2007. 
Physical and functional interactions between homeodomain NKX2.1 and winged 
helix/forkhead FOXA1 in lung epithelial cells. Mol Cell Biol 27:2155-65. 
170. Mira, H., Z. Andreu, H. Suh, D. C. Lie, S. Jessberger, A. Consiglio, J. San Emeterio, 
R. Hortiguela, M. A. Marques-Torrejon, K. Nakashima, D. Colak, M. Gotz, I. Farinas, 
and F. H. Gage. 2010. Signaling through BMPR-IA regulates quiescence and long-term 
activity of neural stem cells in the adult hippocampus. Cell Stem Cell 7:78-89. 
171. Mizutani, K., and T. Saito. 2005. Progenitors resume generating neurons after 
temporary inhibition of neurogenesis by Notch activation in the mammalian cerebral 
cortex. Development 132:1295-304. 
172. Montgomery, R. I., M. S. Warner, B. J. Lum, and P. G. Spear. 1996. Herpes simplex 
virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 
87:427-36. 
173. Morgan, R. A., and W. F. Anderson. 1993. Human gene therapy. Annu Rev Biochem 
62:191-217. 
174. Morizono, K., Y. Xie, G. E. Ringpis, M. Johnson, H. Nassanian, B. Lee, L. Wu, and I. 
S. Chen. 2005. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma 
through intravenous injection. Nat Med 11:346-52. 
175. Nadler, J. V., B. W. Perry, and C. W. Cotman. 1980. Selective reinnervation of 
hippocampal area CA1 and the fascia dentata after destruction of CA3-CA4 afferents 
with kainic acid. Brain Res 182:1-9. 
176. Nakano, T., T. Murata, I. Matsuo, and S. Aizawa. 2000. OTX2 directly interacts with 
LIM1 and HNF-3beta. Biochem Biophys Res Commun 267:64-70. 
177. Neema, M., I. Navarro-Quiroga, M. Chechlacz, K. Gilliams-Francis, J. Liu, K. 
Lamonica, S. L. Lin, and J. R. Naegele. 2005. DNA damage and nonhomologous end 
joining in excitotoxicity: neuroprotective role of DNA-PKcs in kainic acid-induced 
seizures. Hippocampus 15:1057-71. 
178. Ngugi, A. K., C. Bottomley, I. Kleinschmidt, J. W. Sander, and C. R. Newton. 2010. 
Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. 
Epilepsia 51:883-90. 
179. O'Hare, P., and G. S. Hayward. 1985. Three trans-acting regulatory proteins of herpes 
simplex virus modulate immediate-early gene expression in a pathway involving positive 
and negative feedback regulation. J Virol 56:723-33. 
180. Ojala, P. M., B. Sodeik, M. W. Ebersold, U. Kutay, and A. Helenius. 2000. Herpes 
simplex virus type 1 entry into host cells: reconstitution of capsid binding and uncoating 
at the nuclear pore complex in vitro. Mol Cell Biol 20:4922-31. 
181. Orlando, J. S., T. L. Astor, S. A. Rundle, and P. A. Schaffer. 2006. The products of 
the herpes simplex virus type 1 immediate-early US1/US1.5 genes downregulate levels 
of S-phase-specific cyclins and facilitate virus replication in S-phase Vero cells. J Virol 
80:4005-16. 
182. Ortinski, P. I., J. Dong, A. Mungenast, C. Yue, H. Takano, D. J. Watson, P. G. 
Haydon, and D. A. Coulter. 2010. Selective induction of astrocytic gliosis generates 
deficits in neuronal inhibition. Nat Neurosci 13:584-91. 
	   110	  
183. Palmer, T. D., J. Ray, and F. H. Gage. 1995. FGF-2-responsive neuronal progenitors 
reside in proliferative and quiescent regions of the adult rodent brain. Mol Cell Neurosci 
6:474-86. 
184. Paradiso, B., P. Marconi, S. Zucchini, E. Berto, A. Binaschi, A. Bozac, A. Buzzi, M. 
Mazzuferi, E. Magri, G. Navarro Mora, D. Rodi, T. Su, I. Volpi, L. Zanetti, A. Marzola, 
R. Manservigi, P. F. Fabene, and M. Simonato. 2009. Localized delivery of fibroblast 
growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in 
an epilepsy model. Proc Natl Acad Sci U S A 106:7191-6. 
185. Parent, J. M., and G. G. Murphy. 2008. Mechanisms and functional significance of 
aberrant seizure-induced hippocampal neurogenesis. Epilepsia 49 Suppl 5:19-25. 
186. Parent, J. M., N. von dem Bussche, and D. H. Lowenstein. 2006. Prolonged seizures 
recruit caudal subventricular zone glial progenitors into the injured hippocampus. 
Hippocampus 16:321-8. 
187. Parent, J. M., T. W. Yu, R. T. Leibowitz, D. H. Geschwind, R. S. Sloviter, and D. H. 
Lowenstein. 1997. Dentate granule cell neurogenesis is increased by seizures and 
contributes to aberrant network reorganization in the adult rat hippocampus. J Neurosci 
17:3727-38. 
188. Pathan, S. A., Z. Iqbal, S. M. Zaidi, S. Talegaonkar, D. Vohra, G. K. Jain, A. Azeem, 
N. Jain, J. R. Lalani, R. K. Khar, and F. J. Ahmad. 2009. CNS drug delivery systems: 
novel approaches. Recent Pat Drug Deliv Formul 3:71-89. 
189. Paxinos, G., and K. B. J. Franklin. 2004. The mouse brain in stereotaxic coordinates, 
Compact 2nd ed. Elsevier Academic Press, Amsterdam ; Boston. 
190. Perez, M. C., S. P. Hunt, R. S. Coffin, and J. A. Palmer. 2004. Comparative analysis of 
genomic HSV vectors for gene delivery to motor neurons following peripheral inoculation 
in vivo. Gene Ther 11:1023-32. 
191. Perry, L. J., and D. J. McGeoch. 1988. The DNA sequences of the long repeat region 
and adjoining parts of the long unique region in the genome of herpes simplex virus type 
1. J Gen Virol 69 ( Pt 11):2831-46. 
192. Piper, M., G. Barry, J. Hawkins, S. Mason, C. Lindwall, E. Little, A. Sarkar, A. G. 
Smith, R. X. Moldrich, G. M. Boyle, S. Tole, R. M. Gronostajski, T. L. Bailey, and L. 
J. Richards. 2010. NFIA controls telencephalic progenitor cell differentiation through 
repression of the Notch effector Hes1. J Neurosci 30:9127-39. 
193. Pitkanen, A., and T. K. McIntosh. 2006. Animal. models of post-traumatic epilepsy. 
Journal of Neurotrauma 23:241-261. 
194. Pitkanen, A., and T. P. Sutula. 2002. Is epilepsy a progressive disorder? Prospects for 
new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol 1:173-81. 
195. Plata-Salaman, C. R., and J. M. Ffrench-Mullen. 1992. Interleukin-1 beta depresses 
calcium currents in CA1 hippocampal neurons at pathophysiological concentrations. 
Brain Res Bull 29:221-3. 
196. Poirier, J. L., R. Capek, and Y. De Koninck. 2000. Differential progression of Dark 
Neuron and Fluoro-Jade labelling in the rat hippocampus following pilocarpine-induced 
status epilepticus. Neuroscience 97:59-68. 
197. Poon, A. P., H. Gu, and B. Roizman. 2006. ICP0 and the US3 protein kinase of herpes 
simplex virus 1 independently block histone deacetylation to enable gene expression. 
Proc Natl Acad Sci U S A 103:9993-8. 
198. Poon, A. P., H. Gu, and B. Roizman. 2006. ICP0 and the US3 protein kinase of herpes 
simplex virus 1 independently block histone deacetylation to enable gene expression. 
Proc Natl Acad Sci U S A 103:9993-8. 
199. Porter, F. D., J. Drago, Y. Xu, S. S. Cheema, C. Wassif, S. P. Huang, E. Lee, A. 
Grinberg, J. S. Massalas, D. Bodine, F. Alt, and H. Westphal. 1997. Lhx2, a LIM 
homeobox gene, is required for eye, forebrain, and definitive erythrocyte development. 
Development 124:2935-44. 
	   111	  
200. Racine, R. J. 1972. Modification of seizure activity by electrical stimulation. II. Motor 
seizure. Electroencephalogr Clin Neurophysiol 32:281-94. 
201. Ribak, C. E., P. H. Tran, I. Spigelman, M. M. Okazaki, and J. V. Nadler. 2000. Status 
epilepticus-induced hilar basal dendrites on rodent granule cells contribute to recurrent 
excitatory circuitry. J Comp Neurol 428:240-53. 
202. Roberson, M. S., W. E. Schoderbek, G. Tremml, and R. A. Maurer. 1994. Activation 
of the glycoprotein hormone alpha-subunit promoter by a LIM-homeodomain 
transcription factor. Mol Cell Biol 14:2985-93. 
203. Roizman, B., and R. J. Whitley. 2001. The nine ages of herpes simplex virus. Herpes 
8:23-7. 
204. Rolland, A. 2006. Nuclear gene delivery: the Trojan horse approach. Expert Opin Drug 
Deliv 3:1-10. 
205. Rothstein, J. D., M. Dykes-Hoberg, C. A. Pardo, L. A. Bristol, L. Jin, R. W. Kuncl, Y. 
Kanai, M. A. Hediger, Y. Wang, J. P. Schielke, and D. F. Welty. 1996. Knockout of 
glutamate transporters reveals a major role for astroglial transport in excitotoxicity and 
clearance of glutamate. Neuron 16:675-86. 
206. Saeki, Y., T. Ichikawa, A. Saeki, E. A. Chiocca, K. Tobler, M. Ackermann, X. O. 
Breakefield, and C. Fraefel. 1998. Herpes simplex virus type 1 DNA amplified as 
bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus 
progeny and packaging of amplicon vectors. Hum Gene Ther 9:2787-94. 
207. Saenz, D. T., N. Loewen, M. Peretz, T. Whitwam, R. Barraza, K. G. Howell, J. M. 
Holmes, M. Good, and E. M. Poeschla. 2004. Unintegrated lentivirus DNA persistence 
and accessibility to expression in nondividing cells: analysis with class I integrase 
mutants. J Virol 78:2906-20. 
208. Samaniego, L. A., A. L. Webb, and N. A. DeLuca. 1995. Functional interactions 
between herpes simplex virus immediate-early proteins during infection: gene 
expression as a consequence of ICP27 and different domains of ICP4. J Virol 69:5705-
15. 
209. Scharfman, H. E. 2004. Functional implications of seizure-induced neurogenesis. Adv 
Exp Med Biol 548:192-212. 
210. Scharfman, H. E., J. H. Goodman, and A. L. Sollas. 2000. Granule-like neurons at the 
hilar/CA3 border after status epilepticus and their synchrony with area CA3 pyramidal 
cells: functional implications of seizure-induced neurogenesis. J Neurosci 20:6144-58. 
211. Schlessinger, A. R., W. M. Cowan, and D. I. Gottlieb. 1975. An autoradiographic study 
of the time of origin and the pattern of granule cell migration in the dentate gyrus of the 
rat. J Comp Neurol 159:149-75. 
212. Schmued, L. C., and K. J. Hopkins. 2000. Fluoro-Jade: novel fluorochromes for 
detecting toxicant-induced neuronal degeneration. Toxicol Pathol 28:91-9. 
213. Scott, B. W., S. Wang, W. M. Burnham, U. De Boni, and J. M. Wojtowicz. 1998. 
Kindling-induced neurogenesis in the dentate gyrus of the rat. Neurosci Lett 248:73-6. 
214. Segal, M. 1988. Synaptic activation of a cholinergic receptor in rat hippocampus. Brain 
Res 452:79-86. 
215. Seri, B., J. M. Garcia-Verdugo, B. S. McEwen, and A. Alvarez-Buylla. 2001. 
Astrocytes give rise to new neurons in the adult mammalian hippocampus. J Neurosci 
21:7153-60. 
216. Shapira, M., F. L. Homa, J. C. Glorioso, and M. Levine. 1987. Regulation of the 
herpes simplex virus type 1 late (gamma 2) glycoprotein C gene: sequences between 
base pairs -34 to +29 control transient expression and responsiveness to transactivation 
by the products of the immediate early (alpha) 4 and 0 genes. Nucleic Acids Res 
15:3097-111. 
217. Shapiro, L. A., and C. E. Ribak. 2006. Newly born dentate granule neurons after 
pilocarpine-induced epilepsy have hilar basal dendrites with immature synapses. 
	   112	  
Epilepsy Res 69:53-66. 
218. Siminoff, P., and M. G. Menefee. 1966. Normal and 5-bromodeoxyuridine-inhibited 
development of herpes simplex virus. An electron microscope study. Exp Cell Res 
44:241-55. 
219. Smiley, J. R. 2004. Herpes simplex virus virion host shutoff protein: immune evasion 
mediated by a viral RNase? J Virol 78:1063-8. 
220. Smith, R. W., P. Malik, and J. B. Clements. 2005. The herpes simplex virus ICP27 
protein: a multifunctional post-transcriptional regulator of gene expression. Biochem Soc 
Trans 33:499-501. 
221. Sodeik, B., M. W. Ebersold, and A. Helenius. 1997. Microtubule-mediated transport of 
incoming herpes simplex virus 1 capsids to the nucleus. J Cell Biol 136:1007-21. 
222. Soliman, T. M., R. M. Sandri-Goldin, and S. J. Silverstein. 1997. Shuttling of the 
herpes simplex virus type 1 regulatory protein ICP27 between the nucleus and 
cytoplasm mediates the expression of late proteins. J Virol 71:9188-97. 
223. Spear, M. A., F. Sun, D. J. Eling, E. Gilpin, T. J. Kipps, E. A. Chiocca, and M. 
Bouvet. 2000. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with 
oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) 
combined with ionizing radiation. Cancer Gene Ther 7:1051-9. 
224. Staley, K. J., and I. Mody. 1992. Shunting of excitatory input to dentate gyrus granule 
cells by a depolarizing GABAA receptor-mediated postsynaptic conductance. J 
Neurophysiol 68:197-212. 
225. Stavropoulos, T. A., and C. A. Strathdee. 1998. An enhanced packaging system for 
helper-dependent herpes simplex virus vectors. J Virol 72:7137-43. 
226. Steiner, B., S. Zurborg, H. Horster, K. Fabel, and G. Kempermann. 2008. Differential 
24 h responsiveness of Prox1-expressing precursor cells in adult hippocampal 
neurogenesis to physical activity, environmental enrichment, and kainic acid-induced 
seizures. Neuroscience 154:521-9. 
227. Steiner, I., and P. G. Kennedy. 1993. Molecular biology of herpes simplex virus type 1 
latency in the nervous system. Mol Neurobiol 7:137-59. 
228. Stelz, G., E. Rucker, O. Rosorius, G. Meyer, R. H. Stauber, M. Spatz, M. M. Eibl, and 
J. Hauber. 2002. Identification of two nuclear import signals in the alpha-gene product 
ICP22 of herpes simplex virus 1. Virology 295:360-70. 
229. Subramanian, L., A. Sarkar, A. S. Shetty, B. Muralidharan, H. Padmanabhan, M. 
Piper, E. S. Monuki, I. Bach, R. M. Gronostajski, L. J. Richards, and S. Tole. 2011. 
Transcription factor Lhx2 is necessary and sufficient to suppress astrogliogenesis and 
promote neurogenesis in the developing hippocampus. Proc Natl Acad Sci U S A 
108:E265-74. 
230. Suh, H., A. Consiglio, J. Ray, T. Sawai, K. A. D'Amour, and F. H. Gage. 2007. In vivo 
fate analysis reveals the multipotent and self-renewal capacities of Sox2+ neural stem 
cells in the adult hippocampus. Cell Stem Cell 1:515-28. 
231. Suhonen, J. O., D. A. Peterson, J. Ray, and F. H. Gage. 1996. Differentiation of adult 
hippocampus-derived progenitors into olfactory neurons in vivo. Nature 383:624-7. 
232. Sutula, T., G. Cascino, J. Cavazos, I. Parada, and L. Ramirez. 1989. Mossy fiber 
synaptic reorganization in the epileptic human temporal lobe. Ann Neurol 26:321-30. 
233. Tan, W., K. Zhu, D. J. Segal, C. F. Barbas, 3rd, and S. A. Chow. 2004. Fusion 
proteins consisting of human immunodeficiency virus type 1 integrase and the designed 
polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites. J Virol 
78:1301-13. 
234. Tanaka, M., H. Kagawa, Y. Yamanashi, T. Sata, and Y. Kawaguchi. 2003. 
Construction of an excisable bacterial artificial chromosome containing a full-length 
infectious clone of herpes simplex virus type 1: viruses reconstituted from the clone 
exhibit wild-type properties in vitro and in vivo. J Virol 77:1382-91. 
	   113	  
235. Tashiro, A., V. M. Sandler, N. Toni, C. Zhao, and F. H. Gage. 2006. NMDA-receptor-
mediated, cell-specific integration of new neurons in adult dentate gyrus. Nature 
442:929-33. 
236. Temkin, N. R. 2001. Antiepileptogenesis and seizure prevention trials with antiepileptic 
drugs: meta-analysis of controlled trials. Epilepsia 42:515-24. 
237. Theodore, W. H., S. S. Spencer, S. Wiebe, J. T. Langfitt, A. Ali, P. O. Shafer, A. T. 
Berg, and B. G. Vickrey. 2006. Epilepsy in North America: a report prepared under the 
auspices of the global campaign against epilepsy, the International Bureau for Epilepsy, 
the International League Against Epilepsy, and the World Health Organization. Epilepsia 
47:1700-22. 
238. Tian, Y. L., Y. Guo, D. Y. Cao, Q. Zhang, H. S. Wang, and Y. Zhao. 2005. Local 
application of morphine suppresses glutamate-evoked activities of C and Adelta afferent 
fibers in rat hairy skin. Brain Res 1059:28-34. 
239. Toni, N., E. M. Teng, E. A. Bushong, J. B. Aimone, C. Zhao, A. Consiglio, H. van 
Praag, M. E. Martone, M. H. Ellisman, and F. H. Gage. 2007. Synapse formation on 
neurons born in the adult hippocampus. Nat Neurosci 10:727-34. 
240. Triezenberg, S. J., R. C. Kingsbury, and S. L. McKnight. 1988. Functional dissection 
of VP16, the trans-activator of herpes simplex virus immediate early gene expression. 
Genes Dev 2:718-29. 
241. Turner, A., B. Bruun, T. Minson, and H. Browne. 1998. Glycoproteins gB, gD, and 
gHgL of herpes simplex virus type 1 are necessary and sufficient to mediate membrane 
fusion in a Cos cell transfection system. J Virol 72:873-5. 
242. Uchida, H., M. Marzulli, K. Nakano, W. F. Goins, J. Chan, C. S. Hong, L. 
Mazzacurati, J. Y. Yoo, A. Haseley, H. Nakashima, H. Baek, H. Kwon, I. Kumagai, M. 
Kuroki, B. Kaur, E. A. Chiocca, P. Grandi, J. B. Cohen, and J. C. Glorioso. 2012. 
Effective Treatment of an Orthotopic Xenograft Model of Human Glioblastoma Using an 
EGFR-retargeted Oncolytic Herpes Simplex Virus. Mol Ther. 
243. Umbach, J. L., M. F. Kramer, I. Jurak, H. W. Karnowski, D. M. Coen, and B. R. 
Cullen. 2008. MicroRNAs expressed by herpes simplex virus 1 during latent infection 
regulate viral mRNAs. Nature 454:780-3. 
244. Uprichard, S. L., and D. M. Knipe. 1996. Herpes simplex ICP27 mutant viruses exhibit 
reduced expression of specific DNA replication genes. J Virol 70:1969-80. 
245. van Praag, H., A. F. Schinder, B. R. Christie, N. Toni, T. D. Palmer, and F. H. Gage. 
2002. Functional neurogenesis in the adult hippocampus. Nature 415:1030-4. 
246. Vessal, M., C. B. Dugani, D. A. Solomon, W. McIntyre Burnham, and G. O. Ivy. 
2005. Might astrocytes play a role in maintaining the seizure-prone state? Brain Res 
1044:190-6. 
247. Walker, T. L., A. White, D. M. Black, R. H. Wallace, P. Sah, and P. F. Bartlett. 2008. 
Latent stem and progenitor cells in the hippocampus are activated by neural excitation. J 
Neurosci 28:5240-7. 
248. Wandzioch, E., A. Kolterud, M. Jacobsson, S. L. Friedman, and L. Carlsson. 2004. 
Lhx2-/- mice develop liver fibrosis. Proc Natl Acad Sci U S A 101:16549-54. 
249. Watson, R. J., and J. B. Clements. 1980. A herpes simplex virus type 1 function 
continuously required for early and late virus RNA synthesis. Nature 285:329-30. 
250. Watson, R. J., M. Sullivan, and G. F. Vande Woude. 1981. Structures of two spliced 
herpes simplex virus type 1 immediate-early mRNA's which map at the junctions of the 
unique and reiterated regions of the virus DNA S component. J Virol 37:431-44. 
251. Weinandy, F., J. Ninkovic, and M. Gotz. 2011. Restrictions in time and space--new 
insights into generation of specific neuronal subtypes in the adult mammalian brain. Eur 
J Neurosci 33:1045-54. 
252. Wenzel, H. J., P. S. Buckmaster, N. L. Anderson, M. E. Wenzel, and P. A. 
Schwartzkroin. 1997. Ultrastructural localization of neurotransmitter immunoreactivity in 
	   114	  
mossy cell axons and their synaptic targets in the rat dentate gyrus. Hippocampus 
7:559-70. 
253. Wetherington, J., G. Serrano, and R. Dingledine. 2008. Astrocytes in the epileptic 
brain. Neuron 58:168-78. 
254. White, R. E., M. A. Calderwood, and A. Whitehouse. 2003. Generation and precise 
modification of a herpesvirus saimiri bacterial artificial chromosome demonstrates that 
the terminal repeats are required for both virus production and episomal persistence. J 
Gen Virol 84:3393-403. 
255. Wittels, M., and P. G. Spear. 1991. Penetration of cells by herpes simplex virus does 
not require a low pH-dependent endocytic pathway. Virus Res 18:271-90. 
256. Wong, R. J., M. K. Chan, Z. Yu, T. H. Kim, A. Bhargava, B. M. Stiles, B. C. 
Horsburgh, J. P. Shah, R. A. Ghossein, B. Singh, and Y. Fong. 2004. Effective 
intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus 
expressing interleukin 12. Clin Cancer Res 10:251-9. 
257. WuDunn, D., and P. G. Spear. 1989. Initial interaction of herpes simplex virus with cells 
is binding to heparan sulfate. J Virol 63:52-8. 
258. Wysocka, J., and W. Herr. 2003. The herpes simplex virus VP16-induced complex: the 
makings of a regulatory switch. Trends Biochem Sci 28:294-304. 
259. Xu, Y., M. Baldassare, P. Fisher, G. Rathbun, E. M. Oltz, G. D. Yancopoulos, T. M. 
Jessell, and F. W. Alt. 1993. LH-2: a LIM/homeodomain gene expressed in developing 
lymphocytes and neural cells. Proc Natl Acad Sci U S A 90:227-31. 
260. Yang, S., Z. W. Liu, L. Wen, H. F. Qiao, W. X. Zhou, and Y. X. Zhang. 2005. 
Interleukin-1beta enhances NMDA receptor-mediated current but inhibits excitatory 
synaptic transmission. Brain Res 1034:172-9. 
261. Young, S. Z., M. M. Taylor, and A. Bordey. 2011. Neurotransmitters couple brain 
activity to subventricular zone neurogenesis. Eur J Neurosci 33:1123-32. 
262. Zhang, N., and C. R. Houser. 1999. Ultrastructural localization of dynorphin in the 
dentate gyrus in human temporal lobe epilepsy: a study of reorganized mossy fiber 
synapses. J Comp Neurol 405:472-90. 
263. Zhao, C., W. Deng, and F. H. Gage. 2008. Mechanisms and functional implications of 
adult neurogenesis. Cell 132:645-60. 
264. Zhou, B., Q. Zhong, P. Minoo, C. Li, D. K. Ann, B. Frenkel, E. E. Morrisey, E. D. 
Crandall, and Z. Borok. 2008. Foxp2 inhibits Nkx2.1-mediated transcription of SP-C via 
interactions with the Nkx2.1 homeodomain. Am J Respir Cell Mol Biol 38:750-8. 
265. Zhou, G., and B. Roizman. 2000. Wild-type herpes simplex virus 1 blocks programmed 
cell death and release of cytochrome c but not the translocation of mitochondrial 
apoptosis-inducing factor to the nuclei of human embryonic lung fibroblasts. J Virol 
74:9048-53. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   115	  
	  
Il tuo indirizzo e-mail 
vrlglc@unife.it 
Oggetto: 
dichiarazione di conformità della tesi di Dottorato 
Io sottoscritto Dott. (Cognome e Nome) 
verlengia gianluca 
Nato a: 
termoli 
Provincia: 
campobasso 
Il giorno: 
15/03/1983 
Avendo frequentato il Dottorato di Ricerca in: 
farmacologia e oncologia molecolare 
Ciclo di Dottorato 
25 
Titolo della tesi: 
construction of replication-defective herpes simplex viral vectors for 
targeting the lhx2 gene in the central nervous system 
Titolo della tesi (traduzione): 
 
Tutore: Prof. (Cognome e Nome) 
Simonato michele 
Settore Scientifico Disciplinare (S.S.D.) 
bio/14 
Parole chiave della tesi (max 10): 
Herpes vectors gene therapy epilepsy Lhx2 
Consapevole, dichiara 
CONSAPEVOLE: (1) del fatto che in caso di dichiarazioni mendaci, oltre alle 
sanzioni previste dal codice penale e dalle Leggi speciali per l’ipotesi di 
falsità in atti ed uso di atti falsi, decade fin dall’inizio e senza necessità di 
alcuna formalità dai benefici conseguenti al provvedimento emanato sulla 
base di tali dichiarazioni; (2) dell’obbligo per l’Università di provvedere al 
deposito di legge delle tesi di dottorato al fine di assicurarne la 
conservazione e la consultabilità da parte di terzi; (3) della procedura 
adottata dall’Università di Ferrara ove si richiede che la tesi sia consegnata 
dal dottorando in 2 copie, di cui una in formato cartaceo e una in formato 
pdf non modificabile su idonei supporti (CD-ROM, DVD) secondo le 
istruzioni pubblicate sul sito : http://www.unife.it/studenti/dottorato alla 
voce ESAME FINALE – disposizioni e modulistica; (4) del fatto che 
l’Università, sulla base dei dati forniti, archivierà e renderà consultabile in 
rete il testo completo della tesi di dottorato di cui alla presente 
dichiarazione attraverso l’Archivio istituzionale ad accesso aperto 
“EPRINTS.unife.it” oltre che attraverso i Cataloghi delle Biblioteche 
Nazionali Centrali di Roma e Firenze. DICHIARO SOTTO LA MIA 
RESPONSABILITA': (1) che la copia della tesi depositata presso l’Università 
di Ferrara in formato cartaceo è del tutto identica a quella presentata in 
formato elettronico (CD-ROM, DVD), a quelle da inviare ai Commissari di 
	   116	  
esame finale e alla copia che produrrà in seduta d’esame finale. Di 
conseguenza va esclusa qualsiasi responsabilità dell’Ateneo stesso per 
quanto riguarda eventuali errori, imprecisioni o omissioni nei contenuti 
della tesi; (2) di prendere atto che la tesi in formato cartaceo è l’unica alla 
quale farà riferimento l’Università per rilasciare, a mia richiesta, la 
dichiarazione di conformità di eventuali copie. PER ACCETTAZIONE DI 
QUANTO SOPRA RIPORTATO 
Dichiarazione per embargo 
12 mesi 
Richiesta motivata embargo 
5. Tutela della proprietà intellettuale 
Liberatoria consultazione dati Eprints 
Consapevole del fatto che attraverso l’Archivio istituzionale ad accesso 
aperto “EPRINTS.unife.it” saranno comunque accessibili i metadati relativi 
alla tesi (titolo, autore, abstract, ecc.) 
 
 
Firma del dottorando 
Ferrara, li 15/03/2013  
 
Firma del Dottorando  
Gianluca Verlengia 
 
 
Firma del Tutore 
Visto: Il Tutore Si approva  
 
Firma del Tutore  
Simonato Michele	  	  
